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ABSTRACT 
The present study was undertaken to determine th~ ~ffects and possible mechanism of action of 
vitamin E succinate on malignant murine melanoma (BL6) and non-malignant monkey kidney 
(LLCMK) cell growth in vitro. Studies revealed that supplementation of 5, 7 and lOJLg/ml vitamin 
E succinate significantly inhibited BL6 cell growth, while in LLCMK cells no significant increase or 
-- - -'" 
decrease in growth was observed. 
The actual mechanism by which vitamin E succinate inhibits BL6 cell growth is at present unclear. 
Studies have suggested a radical or oxidant involvement in a number of degenerative diseases such 
as cancer, and that supplementation of antioxidant vitamin's such as vitamin E may function to reduce 
cancer cell growth by quenching free radical species and preventing lipid peroxidation. In addition 
to its antioxidant role in a cell, vitamin E is believed to modulate the activities of various enzymes 
and metabolites in the eicosanoid pathway. 
Hence, this study investigated the effects of vitamin E succinate supplementation on free radical and 
lipid peroxidation levels, as well as the activities of various enzymes and metabolites ill the eicosanoid 
pathway. Throughout this study, emphasis was placed on BL6 melanoma cells since the magnitude 
of the relationship between LLCMK growth and the levels of various enzymes and metabolites in the 
eicosanoid pathway varied considerably from one experiment to another and did not show the 
consistent trend found with the BL6 cells. 
A decrease in cell growth was found to be accompanied by a concomitant increase rather than a 
decrease in the levels of free radicals and lipid peroxidation, suggesting that the growth inhibitory 
effects of vitamin E succinate on BL6 cells in vitro was not due to its antioxidant properties associated 
with the vitamin E component, but rather due to one or more of its other potential roles within the 
cell. This proposal was further strengthened by findings that vitamin E succinate, a non-physiological 
antioxidant in its esterified form, did not undergo significant cleavage to free vitamin E in the BL6 
cells. 
Vitamin E succinate is believed to modulate membrane bound enzyme activities through 
physicochemical interactions with membrane lipids and changes in membrane fluidity. Hence, this 
study investigated the role of vitamin E succinate in modulating the activity of various enzymes and 
secondary messengers in the eicosanoid pathway. Supplementation of l-lOjLg/ml vitamin E succinate 
resulted in an overall increase in phospholipase A2 activity while cyclooxygenase and adenyl ate 
cyclase activities were found to be significantly increased at vitamin E succinate concentrations of 7 
and WjLg/ml respectively. A significant increase in" 5-LOX activity was observed a! 10jLg/mi 
.< 
supplementation. The suggestion that vitamin E succinate modulates membrane bound enzyme 
activities was further strengthened by uptake and cellular distribution studies, which showed 
significantly higher levels of vitamin E succinate in membrane fractions of BL6 cells when compared 
with stroma fractions. Another factor which could account for elevated PLA2,-5-LOX and COX 
activities in BL6 cells as a result of vitamin E succinate supplementation, was that of intracellular 
calcium levels. Supplementation of BL6 cells with 1-7 jLg/ml vitamin E succinate resulted in an overall 
increase in intracellular calcium levels. These changes in calcium levels however were positively 
correlated with changes in PLA2 activity only. 
Since the rate of prostaglandin synthesis is controlled by phospholipase A2 activity, and net 
prostagiandin production is dependant on cyclooxygenase activity, the effects of vitamin E succinate 
supplementation on prostaglandin levels in BL6 cells was determined. Vitamin E succinate 
supplementation resulted in a significant decrease in prostaglandin D2 levels at vitamin E succinate 
concentrations of 3, 5, 7 and lOjLg/ml respectively, while prostaglandin F2a levels were significantly 
decreased at 1-10jLg/ml vitamin E succinate. The increases in prostaglandin E2 and 12 levels were 
inversely related to BL6 cell growth suggesting that both prostaglandins may act as negative regulators 
of BL6 cell growth. When comparing prostaglandin E2 levels to prostaglandin 12 levels in BL6 cells, 
significantly higher levels of prostaglandin E2 were found, suggesting that vitamin E succinate effects 
were mediated primarily through an increase in prostaglandin E2 levels. Furthermore, prostaglandin 
E2 levels are believed to modulate adenylate cyclase activity. It is therefore reasonable to conclude 
that the increased adenyl ate cyclase activity found in BL6 cells was dependant on prostaglandin E2 
levels, since increases in prostaglandin E2 levels at 7 and lOjLg/ml vitamin E succinate correlated with 
an increase in adenylate cyclase activity and cyclic adenosine monophosphate levels. 
Thus it appeared that the observed inhibitory effects of vitamin E succinate supplementation on BL6 
cell growth was not due to the antioxidant properties associated with the vitamin E component of the 
vitamin E succinate molecule, but was rather mediated in part through a cascade effect initiated by 
phospholipase A2 activation and archidonic acid release. This initial effect then appeared to result in 
an increase in cyclooxygenase activity and activation of a prostaglandin E2-adenylate cyclase-cyclic 
adenosine monophosphate linked system, ultimately altering cyclic adenosine monophosphate levels 
11 
and inhibiting BL6 cell growth. This was confirmed when BL6 cells were supplemented with 
indomethacin, a cyclooxygenase inhibitor. Supplementation with the inhibitor resulted in vitamin E 
succinate having no inhibitory effects on BL6 cell growth. Furthermore, when comparing the levels 
of prostaglandin ~, adenylate cyclase activity and cyclIC adenosine monophosphate in ind,omethacin 
-< 
treated cultures to non-indomethacin treated cultures, markedly lower levels of these metabolites were 
found in the indomethacin treated cultures. 
r 
The cause of the increase in free radical and lipid peroxidation levels in BL6 cells following vitamin 
E succinate supplementation was further investigated. Cyclooxygenase enzymes are believed to 
generate free radical species and contribute to lipid peroxidation levels during catalytic activity. 
Markedly lower levels of free radicals and lipid peroxidation in indomethacin treated cultures were 
found when compared with vitamin E succinate treated cultures alone, suggesting that the increases 
in free radical and lipid peroxidation levels in BL6 cells supplemented with vitamin E succinate were 
indirectly due to an increase in cyclooxygenase activity in these cells. 
iii 
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1.1 CANCER 
1 
LITERATURE REVIEW 
Cancer can be defined as the uncontrolled growth of abnormal cells. The transf<,!rmation of normal 
cells to cancer cells is actively induced by a variety of agents which are either physical or chemical 
in nature (1-6). These agents can be classified into 4 distinct groups: chemical, physical, biological 
and genetic (1). Groups of these abnormal proliferating cells (tumours) can arise in any part of the 
body, however not all tumours are potentially lethal. Tumour cells that remain localised in certain 
tissues are unable to invade surrounding tissue and are referred to as benign tumours, while those that 
spread from their site of origin through the bloodstream and lymphatic system and destroy 
surrounding tissue and organs, are referred to as malignant (2,3). The availability of highly 
sophisticated molecular and biochemical tools over the past few years has led to considerable progress 
being made in understanding the stages of tumour development. Both epidemiological and 
experimental studies indicate that tumour development occurs through three distinct stages (fi~re 1). 
These include initiation, promotion and progression stages (1,5,7-11). 
INITIATION PROMOTION PROGRESSION 
~- -
-Permanent alteration - Conversion -+ Promotion - Additional genetic 
of cell phenotype. (Stage 1) (Stage 2) alterations? 
-Somatic gene * Partially * Reversible reversible 
mutation. 
Figure 1: Multistage carcinogenesis model of tumour development (5). 
1.1.1 INITIATION 
The first step in the multistage carcinogenesis model is the initiation step. During this stage, a 
permanent and hereditable alteration ofthe cells genetic material may occur (1,5,7-11). Most tumour 
1 
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initiating agents are electrophilic in character, or are metabolically converted to electrophilic agents 
capable of binding to deoxyribonucleic acid (DNA) and other macromolecules within the cells 
(5,7, ro, 11). The initiation phase requires a single app~ication of a carcinogen at sub-threshold level 
(5,7,8), although the efficiency of this step is dependant to a large extent on cell division and DNA 
synthesis (1,5,8). 
1.1.2 PROMOTION 
The promotion step of carcinogenesis involves both the selection and clonal proliferation of cells that 
have undergone initiation (1,5,7-9). This stage occupies a large portion of the latent period of 
carcinogenesis, and is distinguishable from initiation and progression phases by its operational 
reversibility (1,8,11). Furthermore, the promotion stage of the multistage carcinogenic model can be 
modulated by a variety of factors such as frequency of administration of a promoter (1,11), age of 
the individual and composition of the diet (1). Promoting agents are classified into stage one 
promoters (incomplete promoters) which are active in tumour initiation or tumour promotion, and 
stage two promoters (complete promoters) which are active in both initiation and promotional >~tages 
of carcinogenesis (5). Most tumour promoting agents are believed to be membrane active agents, 
which exert their effects on the cell through mediation of receptor linked mechanisms (1,7,9,12). 
Furthermore tumour promoting agents may increase the risk of cancer development, by increasing 
the proliferation rate of normal cells, in turn increasing the probability of propagating a genetic error 
within these cells (1,9). 
Although numerous tumour promoters exist in nature, the events triggering the transformation of a 
normal cell to a tumour cell can be simple, often resulting from damage to the DNA of a critical 
target gene in a particular cell (13,14). Over the past few years, these target genes have been 
identified and are referred to as oncogenes (13). Almost all oncogenes arise from the cellular genes, 
and several lines of evidence suggest that these oncogenes are altered versions of normal cellular 
genes called proto-oncogenes (13-15). When uninterrupted, proto-oncogenes play an important role 
in the control of both cellular proliferation and differentiation of normal cells (13-16). To date, 
oncogenes have been detected in only 15 to 20% of all human tumours, although other as yet 
unidentified growth promoting oncogenes may exist in human tumours (13). Certain tumours may 
arise due to the loss of critical sections of genetic information (13). Recent studies have proposed the 
existence of so-called suppressor genes (anti-oncogenes) (13,14), which when absent result in tumour 
2 
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cells becoming aberrant (13). This notion has further been encouraged by the finding that fusing a 
normal cell with a tumour cell results in the tumour cell ~egaining the genes it lost during its evolution 
towaros malignancy (13): 
1.1.3 PROGRESSION 
In the final stage of carcinogenesis, benign tumour cells progress into a highly malignant rapidly 
-
growing neoplasm (1,7-9). During tumour progression a second discrete and inheritable event occurs 
through direct chemical interaction with the DNA, or transposition of genetic material (1,9). These 
alterations in genomic structure are directly related to the increased growth rate, invasivness, 
metastatic capability and biochemical changes within the cells (8,9,11). One of the most important 
aspects of tumour progression is the ability of tumour cells to undergo metastatic dissemination. This 
process. involves detachment of tumour cells from a primary tumour, infiltration into blood or 
lymphatic system, and transport to distant organs. On reaching distant organs, tumour cells infiltrate 
tissues and begin to proliferate. The ability of tumour cells to inetastasise is one of the primary causes 
of death in cancer patients (17 -19) . 
In conclusion, due to the complexity of various processes involved in cancer development, numerous 
factors, including properties of a particular tumour cell as well as host factors, may all contribute to 
this process. Further studies of these factors may contribute to the overall knowledge of cancer 
development and eventually lead to the development of treatments with far greater success rates .. 
1.1.4 CHEMOPREVENTION 
With the ever increasing number of new cases of cancer occurring each year, and the limited success 
of established preventative and therapeutic strategies, one cannot escape the need for continued efforts 
to develop new and improved therapeutic procedures (11,20,21). Advances in our understanding of 
the various stages involved in carcinogenesis should enable researchers to develop effective treatment 
strategies. Several new therapeutic approaches are currently under investigation. These include 
chemoprevention, which involves the systematic use of specific natural or synthetic agents to block 
or reverse the carcinogenic process prior to the development of invasive cancer (11,20-23). 
Chemopreventers are found in all classes of foods and include non-nutritional components such as 
vitamins, polyphenols and other food ingredients (20-22). 
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Over the past few years numerous studies have shown that a variety of non-nutritive components of 
the diet can protect against cancer development, and fu~hermore that their protective effects are due 
to theIr antioxidant properties (11,22). In addition to their roles as antioxidants, these agents may 
exhibit several other modes of action, which are tumour specific, site oriented and complement the 
total beneficial potentials of chemopreventers (22). Few studies have been carried out to evaluate the 
role of these antioxidants in carcinogenesis, however their potential roles as chemopreventive agents 
has further been strengthened by the fact that free radicals may contribute to the initiation and 
promotional stages of carcinogenesis (8,9). Vitamin E is one such antioxidant whose role in 
chemoprevention is currently being investigated (24,25). 
Since vitamin E and its role in the neoplastic process is the subject of this thesis, the general role of 
vitamin E in cellular metabolism will be considered. 
1.2 VITAMIN E 
1.2.1 HISTORY 
Vitamin E, the generic term for a group of lipid-soluble tocol and tocotrienol (TOT) derivatives 
possessing varying levels of vitamin E activity, was discovered in 1922 by Evans and Bishop during 
a course of experiments examining the relationship between the estrous cycle in female rats and the 
effects of dietary changes on its duration. These studies revealed that female rats fed diets deficient 
in vitamin E suffered a loss of fertility through resorption of foetuses, unless the diet was 
supplemented with small amounts of fresh lettuce, wheat germ or dried alfalfa leaves (26-32). 
Following its isolation in pure form, Evans gave the vitamin a name descriptive of its metabolic 
function. With the aid of Calhoun, a Greek professor from the University of California, they derived 
the name tocopherol (TOH) from the Greek words Tokos (offspring) and Phero (to bring forth) 
(26,28,32). 
1.2.2 STRUCTURE 
At present eight forms of vitamin E are known to exist in nature. These include a-, {3-, 'Y- and 0-
TOTs, which contain saturated phytol side chains, and the a-, {3-, 'Y- and o-TOHs which possess 3 
double bonds in their side chains (25,26,32,33,34). Individual TOHs and TOTs differ according to 
4 
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the position and number of methyl substituents on the aromatic ring (32,33,35,36) . 
. The functional form of vitamin E, ex-TOH, is a 6-~y?roxychroman derivative containing methyl 
groups at carbons 2,5,7,8 and a phytyl chain at carbon two (26,32,34,35,36). Although ex-TOH from 
natural sources is the most biopotent form of vitamin E (27,32,35-38), both TOTs and ex-, {3-, 0-
TOHs do contribute some vitamin E activity (27 ,38). (In this thesis when vitamin E is referred to the 
compound ex-TOH is understood if not otherwise stated). At present, the two principle sources of 
vitamin E being used commercially are the acetate and succinate derivatives of d-ex-TOH (26,36,39-
41). ex-TOH esters are widely used in pharmaceutical formulations and dietary supplements due to 
their relative stabilities and resistance to biological oxidations (36,40-42). The most commonly used 
ex-TOH esters (figure 2) are the non-polar acetate and more polar succinate esters such as ex-TOH 
succinate, although numerous other polar esters such as phosphate, nicotinate and polyethylene glycol 
1 000 succinate are also available (36). Polar ex-TOH esters are frequently used in in vitro studies due 
to their stability and solubility in growth media, their ability to cross cellular membranes and their 
slow conversion to ex-TOH, resulting in intracellular levels of ex-TOH remaining high for longer 
periods (36,42). 
HCXX:a;2CH2 coo 
ex-Tocopherol succinate 
Ol-Tocopherol acetate 
Figure 2: Commercially available ex-Tocopherol esters (43). 
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1.2.3 METABOLISM 
Natural TOHs are essential macronutrients in mammals (34,44,45). The term "essential" implies that 
these vitamins are not synthesised by the body, and therefore have to be acquired through the diet 
(26,44). In humans and animals, TOHs and TOTs are primarily obtained through the ingestion of 
plant materials (44). Recommended daily allowances [RDA's] for vitamin E range from 7 to 13mg 
(10 to 201U) (28,32,46,47), while the average daily intake of this vitamin from a balanced diet is 
approximately 7 to 9 mg (11 to 14IU) (28,32,46,47). Vitamin E, although the least toxic of the fat-
soluble vitamins, can become toxic at doses above 1200IU (805mg/day). Symptoms of toxicity include 
nausea, diarrhoea, intestinal cramps, skin reactions, myopathy, gonadal dysfunction and altered 
vitamin K metabolism (32,46). 
The general overview of vitamin E metabolism is shown in figure 3. In nature a-TOH is found as 
free unesterified RRR -a-TOH (40). The absorption of this fat -solub Ie vitamin depends on pancreatic 
function, biliary secretion, micellar formation and transport across intestinal membranes 
(26,34,41,48). Most pharmaceutical preparations of vitamin E are supplied in the form of ~-TOH 
esters (36,37,40-42). These esterified TOHs are hydrolysed during the absorption process via the 
action of pancreatic enzymes (34,48), resulting in the release of free a-TOH which is absorbed by 
the intestine (26,34,40,41,48). 
1.2.4 PHYSIOLOGICAL PROPERTIES 
All TOH's are light-sensitive viscous oils with the following characteristics. They are insoluble in 
water but soluble in aprotic solvents, stable to heat and alkali in the absence of oxygen, unaffected 
by acids up to 100°C and slowly oxidised by atmospheric oxygen (26). 
1.2.5 DEFICIENCY DISEASES 
Despite many years of intensive research, and its wide acceptance as an essential nutrient, vitamin 
E's status in humans remains unclear. The search for a clinical correlation between TOH deficiency 
and deficiency diseases in humans has been based to a large extent on nutritional deprivation 
experiments in animals (26). In many instances vitamin E deficiency in animals results in diminished 
reproductive capabilities, muscular dystrophy, exudative diathesis, megaloblastosis, gastrointestinal 
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degeneration, pulmonary degeneration and nephrosis (26,37). Attempts to demonstrate clinical signs 
of human TOR deficiency have been unsuccessful due to the existence of extensive stores within the 
body (28,32,49), and the continual regeneration-of bi0logically active a-TOR by various components 
within the cells (32). Deficiencies in vitamin E do however occur in humans suffering from 
malabsorption syndromes and in premature infants (26,32,49). Furthermore these disorders bear 
superficial resemblance to vitamin E deficiencies observed in animals. Studies 4.-aye~suggested that 
alterations in vitamin status in humans may be associated with the development of various cancers 
(24,27,28,46,50,51). To date numerous epidemiological studies have consistently related low intake 
of vitamin E with increased susceptibility to cancer cell development (52-56). 
1.2.6 FUNCTIONS OF VITAMIN E 
Since its discovery, vitamin E has been plagued with exaggerated claims about its possible role in 
human and animal health, although no single primary metabolic role for vitamin E has been 
discovered as yet. Researchers believe that most of its proposed action within a cell, such as tumour 
prevention, may be secondary to its primary role as an antioxidant (32,57,58). 
1.2.6.1 Vitamin E's antioxidant role 
Although oxidation of cellular elements serves an important regulatory role, such as prostaglandin 
(PG) synthesis, this process is often destructive resulting in disruption of various cellular functions 
and causing leakage of intracellular contents (37,59). The oxidation of polyunsaturated fatty-acids 
(PUF A) and corresponding inhibition by an.tioxidants has recently received much attention, since free 
radical oxidation damage has been implicated in the etiology of a variety of human diseases such as 
cancers (8,60-71). 
Antioxidants are defined as a group of compounds protecting biological systems against the potentially 
harmful effects of processes or reactions that cause excessive damage (64,72). These antioxidants 
constitute an important endogenous defence mechanism against oxidative cell and tissue damage 
caused by toxic and carcinogenic chemicals (36). One antioxidant studied from this perspective is 
vitamin E (36,62,63,66-68,73), a major soluble antioxidant whose role in the cell is to prevent 
peroxidation of PUFAs in mammalian membranes (36,37,62,64,68,69,72-80). In addition to its role 
as a chain-breaking antioxidant, recent studies have demonstrated that a-TOR can quench singlet 
oxygen, either physically through an electron transport mechanism or chemically through the 
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formation of various oxidative products (36,81). Furthermore, a-TOH has close to optimal properties 
for trapping peroxyl radicals (39,82-84). These highly efficient antioxidant properties are believed to 
be due to the stereoelectronic effect of the oxygen at@m in the fully methyl substituted chroman ring 
of the vitamin (39,78,82-84), which not only makes the a-TOH react more rapidly with peroxyl 
radicals but gives greater stability to the resulting a-TOH peroxyl radical (39,78). The nature of the 
phytyl chain attached to the chroman moiety is believed to be important in deter,lIlining antioxidant 
effectiveness of the vitamin in vivo (39,77,78,82). The phytyl side chain is required to give the 
vitamin appropriate lipophilicity and solubility in biomembranes (77,78,82,83,85), and furthermore 
positions the vitamin so that the reactive centre is present where it is needed most (77,82,85). 
Figure 3 illustrates the reactions involved in the inhibition of lipid peroxidation by vitamin E. a-TOH 
traps lipid peroxide radicals via a two-step mechanism. In the first step (reaction 1), a peroxyl radical 
abstracts a hydrogen from the a-TOH molecule to yield an unusually stable tocopheroxyl radical (a-
TO") (36,39,72,74,78,79). This a-TO" reacts rapidly with another peroxyl radical via a simple 
coupling reaction to yield a non-radical adduct (reaction 2) (36,39,72,74,78). 
ROO· + a-TOH 
ROO' + a-TO" 
ROOH + a-TO' 
a-T(O)OOR 
(1) 
(2) 
Figure 3: Inhibition of lipid peroxidation by a-Tocopherol (modified from 74). 
Although an effective antioxidant, a-TOH only affords protection when its levels within the cell 
exceed a critical or threshold level (36). In general, approximately one molecule of a-TOH exists for 
every 500-1 000 PUFAs in membranes (36,59,86). Clearly these levels are extremely low and the 
question that may arise is how such low levels of a-TOH protect such large numbers of PUFAs (86). 
It has been suggested that various pathways may exist to maintain cellular a-TOH concentrations in 
membranes. This prevention of a-TOH consumption is often referred to as the "sparing effect" and 
is defined as the ability of one antioxidant to slow or prevent depletion of another. Like other 
biological antioxidants, a-TOH is believed to function through redox cycles, which deliver reducing 
equivalents for antioxidant reactions and link antioxidant function to cellular metabolism (36). 
Recently, numerous studies have shown a synergistic inhibition of oxidative damage with a 
combination of vitamin E and selenium (87,cited in 88); vitamin E and enzymatic reductants such as 
selenium-dependant glutathione reductase (88,89); vitamin E and vitamin C (36,66,67,78,80,90-96), 
as well as vitamin E and ,a-carotene (36,97). These antioxidant interactions strongly indicate a 
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requirement for optimal intake of all antioxidant nutrients, since even a marginal deficiency in one 
ofthese nutrients would result in a subsequent decrease i~ the bioactivity of other antioxidant nutrients 
even fhough recommended levels are consumed (62) •. 
1.2.6.2 Vitamin E and cellular membranes 
All cells are enveloped by membranes, and although they differ widely in chemical composition they 
-
all contain lipids, nature's solvent for vitamin E. Numerous observations have recently suggested that 
membranes are the cellular structures which become impaired during vitamin E deficiency (98). 
Vitamin E is believed to function as a chain-breaking antioxidant, neutralising free radicals and 
preventing peroxidation of lipids within the membranes (26,60,86,90,99). This rather specific 
property of the vitamin appears to reside in the ability of these membranes to bind vitamin E. 
Furthermore it has been shown that even when the diet has a sufficiency of various other synthetic 
antioxidants capable of preventing oxidative damaged in membranes, vitamin E appears to have an 
advantage over these antioxidants, due to its easier access and longer retention within membranes 
(26). a-TOH is believed to play an important physiological role in the stabilisation of biol,9gical 
membranes containing high levels of PUF As through a direct interaction between pnytyl side chains 
of a-TOH and the fatty acyl chains of PUFAs, particularly those of arachidonic acid. In this model, 
the methyl groups at C4 and Cg of the phytyl chain of a-TOH fit into pockets created by the cis 
double bonds of the arachidonyl residues (26,86,98,100), resulting in the hydroxyl group on the 
chromanol ring of vitamin E and the polar group of a membrane phospholipid lying at the same.end 
of the complex, where they are thought to participate in polar interactions at membrane surfaces 
(86,98). This association between methyl groups of a-TOH and pockets created by cis double bonds 
of PUFAs, enables close packing of the vitamin with these PUFAs, resulting in stabilisation of 
membranes and protection from oxidative damage (26,86,98). 
Vitamin E, through its membrane stabilising effect, guarantees that metabolic interactions based on 
and coupled with the membrane surface can occur undisrupted, in turn contributing to normal 
functioning of the cell (86). This suggests that vitamin E deficiency diseases observed at nutritional 
levels could be explained by membrane instability through absence of vitamin E or metabolic failure 
of pathways located in or coupled with membranes. 
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1.2.6.3 Vitamins E and nitrosamines 
Nitrosamines, products of the reaction of nitrite with<amines under conditions of low pH (t01), have 
been shown to induce a wide variety of tumours in most species of animals (58,101-103). Precursors 
of these n-nitroso-compounds, namely nitrates, nitrites and secondary or tertiary amines, are widely 
distributed in nature. Primary sources of these nitrites include water, vegetabI,cs and cured meat 
products (101-103). Nitrates present in these food sources are converted by bacteria in food and saliva 
-
to nitrites (103), which in turn react with primary, secondary and tertiary amines to form nitrosamines 
(10 1, 103). Although daily intake of nitrosamine precursors varies with the dietary habits of the 
individual (102), levels of nitrite in the body fluids are high regardless of whether or not a person 
consumes foods high in nitrite content (101). This suggests that a reduction in nitrosamine formation 
or activity may be a promising avenue for reducing exposure to potential human carcinogens (102). 
One compound with a potential inhibitory effect on nitrosamine formation is vitamin E (58,101-105). 
This antioxidant vitamin is believed to prevent nitrosamine formation in hydrophobic environments 
such as fatty tissue and membranes (101,103,104). Numerous animal studies have demonstrated a 
potential inhibitory role for vitamin E in nitrosamine formation and eventual cancer developmen! (58). 
1.2.6.4 Vitamin E and immunocompetence 
Considerable evidence suggests that a decline in immune function could increase the susceptibility of 
an individual to tumour cell development (60,106,107), and furthermore that numerous antio~idant 
vitamins such as vitamin E may play an important role in the defence against such diseases 
(26,57,58,60,106-108). Vitamin E deficiency is believed to result in a decreased immune response 
(108). The dietary levels of vitamin E which optimally affect the immune response are usually higher 
than what is available in human or animal diets (57), hence supplementation of vitamin E holds 
promise for therapeutic applications in cancer treatment (57,108). Numerous studies have shown that 
supplementation of pharmacological doses of vitamin E significantly increases humoral and cell-
mediated immune responses and phagocytic functions in laboratory animals, farm animals and humans 
(cited 57). The mechanism of immunostimulation by vitamin E is largely unknown, however studies 
suggest that the antioxidant properties of this vitamin may play an important role in protecting one 
or more of the cell types of the immunopoietic system (57,108,109) against peroxidative damage by 
free radicals, peroxides and superoxides (57). Recently however, a more indirect role for vitamin E 
in immunostimulation has been proposed. This theory suggests that vitamin E functions as a potent 
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immune modulator by down-regulating production of immune suppressive PG (57,106,108,110). PG 
production results in immunosuppression through the generation of cyclic adenosine monophosphate 
(cAMP), a known suppressor of immunological cellular activities (108). Studies by Meydani et al 
(106) have shown that a-TOH acetate enhanced immune response in aged mice and that these effects 
were associated with a decrease in PG synthesis. Further studies by Watson (cited in 58) demonstrated 
that vitamin E modulates retrovirus-induced immune dysfunctions by down-regul~ting prostaglandin 
E2 (PGE2) production in macrophage cells and up-regulating interleukin-2 production. The mechanism 
by which vitamin E functions to inhibit PG synthesis is at present unclear, but studies suggest that 
inhibition of PG production may be due to an inhibition of both the phospholipase A2 (PLA2) and 
cyclooxygense (COX) enzymes (cited in 110), or PLA2 enzyme alone (111). Since vitamin E may 
function as an immunostimulant, the potential use of vitamin E in immuno-therapeutic treatment of 
cancer may be an effective approach to treatment of this disease. 
1.2.6.5 Vitamin E and gene expression 
The P53 gene was discovered in 1979 as a host cell protein binding to DNA virus sv40 (112~,. This 
gene is commonly referred to as the "GUARDIAN OF THE GENOME" due to the faCt that it 
becomes active when DNA damage occurs. In essence, the P53 gene determines whether or not a 
damaged cell repairs itself or commits suicide (112-115). When a cell suffers DNA damage, the P53 
gene produces a 53 kDa protein which attaches to other genes and regulates their activities (112,113). 
Studies revealed that P53 proteins function to switch on a growth-arresting gene called CIPIWAF1 
(114). Activation of this gene results in the production of a protein which inhibits CdK2 kinase 
activity, an important factor in initiating cell division. This suggests that the P53 genes may help to 
check uncontrolled growth of damaged cells either by inhibiting cell growth directly (112) or 
stimulating apocytosis and programmed cell death (112-115). 
This may have important consequences for cancer development, since most cancer cells examined to 
date have mutated P53 genes. These mutant P53 genes render them unable to 'commit suicide' in 
response to DNA damage, and as a result proliferate out of control (112-114). Studies by Yamada 
et al (116) have found no P53 mutations in 19 primary lesions of gastric cancers, while in metastatic 
lesions, mutant P53 gene expression occurred. Tumour cells containing the mutant P53 genes are the 
most aggressive tumours and are particularly likely to spread and cause death (113). Recent studies 
by Schwartz et al (112) have shown that vitamin E succinate supplementation may inhibit squamous 
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cell carcinoma growth by stimulating the expression of wild type P53 gene (suppressor gene) and 
diminishing expression of mutant P53 gene. The mechanism(s) by which vitamin E may function to 
alter the levels of these genes is unclear, however Jh!ee possibilities have been suggested. These 
include a) direct stimulation of a cancer repressor gene; b) preventing mutation of P53 to an 
oncogenic form by promoting DNA repair during the transformation step; c) preventing mutation of 
other protooncogenes that function together with mutant P53 (112). 
1.2.6.6 Vitamin E and cancer 
The geographical distribution of various cancers, the changing patterns in migrant populations, and 
the varying incidence of specific tumours by socioeconomic groups, all point to diet and nutrition as 
important factors in the possible control and prevention of human cancers (46). Although there is no 
conclusive evidence that antioxidant nutrients administered in large doses have antineoplastic effects, 
the possibility exists that megadoses of vitamins may affect tumour incidence in mammals (50,51). 
One antioxidant nutrient currently receiving attention as a possible inhibitor of cancer is vitamin E. 
The anticarcinogenic effects of vitamin E have both been suggested (22,24,42,46,52,54,55,58,104, 
105,110,112,117-130) and disputed (24,25,52,104,105,119,120,129,131) by numerous researchers. 
Several animal (24,46,58,117,118,120,122) and human epidemiological studies (52,54,55,105,119-
121,130) have shown that vitamin E may protect against cancer incidence. 
The mechanism(s) by which vitamin E and its derivatives (vitamin E succinate) exert anticarcinogenic 
effects both in vivo and in vitro are unclear, however discrete modulatory effects have been explained 
in part by biochemical strategies utilized by these vitamins. It has been suggested that anticarcinogenic 
effects of vitamin E may be due to its antioxidant properties and ability to scavenge free radicals 
(22,24,46,54,58,105,109,112,117-122,127). Furthermore, the effect of vitamin E and its derivatives 
on tumour cell growth could be mediated through various metabolic pathways. One such pathway is 
the metabolism of arachidonic acid (AA) or the AA cascade (figure 4). This pathway converts AA, 
released via PLA2 activity, primarily to PGs through the action of prostaglandin H synthase (PGH 
synthase) and adenylate cyclase (A C) enzymes. This pathway is influenced by PLA2 activity and 
subsequent mobilization of the precursor fatty acid AA, as well as the calcium (Ca2+) requirement of 
a number of enzymes. Furthermore membrane stability and oxidative damage to membrane structures 
may play an important role in modulating the activity of these enzymes. Since this study involves an 
investigation of the influence of vitamin E supplementation on oxidative damage, as well as possible 
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influences on various metabolites mentioned above, their interrelationships, and possible role in 
tumour cell growth, a review of this pathway and its metabolites is necessary. 
Autoxidation 
YIembranes Lipid peroxidation - ~mA 
5-LOX I 
Tissue damage 
Phospholipase A 2 
LT - Arachidonic Acid (AA.) I Cyclooxygenase 
Prostaglandin G 
2 PGH Synthase I Hydeop,,"xide,, 
synthase 
Prostaglandin H (PGH ) ---, Prostaglandin D
2
,F
2 
,1
2 2 2 enzymes I PGE, ,ynthe" 
Prostaglandin E2 
I 
Adenylate Cyclase 
I 2+ Ca ,ATP Phosphodiesterase 
Cyclic Adenosine ~1onophosphate ------.. , 5:....A~IP 
I 
Effect 
Figure 4: Schematic representation of the AA cascade pathway examined in this project. (AMP-
Adenosine monophosphate, ATP-Adenosine triphosphate, LT-Leukotrienes, LOX-Lipoxygenase, 
MDA-MalondiaJdehyde). 
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1.3 FREE RADICALS AND LIPID PEROXIDATION 
-
Although an aerobic lifestyle is advantageous in many ways, the utilization of oxygen by cells results 
in the production of highly reactive oxygen-containing species called free radicals (60,61,75). A free 
radical is defined as a molecular species capable of independent existence and possessing one or more 
unpaired electrons (8,61,62,64,65,132). In biological systems free radical species.can be formed in 
one of three ways. These include homolytic cleavage (65,133), heterolytic fission (65) and electron 
transfer reactions (65,133). Except in unusual circumstances, free radical production in mammalian 
cells generally occurs via electron transfer reactions. These reactions can be mediated both 
enzymatically through the action of various enzymes and non-enzymatically through the redox 
chemistry of various transitional metal ions. Arguably the most common free radical generated in vivo 
is the hydroxyl radical (OR), which is derived from the breakdown of hydrogen peroxides (R20 2) 
in the presence of transitional metal ions (65). These radicals are extremely reactive oxidising agents 
which react with numerous macromolecular structures causing extensive damage (5,61,65,75). Under 
normal circumstances the major source of free radicals in mammalian cells is through electron leakage 
from the electron transport chains located in the endoplasmic reticulum and mitochondria. 
Of all the major classes of biomolecules attacked by OR radicals, membrane lipids are probably the 
most susceptible, due to the high levels ofPUFAs (65). The oxidative destruction ofPUFAs is known 
as lipid peroxidation and is extremely damaging as a result of the self-perpetuating chain reactions 
they cause (65,75,133). Figure 5 illustrates the 3 features which characterise the lipid peroxidation 
process. During the initiation step (reaction 1) PUFAs are attacked by free radical species (In"), 
resulting in abstraction of a hydrogen atom from precursor PUF A (RH) and formation of delocalized 
pentadienyl radical (R). The propagation step (reaction 2) normally begins with the rapid addition 
of molecular oxygen to R, to form lipid peroxyl radical (ROO"), followed by a rate limiting step 
(reaction 3), whereby the ROO- abstracts a hydrogen from another PUFA, in turn generating lipid 
hydroperoxide (ROOR) and another R. This propagation step results in a chain reaction being set in 
motion which proceeds through reactions 2 and 3 for a number of cycles (39,65,72,75,133,134). The 
third and final step (reaction 4) is the termination step, which results in 2 ROO- radicals reacting 
together to form non radical products (39,72,75,134). 
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Initiation: In' + RH InH- + R Reaction 1 
Reaction: 'Ron Reaction 2 (Fast) 
Ron + RH -+ R + ROOH Reaction 3 
Termination: 2ROO' Non-radical 
products 
Figure 5: Chain sequence for free radical autoxidation (134). 
Reaction 4 
Since some free radical production is inevitable in cells, and lipid peroxidation is the major 
consequence of free radical action, several finely balanced enzymatic and non-enzymatic (vitamin and 
mineral) antioxidant defence mechanisms have evolved to protect cells (62). This suggests that even 
slight alterations in antioxidant balance, through exposure of cells to sources which overwhelm 
antioxidant defences, or inadequate uptake of nutrients such as vitamin E, could contribute to a 
prooxidant state and the development of various cancers. 
1.3.1 FREE RADICALS, LIPID PEROXIDATION AND CANCER 
Substantial evidence has implicated free radicals, particularly those derived from oxygen, in both the 
initiation (8,135,136) and promotion (5,7-9,135-137) stages of carcinogenesis. Numerous1!Irnour 
initiators have been shown to produce oxygen radicals during their action. Furthermore in recent 
years it has become clear that free radicals may be involved in the enzymatic activation of various 
chemical carcinogens. One example is the reaction of peroxyl radicals with 7,8-dihydroxy-7,8-
dihydro-benzo-(a)-pyrene which results in the formation of dihydrodiolepoxide, the ultimate 
carcinogenic form of benza-(a)-pyrene (8). Many classes of tumour promoters are believed to act 
through an oxidant mechanism (7-9,12). 
Although evidence at present suggests a link between the generation of free radical species and tumour 
initiation (8,136) and promotion (5,7-9,136,137), the molecular mechanisms involved in alteration 
of a normal cell to a malignant cell are unclear. One potential mechanism by which free radicals may 
modify phenotypic expression is through interaction with a variety of macromolecules within the cell 
(5,7-9,132). DNA is one potential target for free radicals. Damage to DNA by these radical species 
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can cause mutations that may be carcinogenic (5,7-9,62,121). Recently lipid peroxidation, a 
consequence of free radical attack of PUF As, has been linked to events promoting carcinogenesis 
(138,139). It has been suggested that peroxidation prOducts such as malondialdehyde (MDA) (7,138-
140) and 4-hydroxynonenal (135,138) are potential mutagens capable of binding to DNA and causing 
DNA damage and mutagenesis. Furthermore ROO- derived from peroxidation of PUFAs, and 
hydroxyl radicals have been implicated in protein damage. Free radical protein- damage is often 
complex and irreversible, and frequently leads to large scale structural changes such as protein 
unfolding, polypeptide chain scission and crosslinking (132). These structural alterations of proteins 
within and around the cell may play an important role in transformation of normal cells to tumour 
cells. 
1.4 CELL MEMBRANES 
Biological membranes are essential for cellular life and function as compartmentalizing structures, 
separating tissues from cells, and cells into organelles. This compartmentalising effect of membranes 
not only brings together molecules taking part in metabolic reactions, but also regulates the 
concentration of ions and molecules within these compartments. Furthermore cell membranes allow 
specific and spatial organisation of macromelecular complexes, which function as sensors of external 
signals and enable the cells to change their behaviour in response to these signals (98,141). Despite 
their varying functions, cell membranes have a common structure. The currently accepted model of 
membrane structure was put forward by Singer and Nicholson in 1972. They proposed a fluid mosaic 
model for the gross structural organisation of biological membranes (98,142,143). In this model, 
biological membranes are believed to be a dynamic, irregular lipid mixture of phospholipids and 
cholesterol with a heterogenous set of globular proteins embedded across the membranes to varying 
degrees (98,141-145). Phospholipids are the most abundant lipids found in cellular membranes 
(141,143). These lipid molecules are amphipathic due to their polar head groups and non polar 
hydrocarbon tails. This amphipathic nature allows phospholipids to spontaneously form bilayers in 
aqueous solutions (98,141,143). Apart from their role in bilayer arrangement, phospholipids may be 
closely associated with integral proteins or loosely associated with peripheral proteins (98,141-
143,145). These proteins have important cellular functions as receptors (141,142,144,146-148), 
transporters (142,146,148) and enzymes (144,146-148). The protein content of membranes varies 
among different membranes and appears to be directly related to the functional role of these 
membranes (142). Besides their self-sealing properties, lipid bilayers have numerous other properties 
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which are believed to be important for maintenance of cellular functions (141). The most important 
of these is fluidity, which is believed to be important for the functioning of those proteins whose 
actions depend on mobility within the plane oIthe membrane (147). Changes in membrane fluidity 
through physical and chemical perturbation are believed to alter numerous membrane functions such 
as receptor characteristics (146,147,149), transport (144-146,150-152), and activities of membrane-
bound enzymes (144-149,153-157). r _ ~ 
1.4.1- TUMOUR CELL MEMBRANES 
Membrane fluidity is now believed to play an important role in processes ranging from passive 
permeability and lateral diffusion to cell recognition, differentiation and malignant transformation 
(158). Cell membranes isolated from tumours show significant alterations in membrane composition 
(159-161), structural organisation (143,159-162), and functional properties (159,160). One important 
characteristic of tumour cell membranes is that they generally exhibit decreased membrane fluidity 
(39,159,161). These changes in physical (membrane fluidity) and chemical properties of tumour cell 
membranes are believed to be due to a free radical-mediated mechanism involving lipid peroxi~ation 
(159). Numerous studies have shown that oxidative modification of PUFAs by liptd peroxidation 
results in a significant decrease in membrane fluidity (increased membrane rigidity) (150-
152,156,159,163,164). This peroxidation-induced alteration in membrane fluidity is believed to be 
due to a decrease in unsaturated:saturated fatty acid ratio, a change in chain length percentage 
distribution of fatty acids, and possibly covalent crosslinks between adjacent lipid radicals fOI:ll)ed in 
membranes (151,152). 
1.5 PROSTAGLANDIN H SYNTHASE AND PROSTAGLANDINS 
PG synthesis is characterised by three distinct phases. These are; a) activation of specific PLA2 and 
release of the precursor fatty acid AA; b) sequential conversion of AA by PGH synthase to 
prostaglandin G2 (PGG2) and then prostaglandin H2 (PGH2); c) isomerisation or reduction of PGH2 
to biologically important prostanoids eg prostaglandin D2 (PGD2), E2 (PGEz), F2a (PGF2J, 12 (PGI2) 
and thromboxane A2 (TXA2) (165,166). The rate of synthesis of PGs is believed to be regulated by 
PLA2 activity and AA release, while net production of PGs is dependant on the levels of the PGH 
synthase enzyme (166). 
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1.5.1 STRUCTURE AND PROPERTIES OF PROSTAGLANDIN H SYNTHASE ENZYME 
The PGH synthase (Ec 1.14.99.1) is found in virtually all mammalian tissues (167-170), and functions 
primarily to catalyse the first committed step in the AA cascade pathway that produces PGs, 
thromboxanes (TXs) and prostacyclins (165,166,171-174). This enzyme is a haemoprotein which has 
two activities, a COX activity which catalyses the bis-dioxygenation of A~_ to hydroperoxy 
endoperoxide PGG2 and a peroxidase activity which reduces PGG2 to its 15-hydroperoxy analogue 
PGH2 (165-169,173-179). Both activities require heme (167-169,174,176,178,179) and are believed 
to reside in a single polypeptide of MW 69 000 (167). 
The COX reaction requires fatty acid substrates containing at least three methylene-interrupted cis-
double bonds (165,167,180) and the continued presence of a hydroperoxide activator (165,168,169, 
175,176,181-183) during catalysis. The most common COX sllbstrate in vivo is AA (165), although 
a variety of hydro peroxides can trigger the COX activity (168,182) of which lipid peroxides generated 
by LOX activity are the most potent (182). Numerous non-steroidal anti-inflammatory drugs compete 
with substrate AA for binding to the cyclooxygenase active site and result in irreversible inacti,yation 
of the cyclooxygenase enzyme (167,174). The peroxidase activity ofPGH synthase oil the dtlier hand 
is not inhibited by non-steroidal anti-inflammatory drugs and exhibits less substrate specificity 
(165,171,179,184,185). PG hydroperoxidases, like most peroxidases, utilize a wide variety of 
hydroperoxides and reducing substrates (171,177,184, 185). 
Both the COX and peroxidase activities of PGH synthase enzyme are irreversibly inactivated 
following several thousand turnovers (approximately 1 in 5000) (171,186). It has been proposed that 
this inactivation results from the attack of a free radical species (oxidising agent) formed by the 
hydroperoxidase activity. Such a deactivation process can be partially prevented but not reversed by 
a variety of reducing agents, resulting in an increased number of enzyme turnovers 
(171,184,185,187). The presence of a highly efficient hydroperoxide reducing activity appears 
essential for the protection of COX capacity of PGH synthase. At present two isoforms of PGH 
synthase are believed to occur, a PGH synthase-l (COX-I) enzyme and a PGH synthase-2 (COX-2) 
enzyme (170,174,188-194). These two enzymes, although similar at the protein level, differ markedly 
at the gene level (194). The COX-l enzyme is believed to be constitutively expressed (174,188-
190,192,194) and is characterised by a 72 kDa, membrane bound, N-glycosylated heamoprotein 
(170,174). Most of the current knowledge on PGH synthase enzyme structure and function has come 
18 
1. Literature Review 
from studies with the COX-l enzyme (174). It is generally believed that this enzyme is located in the 
endoplasmic reticulum and/or nuclear membrane (170,172-174,195), although other studies have 
shown the presence of COX-l in plasma membranes .(196) and non-membrane bound lipid bodies 
(197). Figure 7 illustrates the predicted topology of the cyclooxygenase enzyme in the endoplasmic 
reticulum with its various functional domains. In this model the terminal amino (NH2) and carboxyl 
(COOH) groups are separated by a single transmembrane spanning region (see figure 6). The COOH-
r - _ ... 
terminal end of the protein is believed to be cytoplasmic and contains both the peroxidase and COX 
domains. The NHz-terminal portion of the protein on the other hand has three glycosylation domains 
and possibly an epidermal growth factor-like domain (173,198). 
GLYCOSYLATION SITES 
EPIDERMAL GROWTH FACTOR 
DOMAIN 
................... , 
MEMBRANE 
••••••••••••••••••• 1 
PEROXIDASE DOMAIN 
CYTOPLASMIC DOMAIN 
DIOXYGENASE DOMAIN 
COOH 
Figure 6: Predicted topology of cyclooxygenase enzyme in the endoplasmic reticulum (173). 
The COX-2 enzyme is not expressed constitutively but rather induced rapidly and transiently by a 
variety of factors such as reactive oxygen species (199), PGE2 (189,192), PGF2c<, PGD2 (189), 
interleukin-l/3 (191) and lipopolyssacharides (188,192). COX-2, like COX-I, is located in the 
endoplasmic reticulum and nuclear membrane (174). Comparison of the primary amino acid sequences 
of COX-l and COX-2 have shown dissimilar signal peptides in these enzymes and a unique C 
terminal segment of 18 amino acids, present only in the COX-2 enzyme (170,174). 
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1.5.2 MECHANISM OF PROSTAGLAl'{DIN H SYNTHASE ACTION 
. AA, or 5,8,1l,14-eicosatetranoeic carboxylic acid, is ':l 20 carbon PUFA which contains-4 carbon 
double bonds at C 5,8,11 and 14. This PUFA is a precursor fatty acid for the two-series PGs (200). 
The conversion of AA to PGG2 (175,178,181-183,186,201) and PGG2 to PGH2 (175,178,179, 
181,183-187,201,202) has been extensively studied and is shown schematically inJigyre 7. 
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Figure 7: Proposed mechanism for prostaglandinH synthase enzyme (168). (Steps 1-6 represent the 
COX activity while steps a-d represent those catalyzed by the peroxidase activity. FH- PUFA, F-
Lipid radical, CH- Reducing reagent). 
When the COX reaction is initiated, ROOH interacts with the enzyme (EHEME) to form an enzyme-
bound hydroperoxy radical (EHEME_ROOH-F02) (175,181). Next the FA radical reacts with oxygen 
at carbon 11 resulting in cyclisation and the addition of another oxygen molecule .at C15 
(173,175,181,202). To complete the cycle, the resulting 15-hydroperoxy radical (EHEME_ROOH-F02-) 
abstracts a hydrogen from the enzyme-bound ROOH to yield the end product PGG2 and initiates 
another cycle (175,186). The self-catalyzed destruction of the COX enzyme is represented in figure 
7 by reaction 6. This self-catalyzed inactivation is a separate feature intrinsic to COX catalysis (181) 
and is believed to result from the intramolecular collapse of the enzyme (175). 
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The peroxidase enzyme converts PGG2 to PGH2 by reducing the hydroperoxide group on C15 of 
PGG2 to a hydroxyl group (177 ,179,184,186). Peroxidase cosubstrates (reducing agents) significantly 
increase COX activity prior to self-catalyzed inactivation (175,181). During peroxidase activity (steps 
a to d in figure 7), non-productive oxidised forms of the COX enzyme (EHEME_O) occur. Various 
reducing agents convert these inactive oxidised forms of the COX back to an active reduced form 
(EHEME), and in turn stimulate PGH synthase activity (181). This suggests that ,YjtC!Jllin E with its 
ability to act as a reducing agent could increase the activity of the PGH synthase enzyme by 
-preventing the formation of these oxidised forms of the COX enzyme. 
1.5.3 PROSTAGLANDINS 
In the early 1930s studies by Kurzok and Lieb revealed that human semen contained a factor which 
caused the uterine tissue to contract or relax violently. At about the same time van Euler characterised 
the biological effects and the chemical nature of this unknown factor and described it as an acidic lipid 
which he later named PG (203,204). It is now well established that PGs are a series of closely related 
20 carbon unsaturated fatty acids (203,205-207), derived both enzymatically and non-enzyma!ically 
from AA (204,205). ' 
1.5.4 BIOSYNTHESIS OF PROSTAGLANDINS 
PGs are not stored to any great extent in mammalian tissues (203,208-212), but are r~pidly 
synthesised upon physiological simulation (208,209,212). This process involves release of the 
precursor fatty acid AA and subsequent oxidation by PGH synthase to endoperoxide PGH2 (see 
section 1.5.2). PGH2 is an important intermediate in that it occupies a pivotal position in the 
divergent pathways (figure 8) which lead to the synthesis of various PGs and TXs 
(165,167,169,173,208,209). 
The amount and type of PG synthesised by a cell depends largely on the cell or tissue type 
(165,166,169,200,205,209,213), although most PG synthesising cells predominantly synthesise one 
type of PG due to the existence of a single PGH2 metabolising enzyme (165,169). The formation of 
biologically active PGs from PGH2 occurs through the action of specific synthase enzymes called PGD 
synthase, PGE synthase, PGF synthase and PGI synthase respectively (165,169,173). 
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Figure 8: Divergent biosynthetic pathways of Prostaglandin and Thromboxane synthesis (169). 
1.5.5 PROSTAGLAl\TJ)IN SYNTHASE ENZYMES 
1.5.5.1 Prostaglandin D synthase 
, 
This enzyme is found predominantly in the cytosol of the cell (169,195,204), where it functions to 
convert PGH2 to PGD2 (165,169,173,176,195). This conversion involves the isomerisation of the 
9,II-endoperoxide moiety ofPGH2 to 9 a-hydroxy and ll-keto groups (figure 8) (165,169). 
1.5.5.2 Prostaglandin E synthase 
PGE synthase catalyses the conversion of PGH2 to PGE2 , and is involved in the isomerisation of 9,11 
endoperoxide to 9-keto and 1 la-hydroxyl groups (see figure 8). This enzyme is membrane bound 
(195) and requires coenzyme glutathione for activity (169). The formation ofPGE2 from PGF2a may 
also occur in the presence of the enzyme 9-hydroxy dehydrogenase (204). 
1.5.5.3 Prostaglandin F synthase 
Figure 8 depicts three possible ways in which synthesis of PGF2a can occur. In the first mechanism, 
PGF synthase enzyme catalyses the reductive cleavage of the 9,1l-endoperoxide of PGH2 to form 
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PGF2a, although at present the nature of the enzyme and reducing agent remain unclear (169,214). 
The second pathway involves the conversion of PGE2 to PGF2a• This reaction is catalysed by the 
enzyme 9-keto reductase -and involves the reductiono( the keto group at C-9 in PGE2 to a hydroxyl 
group (PGF2J (169,200,204,214). The reduction of the 11-keto group ofPGD2 via the action of 11-
keto-reductase is a third possible mechanism through which PGF synthesis may occur (169,205,214). 
1.5.5.4 Prostaglandin I synthase 
The formation of PGI2 from PGH2 is catalysed by PGI synthase and involves the isomerisation of 
9, 11-endoperoxide ofPGH2 into a 6,9-epoxide and an 11a-hydroxyl group (see figure 8) (169). PGI 
synthase is a membrane bound enzyme (176,196) which is inactivated by a variety of lipid 
hydroperoxides (169,176,215-217) and oxygen-containing free radic .. ls generated during PGH 
synthase activity (200). 
1.5.6 FUNCTIONS OF PROSTAGLANDINS 
PGs are cell-to-cell messengers produced by eukaryotic cells in response to external stimuli (213). 
Over the past few years, PGs have attracted a great deal of attention due to their versatility and wide 
range of biological effects (203,204,207,210). These effects may be specific within a cell, although 
in general PGs effects are based on certain broad processes such as regulation of blood pressure, 
reproduction, neural and cardiovascular systems (203,207,210). Furthermore these wide-rap.ging 
effects are believed to be mediated via a common mechanism involving alterations in cAMP levels 
(203,207,210,218). Evidence suggests that PG production is related to cell growth (210,219), and that 
cells in the quiescent state are the most active PG producers (219). 
1.5.6.1 Prostaglandin ~ Functions 
PGE2 is known to be a potent vasodilator (173,200,203) and bronchodilator (173,200,203,204) in 
vivo. In addition to this, E2 PGs are believed to regulate the cell kinetics of the gastrointestinal 
epithelium cells (220), and are capable of increasing cAMP levels in certain cells via the activation 
of the adenyl ate cyclase enzyme (210,218,221-224). 
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1.5.6.2 Prostaglandin Dz Functions 
The bIological function of PGD2 is at present uncle<w (225) although PGD2 has been described as an 
antithrombotic agent (176,225,226) and neuromodulator (169,225). Furthermore PGD2 has been 
shown to inhibit DNA (225-230), RNA and protein synthesis in various cell lines (225,229,230). 
1.5.6.3 Prostaglandin Flo< Functions 
PGF2a is a potent vasoconstrictor (173,200,203) and bronchoconstrictor (173,200,204). These effects 
are in contrast to PGE2 effects, and have important implications in certain systems such as the 
cardiovascular (203,210) and pulmonary systems (173,210). 
1.5.6.4 _ Prostaglandin Il Functions 
PGI2 is a potent inhibitor of platelet aggregation (173,176,210,226) and in some systems is thought 
to act as a vasodilator (173,176,210). In addition to this, PGI2 is believed to elevate cAMP ley'els in 
various cell lines (176,223,224), possibly via a PG~ receptor-linked AC enzyme (176). Tiiis PG~­
induced increase in cAMP levels is believed to mediate anti-aggregatory properties of PG~ on 
platelets (176). 
1.5.7 PROSTAGLANDINS AND CANCER 
PGs and related eicosanoids have been implicated as modulators of tumour metastasis 
(205,207,209,231-235), tumour promotion (205,207,209-211 ,234,236), host immunoregulation 
(205,206,211,233-235,237) and cell proliferation (205,209,211,218,221,222,234,237-241). This 
suggests that an oversynthesis or imbalance in PG synthesis could promote tumour cell development 
(210). Some of the earliest studies to demonstrate a link between PGs and carcinogenic tissue were 
those of Williams in 1966 (cited in 207,210,241), in which elevated levels ofPGE2 and PGF2" were 
found in tumour tissue and plasma of patients with medullary carcinoma of the thyroid. Since these 
discoveries, a large body of experimental evidence has suggested that PG levels, in particular PGs 
of the E-series, were greatly enhanced in a number of tumour cells (205-207,209,210,234,241-244). 
These prostaglandins are potent immune suppressors, and are believed to facilitate tumour growth by 
compromising the immune system (206,207,232,234,235,245,246). In contrast, other researchers have 
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proposed that increases in PG synthesis observed in tumour cells may represent a homeostatic 
response directed towards limiting tumour cell growth (207,210). PGEz has been shown to 
significantly inhibit the growth of various tumour cell lines, both in vitro (247-251) and in vivo 
(252,253). This inhibitory effect is thought to be associated with activation of the AC enzyme and 
synthesis of cAMP (205,248). 
It is well established that tumour cells can induce platelet aggregation (cited in 232). This inherent 
property may play an important role in guaranteeing the survival of tumour cells and their ability to 
metastasise (254). Both PGDz and PGIz are potent inhibitors of platelet aggregation (see section 
1.5.6.2 and 1.5.6.4). The metastatic potential of tumour cells is believed to be inversely related to 
PGDz (255-257) and PGIz (254) formation in these cells. Furthermore, both PGDz (227-230,258-260) 
and PGIz (261) have been shown to significantly inhibit the growth of various tumour cell lines in 
vitro. 
1.6 CALCIUM 
Calcium ions are the most abundant cations found in vertebrates, making up approximatelY 20-30g 
per kilogram of body weight in humans. The majority of this calcium is trapped in bones where it 
plays both a structural and functional role (262). In this study the association of Ca2+ with COX, 
LOX, PLAz, AC and phosphodiesterase (PDE) activity will be highlighted. 
1.6.1 CHARACTERISTIC PROPERTIES OF CALCIUM 
Although Caz+is present in large amounts in the diet, its function for the survival of an organism is 
so important that cells have developed numerous ways to utilise these large Caz+ deposits (262). To 
date Caz+ ions, characterised by their charge, coordination number, and unhydrated radius (263), are 
known to play an important role in processes such as muscular contraction, stimulus secretion 
coupling, transduction of hormonal information and neuronal conduction (145). More recently the 
discovery of calcium-dependant regulatory proteins has suggested a role for Caz+ in the modulation 
of various metabolic processes within the cell (263-265). One such Caz+ binding protein is calmodulin, 
a ubiquitous, acidic low molecular weight Caz+ binding protein whose role in mammalian cells is to 
modulate the activity of a large number of enzymes (265,266). 
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1.6.2 FUNCTIONS OF CALCIUM 
1.6.2.1 Calcium and enzymes 
PLA2 (267-274), AC (263,265,266,275), PDE (263,264,275), COX and LOX (276) are all examples 
of enzymes whose activities are modulated by Caz+ or Caz+ -binding proteins such,as c~lmodulin. The 
role of Ca2 + in regulating PLA2 activity is believed to be 3-fold, namely through activation of protein 
-
kinase C and subsequent phosphorylation of PLAz, direct stimulation of PLA2 activity and through 
a Ca2+ requirement of G-proteins involved in PLA2 activation (267,272). AC enzymes are closely 
associated with sites of Ca2+ entry (263,277) into the cell, where they form a reversible Caz+-
dependant complex with calmodulin during Ca2+ influx (263). Furthermore it has been proposed that 
millimolar concentrations of Ca2+ may alter membrane fluidity in a variety of tissues and that these 
changes _ in bilayer fluidity may affect the activities of a number of membrane-bound enzymes (cited 
in 145). 
1.6.2.2 Calcium and cell proliferation 
CaZ+ metabolism is of paramount importance to cell proliferation, and may be involved in the 
regulation of numerous biochemical activities (278,279). Caz+ availability is the key regulator of cell 
proliferation in multicellular organisms, and a defect in the Ca2+ system is believed to be the common 
cause of unrestrained proliferation in cancer cells (278). 
CaZ+ (278,280,281), as well as calmodulin (279,281,282), have been implicated in the control of 
some of the most important transitions of the cell cycle, suggesting that proliferation rates of both 
normal and cancer cells may be controlled by the availability of Caz+ Icalmodulin within the cell at 
specific points and times during the cell cycle. Unlike normal cells, malignant cells loose the ability 
to maintain cytoplasmic Ca2+ concentrations below a critical point (283), and as a result 
hypercalceamia is a common complication of various types of cancers (284-287). One important 
consequence of this is that Caz+requirements of neoplastic cells are very low in comparison to normal 
cells (278). Numerous in vitro studies (279,288,289) have shown that various neoplastic cell lines 
have the ability to proliferate in Ca2+deficient media, whereas non-neoplastic cells require the 
presence of Ca2+ supplemented media for growth. This suggests that the unrestrained growth observed 
in various cancers may be due to a bypass or overriding of Caz+control processes present in normal 
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cells. 
1.7 PHOSPHOLIPASE A2 
Over the last few years, knowledge of the diversity of forms and functions of mammalian 
phopholipases has increased to a great extent, although the importance and functions of various PLAz 
isoforms have yet to be fully defined. 
1.7.1 CLASSIFICATION AND PROPERTIES OF PHOSPHOLIPASE A2 
PLA2 activity has been found in almost every cell where it has been sought (290). The A2 
phopholipases are a heterogenous family of enzymes, classified into low MW 14 kDa secretory PLA2 
(sPLA2) and the more recently identified high MW 60-110 kDa cytosolic PLA2 (cPLA2) (291-297). 
The most thoroughly characterised PLA2s are the 14 kDa sPLA2s. Mammalian group II PLA2s are 
found abundantly at inflammatory loci, and are believed to play an important role in both the initiation 
and progression stages of inflammatory responses (291,298). The 14 kDa PLA2 enzyme ha~ been 
biochemically characterised as active at neutral to alkali pHs (293,295) and requires Ca2+ in the 
millimolar range for typical activity (272,293-296,299). Furthermore this enzyme shows no selectivity 
towards fatty acids at Sn2 position of phospholipids (292-294,299). The 85 kDa cPLA2 is present in 
the cytosol of many cells and differs from the 14 kDa PLA2 enzymes, in that it is translocated to the 
membranes in response to JLM Ca2+ concentrations and preferentially hydrolyses arachidonic -acid 
esterified at Sn-2 position of phospholipids (291,293,295,297,299). In addition to this, cPLA2s have 
Ca2+ binding sites similar to protein kinase C and GTPase activating protein (299). 
Numerous factors influence the activity of PLA2 enzymes within a cell. Studies with both pancreatic 
and serum PLA2s have shown that substitution of Ca2+ with various other ions such as Sr2+ 
completely inhibits the activity of these enzymes (300). PLA2 activity is enhanced when non-ionic 
phospholipids are hydrolysed as opposed to hydrolysis of neutral phospholipids (268,290,292,300, 
301). This increase in PLA2 activity is due to anionic phospholipids enhancing the affinity of PLAz 
enzymes for Ca2+ (268,292). The activity of PLA2 in human platelets has been shown to be 
significantly increased when separated from endogenous lipid inhibitors (302,303). Evidence suggests 
that the endogenous lipid inhibitor may be associated with a mixture of PUF As (302), and 
furthermore that PUFAs, in particular AA, inhibit PLA2 either competitively (304) or non-
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competitively (302). This inhibition of PLAz activity by AA suggests that a negative feedback 
mechanism may be operating to regulate PLAz activity (304) and the levels of free AA within a cell 
-
(274). In contrast to endogenous inhibitors, PLA2-aetivating proteins (PLAP) have been'identified 
(293,305) which function to stimulate PLAz activity by directly interacting with the enzyme 
(293,295,305). 
1. 7.2 PHOSPHOLIPASE A2 FUNCTIONS 
PLA2 plays a key role in membrane turnover, membrane remodelling, exocytosis (297) and repair of 
oxidative damage (297,306). In addition to this, PLAz plays a crucial role in normal cellular 
metabolism, where it functions to produce rate-limiting substrate AA for synthesis of important lipid 
mediators such as eicosanoids (273,291:-297,299,304) and platelet activating factor (272,291-
294,297,299). Products of PLA2 catalysis, such as free fatty acids and lysophospho- glycerides, may 
also function as intracellular or intramembrane signalling molecules (297,300). 
1.7.3 REGULATION OF PHOSPHOLIPASE A2 ACTIVITIES BY G-PROTEINS 
Two major routes of receptor-mediated regulation have been implicated in the control of AA 
mobilisation and release (293). These two routes include direct activation of PLA2 via a receptor-
linked G-protein (272,293,307-318) and indirect activation through a phospholipase C-mediated 
pathway, increasing Caz+ levels (269,274,293) and activating protein kinase C (267,270,274,293, 
299,308,310,312). 
Several receptors have now been characterised that are coupled to G-proteins (319). These G-proteins 
are found in all eukaryotic organisms and are believed to play an important role in linking surface 
receptors to membrane-bound effector proteins (319,320). Although several G-proteins have been 
characterised, the G-proteins that are coupled to PLAz enzymes have not been identified (307). 
Numerous studies (308,316-318) however have shown that G-protein-dependant PLA2 activity exhibits 
characteristics which deviate from a typical G-protein-coupled effector system (308) in that {3'Y 
subunits stimulate PLAz activity while a-subunit inhibit the enzyme by facilitating reassociation of 
heterotrimeric complex (a{3'Y) of G-protein. 
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1.8 ADENYLATE CYCLASE, PHOSPHODIESTERASE AND CYCLIC ADENOSINE 
MONOPHOSPHATE 
The AC enzyme was first discovered in 1957 by Sutherland and RaIl (321). This enzyme catalyses 
the conversion of adenosine triphosphate (ATP) to cAMP (265,321), an important intracellular 
mediator of the action of various hormones (157,265,322-324) such as biogenio-arnines, proteins, 
polypeptides and some PGs (265). PDE enzymes on the other hand catalyse the non-reversible 
hydrolysis of cAMP to 5'-AMP (324-326). These enzymes share with the adenyl ate cyclases the 
important functions of both the delicate control of cyclic nucleotide levels and their myriad important 
effects within the cell (324,326). 
1.8.1 ADENYLATE CYCLASE STRUCTURE AND PROPERTIES 
The AC enzyme is a membrane bound enzyme (157,321,323) found in most types of mammalian cells 
(168,233), lower animals, unicellular organisms, bacteria and probably plants (321). Cloning ofthese 
enzymes has revealed that ACs are large polypeptides (figure 9) of 1080-1248 amino acids which 
- -..,' 
cross the membranes 12 times in two cassettes of 6 transmembrane-spanning domains, with each 
cassette followed by a large cytosolic domain (277 ,327). 
Figure 9: Structural model of adenylate cyclase (modified 327). (N- amino terminal region of 
proteins; M j and M2 - first and second membrane-spalming domains. C j and C2 -predicated 
cytoplasmic domains). 
Initially the hormone sensitive AC was believed to be composed of three distinct protein components, 
namely a receptor for binding hormones, a catalytic unit for producing cAMP from A TP, and a 
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guanine nucleotide binding protein (G-protein), which acts as a transducer between receptor and 
catalyt:ic subunits (144,145,154,157,265,328-330). More recently however, the hormonally regulated 
adenyl ate cyclase system was shown to include S components: a stimulatory receptor (Rs); a 
stimulatory guanine nucleotide binding protein (Gs) composed of 3 subunits a, (3 and '1'; a catalytic 
moiety of AC; an inhibitory receptor (Ri); and an inhibiting GTP-regulatory protein (Gi), composed 
of a, (3 and '1' subunits (145). These components are asymmetrically dispersedrwithin the plasma 
membranes (145,157), such that the receptor components which interact with specific circulating 
hormones face the external surface of the cell, while the catalytic unit responsible for the formation 
of cAMP from ATP faces the inside of the intact cells (145,265,331). These components are believed 
to be able to undergo independent lateral diffusion within the plane of the membrane, interacting 
functionally and structurally only in the presence of appropriate stimulatory ligands (145,157,265). 
1.8.2 -PROPERTIES OF ADENYLATE CYCLASE COMPONENTS 
1.8.2.1 Receptor component 
' .. 
Receptors for various hormones are individual proteins distinct from adenylate cyclase enzyme. These 
receptors are located on the external surface of the cell and interact with the membranes via a small 
hydrophobic region (265). Various hormones which act via the AC enzyme are believed to recognise 
and bind to specific receptors on the cell surface (332-335), although some receptors are able to bind 
more than one hormone (265). 
1.8.2.2 Nucleotide regulatory proteins 
The G-proteins, located on the cytosol-facing half of the membrane (145), play an important role in 
that they modulate the activity ofthe hormone-sensitive AC enzyme (265,328,329,336,337) and exert 
specific regulatory effects on agonist binding to receptors (265,329). The AC enzyme is believed to 
possess two separate guanine nucleotide regulatory sites. These include a Gi or Ni site which mediates 
the inhibition of the AC enzyme (154,274,306,311,321,322,337-339) and a Gs or Ns site which 
stimulates the AC enzyme (154,274,321,322,328,337,338). These regulatory proteins are important 
in that they functionally couple agonist occupancy with activation of the AC catalytic moiety (329). 
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1.8.2.3 Catalytic component 
This component has a relatively large hydrophobic surface area (145,265), and is believed to have 
a substrate site for A TP, as well as a binding site for the divalent cation magnesium (Mg2+). Binding 
of the A TP and Mg2+ to the catalytic unit presumably occurs as a Mg2+ -A TP complex (265), and is 
essential for AC activity (274). r _. 
1.8.3 MECHANISM OF ADENYLATE CYCLASE ACTION 
Guanosine triphosphate (GTP) plays an important role in the regulation of the AC enzyme activity 
(328). Under conditions where GTP levels are low, hormonal activation of the AC enzyme occurs 
through a mobile receptor mechanism, whereas in the presence of optimal or elevated levels of GTP, 
activation occurs via a collision coupling mechanism (145,157). In general however, hormonal 
-
activation of AC (figure 10) in the presence of GTP occurs through a collision coupling mechanism 
(145). The binding of a hormone to its receptor facilitates the interaction of the hormone receptor 
complex with stimulatory G-protein (Gs). This interaction results in the exchange of guanine 
diphosphate (GDP) for GTP at Gs, and subsequent release of the a-GTP complex. The a-GTP 
complex in tum activates the AC catalytic unit, leading to an increase in intracellular levels of cAMP 
(157,322,340). The adenylate cyclase enzyme is believed to possess a distinct Gi protein which 
mediates inhibition of AC enzyme (338-340). Stimulation of the inhibitory receptor (Ri) results in Gi 
coupling to the receptors, and inactivation of the AC enzyme (337,339). 
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Figure 10: Hormonal activation of adenylate cyclase enzyme (340). 
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1.8.4 FACTORS INFLUENCING ADENYLATE CYCLASE ACTIVITY 
1.8.4.1 Membrane fluidity 
Like many integral membrane-bound enzymes, the activity of the AC enzyme is influenced by the 
nature of its membrane lipid environment (145,149, 157). Physical properties of the-lipid bilayer, such 
as the_ fluidity or rigidity of the membrane, can affect AC activity-presumably by altering the various 
constraints imposed upon the enzyme by the lipid bilayer (145). In general, an increase in membrane 
fluidity augments AC activity (145,157,341), whereas a decrease in membrane fluidity inhibits AC 
activity (157). More recently however, several studies have shown significant increases in adenyl ate 
cyclase activity when membrane fluidity decreases (147, 149,cited in 154). The ability of membrane 
fluidity to alter AC activity is believed to be due to its effects on the conformational flexibility of 
intrinsic proteins (149,157) and/or alterations in the efficacy of the interaction of various components 
of the AC system (145,149,157). 
1.8.4.2 Prostaglandins 
In addition to membrane fluidity various PGs are known to influence AC activity (154,342). In 
general, the actions of these PGs are associated with activation of AC and increased intracellular 
cAMP levels (154,343,344), although in some cases PGs may inhibit AC activation (154,343). PGs 
mediate their effects on AC activity through binding to specific receptors on the plasma membranes 
(335,337,345). These receptors are believed to belong to a superfamily of G-protein coupled receptors 
(332). Binding of PGs to these receptors activates the receptor and results in the transfer of a signal 
via G-proteins to an effector component (332,346,347), such as the AC enzyme. 
PGE2 has been reported to have both stimulatory (332,344-349) and inhibitory (337,345,350) effects 
on AC activity. These dual effects of PGE2 are believed to be due to PGE2 receptors coupling to 
stimulatory Gs (332,345,347) and inhibitory Gi (332,337,345,350) proteins. In addition to PGEz, 
prostaglandins Iz (PGI2) (333,351), PGD2 (333) and PGF2a (347) have all been shown to stimulate AC 
activity. These stimulatory effects of PGD2, PGI2 (332) and PGF2a (347) are believed to be mediated 
via a receptor linked Gs protein. 
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1.8.4.3 Calcium 
Both functional and ultrastructural studies have shown ail intimate association between the AC enzyme 
and sites of Ca2+ entry into the cell (cited in 277). The Ca2+ binding protein, calmodulin, mediates 
many of the intracellular actions of Ca2+ (266). 
1.8.5_ CYCLIC ADENOSINE MONOPHOSPHA TE 
Since the discovery, by Earl Sutherland in the 1960s, that cAMP acts as a secondary messenger for 
the action of various polypeptide hormones, increased attention has focused on the role of cAMP in 
the control of many physiological processes at the cellular level (352-354). 
1.8.5.1· Biological role of cyclic adenosine monophosphate 
Cyclic adenosine monophosphate, the product of AC activity, is a ubiquitous molecule which regulates 
numerous functions within a cell (355,356). In normal cells cAMP functions to regulate numerous 
physiological phenomena which are of significance in transformed cells, such as cell morphology, 
adhesiveness to substratum, motility, growth and synthesis of proteoglycan (355-357). In addition to 
this, cAMP is believed to regulate the activity of various enzymes (355) in addition to increasing the 
differential rate of synthesis of various inducible enzymes (355,358) such as ,6-galactosidase and 
tryptophanase (358). More recently it has been suggested that cAMP modulates the activity ofvatious 
oncogenes and growth factors (352). 
Accumulated evidence indicates that cAMP plays an important role in the mammalian cell cycle, and 
that endogenous cAMP levels fluctuate considerably during various stages ofthis cycle (354,359-361). 
These fluctuating levels of cAMP are believed to play a significant role in regulating cell cycle 
activity (360,361). The cell cycle is composed of a regulated program of specific gene activations, 
transcriptions as well as surges of regulatory components and sequential bursts of enzyme activators 
(362). These events (figure 11) have been classified into 4 distinct stages, and include the Gcphase, 
S-phase, M-phase (360,362) and Go-phase (quiescent) (360) or probabilistic A state (362). 
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Figure 11: Model depicting various stages of the cell cycle. (Go- Quiescent or resting phase, Gl-
Prepares to replicate chromosomes, S- DNA synthesis, G2- Preparation for mitosis and cytokinesis, 
M- Mitosis). 
Although the Go phase is depicted as a unique cell state, it is unclear whether this is in fact the, case 
'"" 
or whether it forms part of the Gl-phase (360). This Go stage is believed to act as a transition phase 
into which the cell enters after completion of each cell cycle. The eukaryotic cell cycle begins with 
the birth of the cell at cytokinesis or cell division. As the cell ages, it enters the Gl or Gap-l phase 
where it prepares itself to replicate its chromosomes; then goes through an S-phase or DNA synthetic 
phase during which it replicates its chromosomes; then passes into a second gap or G2-phasewhere 
it prepares for mitosis and cytokinesis; and finaIly.enters the M-phase or mitosis phase, ending its life 
as an individual cell upon dividing into two new individuals (362). 
cAMP exerts its inhibitory effects at numerous points in the cell cycle (figure 11). The Gl phase is 
very sensitive to inhibition by shortages of essential nutrients and is most responsive to growth factors 
and hormones (360,362). Contact-inhibited cells have high levels of cAMP and are usually arrested 
in the early Gl or Go stage of the cell cycle (355). This suggests that a decrease in cAMP ievels is 
an important signal for the transition of cells from a Go state to a Gl state, and that preventing a 
decrease in cAMP levels may inhibit proliferative capacity of a cell by retaining it in a Go state 
(360,362,363). Upon release from the Go state, a relatively prolonged cAMP surge occurs in the Gl 
phase (354,360-362). A second surge in cAMP occurs in the late S phase or G2 of some cells 
(354,359-362). These cAMP surges function as negative regulators of the cell cycle, inhibiting DNA 
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synthesis for substantial lengths of time in mid cycle (362). Transformed or malignant cells have cell 
cycles similar to those of normal cells, however the former cell types have lost the regulator (probably 
cAMP) which allows them to enter Go state and as a<result continue to replicate (360). 
1.8.5.2 Cyclic adenosine monophosphate and Prostaglandins 
PG a.s;tion is believed to be mediated through changes in the intracellular levels of secondary 
messengers such as cAMP (334,344,347,364). These effects on cAMP are believed to be stimulatory 
or inhibitory depending on the cell type (cited in 346). PGs of the D, E and I series are capable of 
increasing cAMP formation in various systems (345). PGE2 has been shown to stimulate cAMP 
production in numerous cell lines such as gastric carcinoma (KATTO III) (248,347), mastocytoma 
P-815 (334), fibroblasts (365) and mouse embryo limb cell lines (366). 
In addition to PGE2, a number of other PGs such as PGI2, PGD2 (333,334,351) and PGF2a 
(248,347,364,365) have been shown to stimulate cAMP production in various cell lines. PGs are 
known to influence the growth of not only normal cells but also tumour cells (347). Furth~rmore 
several studies (334,347,364,367) have suggested that cAMP mediates the growth iIlhibitory effects 
of these PGs. In general PGE2 is believed to stimulate cAMP formation directly through a PGE2-
receptor-cAMP linked system (366), with the cAMP acting as a secondary messenger for PGEz-
mediated modulation of biological activity in various cells (368). 
1.8.6 PHOSPHODIESTERASE 
PDE was first discovered in 1958 by Sutherland and Hall (369-371). These enzymes, as previously 
mentioned, function to catalyse the hydrolysis of the 31-bond of cyclic nucleotides to a non-cyclic 
product 51 -monophosphate derivative. Hydrolysis of cAMP by PDE enzymes is the major 
physiological pathway for the termination of the intracellular effects of cAMP (326). 
1.8.6.1 Properties and structure of phosphodiesterase 
PDE's occur widely in biological systems and are present in all mammalian tissues, with the 
exceptions of red blood cells and isolated rat adrenal cells. Since their discovery, numerous forms 
of the PDE enzyme have been shown to exist under a variety of conditions and from various sources 
35 
1. Literature Review 
(326). The pattern and ratio of these PDE enzymes varies according to the cell or tissue type (371), 
and they are believed to differ in their kinetic behaviour., substrate specificity (326,371), subcellular 
- -
localisation and possibly function (326). Although vaHous studies (324,cited 326) have demonstrated 
the existence of multiple forms of the enzyme, it is now believed that two distinct forms of PDE exist 
(326). These two forms of the enzyme differ in a number of aspects, but primarily in their affinity 
for two naturally occurring substrates namely cAMP and cyclic guanosine-3~5'-monophosphate 
(cGM.P) (324,353,369,370,372). 
The high Km (low affinity) PDE (sPDE) enzyme is largely found in the soluble (cytosolic) portion 
of cell extracts and has a MW of approximately 400000 (369,370). This enzyme exhibits a higher 
affinity for cGMP than for cAMP (324,326,353,369,370,372) and is believed to be sensitive to a 
calcium-dependant protein activator (326,370-372). The low Km (high affinity) PDE (PPDE) enzyme 
on the other hand has a MW of approximately 200 000 (369,370) and is mainly associated with 
various membranes. This enzyme hydrolyses cAMP in a negatively co-operative manner (353,369-
371) and has a far higher affinity and specificity for cAMP than does the sPDE enzyme 
(324,326,353,369,370,372). Furthermore, several hormones as well as intracellular activators such 
as cAMP are known to stimulate the pPDE enzyme (326,370,372). This suggests that any agent 
capable of increasing intracellular cAMP levels such as the PGs (see section 1.8.5.2), could mediate 
their effects on the cell through the induction of the pPDE enzyme. The presence of various forms 
ofthe PDE raises the question as to which form of the enzyme is important in controlling intracellular 
cAMP levels. Because the intracellular levels of cAMP are in the {tM range or lower, it has been 
suggested that only those PDEs with high affinity for cAMP ie low Km PDEs or pPDEs, could fulfil 
this role (326). 
1.8.7 Adenylate cyclase, cyclic adenosine monophosphate, phosphodiesterase and cancer 
Of the many diseases associated with altered cyclic nucleotide metabolism, cancer has received the 
most attention (371). Generally malignant or transformed cells in culture have been found to have 
lower levels of cAMP than normal or untransformed cells (353,357,361,373-377). Since intracellular 
levels of cAMP are determined by the activity of the AC and PDE enzymes (325,378), lower levels 
of cAMP in malignant cells may be due to alterations in one or both of these enzymes (354,361,379). 
Numerous studies have shown significant decreases in basal (311,323,357,361,374,377,380) AC 
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activity, as well as a decreased responsiveness to various hormones (353,361,380,381) following 
transf()rmation. These changes may be due to alterations ·in the catalytic component of the AC enzyme 
(353,357). The AC enzyme is believed to have twobiilding sites for the Mg2+, one at the catalytic 
site of the enzyme and the other at the Gs site, which functions to stimulate the activity of the enzyme. 
During transformation, alterations in the Gs site are believed to occur, resulting in Mg2+ being unable 
to enhance AC activity. Furthermore the transformation of normal cells to tumonr cells results in a 
number of changes in the plasma membranes (357,361). Since the adenylate cyclase enzyme is 
intimately associated with the plasma membrane, these changes could possibly alter AC receptor sites, 
resulting in decreased AC activity and lower intracellular levels of cAMP (361,374). Lipid 
peroxidation, as mentioned in section 1. 3.1, is believed to be involved in tumour promotion 
(138,139). Once initiated, this process results in the polymerisation and depletion of membrane 
PUFAs, decreased membrane fluidity (150-152,156,159,163,169) and inhibition of AC activity 
(382,383). Although no universal correlation between AC activity and tumour growth rate has been 
shown in any studies to date, there is a much more consistent pattern during oncogenesis, when AC 
activity and cAMP levels are found to be elevated (354). At present however, no direct evidence 
exists to suggest that cAMP is a secondary messenger for the action of any oncogenes (352,354). 
As regards PDE activity in normal and malignant cells, the activity is generally found to be lower in 
malignant cells (325,361), although some studies have reported significant increases (372,374,379). 
Like normal cells, alterations in PDE activity in malignant cells are regulated by intracellular cAMP 
levels (325). Furthermore it has been suggested that transformed cells show some selective alterations 
in the different forms ofthe enzymes (361). Transformed chicken embryo fibroblasts show significant 
increases in the ratio of low Km to high Km PDE enzymes when compared to their normal cell 
counterparts (374). This increase in the ratio of low Km to high Km PDE activity would account for 
lower levels of cAMP in transformed cells. Numerous in vitro studies (355,356,360,361,374,375,384-
386) have shown an inverse relationship between intracellular cAMP levels and tumour cell 
proliferation. 
Furthermore many of the characteristic properties of cancer cells, such as abnormal morphology, 
rapid growth rates, decreased adhesiveness and loss of contact inhibition of growth can be reverted 
towards those of normal cells, by treatment with dibutyryl cAMP (dcAMP) or agents which increase 
intracellular cAMP levels (355-357,361). It is reasonable to assume therefore that the abnormal 
properties of transformed cells could be a consequence of lower intracellular cAMP levels 
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(357,361,387) as a result of reduced AC activity, although numerous in vivo studies (388-392) have 
reported significant increases in cAMP levels in transformed cells as compared with their normal cell 
counterparts. 
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1.9 PROJECT OBJECTIVES 
As previously mentioned, the mechanism(s) by which vitamin E and its derivatives exert 
anticarcinogenic effects in vitro are unclear, although it has been suggested that these effects may 
be due to their antioxidant properties and/or their effect on various metabolic pathways such as the 
AA cascade pathway shown in figure 4 (repeat of figure on page 13). 
Autoxidation 
:Membranes 
I Tissue damage 5-LOX Phospholipase A 2 
LT I Arachidonic Acid C~;\) I CycJooxygenase 
Prostaglandin G2 
I Hydroperoxidase 
Prostaglandin H2 (PGH2) I PGE, ,)~th"" 
Prostaglandin E2 
I 
Adenylate Cyclase 
I 
Lipid peroxidation - MDA 
PGH Synthase 
synthase 
---..... , Prostaglandin D? ,F2 ,1 2 enzymes 
Phosphodiesterase . 
Adenosine ~fonophosphate -------, 5-A~lP Cyclic 
I 
Effect 
Figure 4: Schematic representation of the AA cascade pathway examined in this project. (AMP-
Adenosine monophosphate, ATP-Adenosine triphosphate, LT-Leukotrienes, LOX-Lipoxygenase, 
MDA-MaJondiaJdehyde). 
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This pathway shows the metabolites influencing, and sequential steps involved in, the release and 
conversion of AA to various PGs, with the _possible effects of PGE2, on AC activity, cAMP 
production and PDE activity. 
The objectives of this study were to determine the effect of vitamin E succinate supplementation on 
the in vitro growth of malignant murine melanoma (BL6) and non-malignant lflonkey kidney 
(LLCMK) cell lines, and to evaluate the effect of this supplementation on free radical formation, lipid 
peroxidation and the activity and metabolism of the pathway shown in figure 4. In addition to this the 
role of COX and 5-LOX activity in AA metabolism as well as their role in free radical formation and 
induction of lipid peroxidation was examined. 
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NUTRIENT SUPPLEMENTATION AND CELL GROWTH 
2.1 INTRODUCTION 
,- - -_".: 
With _an ever-increasing number of new cases of cancer expected each year, and the lack of success 
of established preventative and therapeutic strategies in controlling the high incidence and low survival 
rates of patients with solid tumours (11,20), there is a need for new and improved therapeutic 
strategies (11). Over the past few years, the issue of chemoprevention (see section 1.1.4) has received 
increased attention as a possible, realistic and inexpensive means of reducing cancer incidence 
(11,20,22). This idea has been designed to work as an adjuvant therapy rather than as a replacement 
therapy for established strategies (20). A nutrient which· has received recent attention as a 
chemopreventative agent is a-TOH (11,22,24,46,50). Both animal (117,122) and human (22,52-
55,105) studies have provided evidence which suggests an inverse relationship between the levels of 
essential antioxidant nutrients such as a-TOH and the risk of cancer development. It is tempting to 
speculate that the characteristics of various tumour cells may in part be due to the absence of an 
essential nutrient such as vitamin E, and that supplementation of this nutrient may reverse the 
neoplastic state. Vitamin E in combination with various tumour therapeutic agents such as adriamycin, 
R020-1724, vincristine, sodium butyrate and chlorozotocin, produce synergistic or additive growth 
inhibitory effects on both glioma (C6) and neuroblastoma (NB) cells in culture (128). Furthermore, 
vitamin E succinate in combination with 6OCo-I'-irradiation has been found to potentiate cell death and 
growth inhibition of neuroblastoma cells (393,394) as well as enhance the growth inhibitory effects 
of PGE2 (110), t:. 12_PGJ2 and PGJ2 on human oral squamous carcinoma cells in culture (123). 
Tissue culture has been widely used in studies of the functional roles of a-TOH (395). This technique 
has expanded considerably over the past few years and is now widely accepted in many aspects of 
biological research. The development of continuous transformed cell lines has attained great 
importance in research. The advantages of continuous cell lines are their ease of maintenance in 
simple media and their ability to grow to high cell densities resulting in higher yields (396). In 
addition to this, the growing of cells in cultures that are no longer organised into tissues, allows for 
the supplementation of these cells with various nutrients eg vitamin E, and the monitoring of the 
effects of this supplementation on cell growth and various aspects of cell metabolism, without the 
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problems of the host immune system and non-specific cells generally found in vivo. In this study the 
effects of vitamin E succinate supplementation on the. in vitro growth of non-malignant LLCMK 
- -
(monkey kidney) and malignant BL6-F1O (murine melanoma) cell lines were determined.-
2.2 MATERIALS AND METHODS 
MATERIALS 
Highly metastatic murine melanoma BL6-F1O (BL6) and non-malignant monkey kidney (LLCMK) 
cells were obtained from Highveld Biological Association, South Africa. Basal Minimum Essential 
Media (MEM), L-Serine, trypsin, succinic acid disodium salt hexahydrates, and (+) a-tocopherol 
acid succinate (vitamin E succinate) were purchased from Sigma Chemical Co., USA. (U-3H)-vitamin 
E succinate eH-vitamin E succinate) (lmCi/ml) was purchased from Amersham International, 
England. Foetal Calf Serum (FCS) was obtained from Delta Bioproducts South Africa, while sterile 
disposable tissue culture flasks (25cm2 and 75cm2) were purchased from Corning, USA. Sodium 
Hydrogen Carbonate (NaHC03), Sodium Chloride (NaCl) , anhydrous Sodium Dihydrogen 
Orthophosphate (NaH2P04), Potassium Dihydrogen Orthophosphate (KH2P04) - and 'Dimethyl 
Sulphoxide (DMSO) were purchased from Unilab, South Africa. Potassium Chloride (KCI) and 
Ethylenediamenetetracetic Acid (EDTA) were supplied by Holpro Chemical Co., South Africa. 
Phenol red, D-glucose and glycine were obtained from BDH Chemicals LTD, England. Sodium 
Benzylpenicillin (Novo-Pen) and Streptomycin Sulphate (Novo-Strep) was supplied by Novo Industries 
(Pharmaceutical LTD), South Africa. Haemocytometers were purchased from Neubauer, Germany. 
METHODS 
2.2.1 PREPARATION OF CULTURE REAGENTS 
2.2.1.1 Preparation of cell culture media 
Preparation of culture media was carried out as follows. To basal MEM media containing Hanks salts 
and glutamine but no NaHC03, was added serine (0. Ig/l) , glycine (0.06g/l), NaHC03 (0.75g/l) and 
5.0ml of a combined sodium benzylpenicillin and streptomycin sulphate antibiotic solution (one vial 
of sodium benzylpenicillin (106 U) and one vial of streptomycin sulphate (106JLg) were combined and 
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made up to 100ml with milli Q water). Media preparation was always carried out in batches of 10 
litres using milli-Q water. 
2.2.1.2 Media Filtration 
Media was sterilised immediately by positive filtration (figure 12) through a millipere filtration unit 
(Millipore Corporation, USA) using the following filters: a prefilter, type SM42 "membrane filter" 
50K (size 130); a 0.45, 142mm type NA filter (hawp 14250); and a O.22jim, 142mm type GS filter 
(GSWP 14250). 
Pressure regulator 
Pressure Media holding Riter 
tank pressure vessel holder 
Figure 12: Positive pressure filtration system. 
Dispensing 
clamp 
Dispensing 
bell 
During filtration, the initial 200ml of the medium was discarded while the remainder of the medium 
was collected into sterile cell culture bottles. Sterilisation of cell culture bottles was carried out by 
autoclaving for 45 minutes in an Everlight vertical type autoclave. Aseptically dispensed media was 
then incubated at 37°C for one week to test for contamination. 
2.2.1.3 Gro~1h media preparation 
Growth media was prepared by filtering FCS through a 0.45jiM Millipore filter using a Swinex-25 
holder (Millipore Corporation, USA), until the media contained 10% (v/v) FCS. This media was 
further incubated at 37°C for 48hrs to test for contamination. Media used in the first 24 hour growth 
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period of cells defrosted from frozen stocks contained 20% FCS. 
2.2.1.4 Freezing media- preparation 
Freezing media was prepared by filtering FCS and DMSO through a 0.45jLM millipore filter using 
a Swinnex-25 holder, until the media contained 20% (v/v) and 10% (v/v) DMSO . ..Alkfreezing media 
was stored at -20°C until required. 
2.2.1.5 Trypsin preparation 
To one litre of milli-Q water was added 8.0g NaCI, O.4g KCI, 1.0g D-glucose, 0.58g NaHC03 , 0.2g 
EDTA, 0.02g phenol red indicator, 0.033g trypsin and lOml of a Novo-Strep:Novo-Pen solution 
prepared as described in section 2.2.1.1. All trypsin solutions added to culture flasks were filtered 
through a 0.45jLM millipore filter using a Swinnex-25 holder. Trypsin was stored at -20°C until 
required. 
2.2.1.6 Preparation of vitamin E succinate and succinic acid containing media 
Stock solutions of vitamin E succinate (l-lOmg/ml) were prepared freshly in absolute ethanol and 
diluted 1:1 000 in media containing 10% (v/v) FCS to give final concentrations of 1, 3, 5, 7, and 
10jLg/ml vitamin E succinate respectively, in 0.1 % final concentration of ethanol. Vehicle controls 
containing equivalent amounts of succinic acid and absolute ethanol were prepared as follows. Stock 
solutions of succinic acid 1.89mg/ml were prepared in milli-Q water and diluted 1: 1 000 in media 
containing 10% (v/v) FCS and 0.1 % absolute ethanol to give a final succinic acid concentration of 
1.89jLg/mi. Other concentrations of succinic acid (0.19, 0.57, 0.89, 1.32mg/ml) were prepared by 
serial dilution of the 1.89mg/ml stock. 
2.2.1.7 Preparation of Phosphate Buffered Saline solution 
Phosphate Buffered Saline (PBS) pH 6.6, was prepared by the addition of 8.0g NaCI, 0.2g KHZP04, 
0.2g KCI and 0.15g of NaHP04"2HzO to one litre of milli-Q water. 
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2.2.2 CELL CULTURE 
2.2.2.1 Routine cell culture procedure 
All cell culture procedures were conducted on a laminar flow bench which had previously been 
sterilised by regular swabbing with 70% ethanol and exposure to ultraviolet light An addition to this, 
all eq~ipment used under the lamina flow bench was either purchased sterile, autoclaved or swabbed 
with 70% ethanol prior to use. When not required for experimental purposes, both non-malignant 
LLCMK and malignant BL6 cells were incubated at 37°C in 75cm2 flasks containing 30ml of 10% 
(v/v) FCS supplemented media. Media was changed on a regular basis (approximately once a day) 
during maintenance of these cell lines. To passage or subculture cells, the growth media was 
discarded and lOml of trypsin was added to each flask, followed by incubation at 37°C for 10 
minutes. During the incubatory period cells detach from the surface of the flask. These cells were 
then passaged into three or four flasks followed by the addition of media containing 10% (v/v) FCS. 
2.2.2.2 Freezing of cells 
Upon reaching confluency, a cell line may be subcultured or stored in a frozen state. This latter 
procedure involves the harvesting of near-confluent flasks of cells and the storage of these cells frozen 
in 2.0ml of freezing medium in cryogenic vials under liquid nitrogen. 
2.2.3 THE EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON BL6 AND 
LLCMK CELL GROWTH 
2.2.3.1 Cell culture procedure 
Confluent flasks (75cm2) of BL6 and LLCMK cells were trypsinised with lOml of trypsin. These 
flasks were incubated at 37°C until cells detached from the flask surface. The resulting cell suspension 
was then poured into sterile 15ml centrifugation tubes and spun at 3 OOOg for 10 minutes. Following 
centrifugation, the supernatant solution (trypsin) was discarded and resulting cell pellet was 
resuspended in 2.0ml of MEM basal medium containing 10% (v/v) FCS. Using a sterile pasteur 
pipette, a suspension of cells was placed onto a haemacytometer and counted. Counts obtained were 
then used to calculate the volume of cell suspension required to seed 300 000 cells per 25cm2 flask 
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or 500 000 per 75cm2 flask. 
-
In the experiments relevant to 3.2.2 and 3.2.3, for which further analytical procedures arid data are 
described in chapter 3 (the numbering denoting the relevant experiments), 3 X 105 BL6 or LLCMK cells 
were seeded into 7 sets of 5 25cm2 flasks. To 5 of the 7 sets of flasks, lOml of MEM basal medium 
containing 10% (v/v) FCS and varying levels of vitamin E succinate (l-lOjLg/ml) was added. The 
sixth set of flasks each received lOml of 10% (v/v) FCS medium, and were referred to as control 
cultures (0), while the seventh set of flasks received lOml of 10% (v/v) FCS medium containing 0.1 % 
final concentration of ethanol and were referred to as control cultures OE. In the experiments relevant 
to 3.3, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6.2,4.6.4,4.7 and 4.8, for which further analytical procedures and 
data are described in chapters 3 and 4 respectively (the numbering denoting the relevant experiments), 
5xl05 BL6 or LLCMK cells were seeded into 7 sets of 3 75cm2 flasks. To 5 of the 7 sets of flasks 
was added 30ml of MEM basal medium containing 10% (v/v)FCS and varying levels of vitamin E 
succinate (l-lOjLg/ml). The sixth set of flasks received 30ml of medium containing 10% (v/v) FCS 
and were referred to as control cultures (0) while the seventh set of flasks received 30ml of 10% (v/v) 
FCS supplemented medium containing 0.1 % final volume ethanol and were referred to as ~ontrol 
cultures OE. All flasks were incubated at 37°C for the duration of the experiment with one medium 
change during this period. 
2.2.3.2 Harvesting of cells 
When the first set of flasks reached confluency after 5-7 days (determined by viewing under a 
microscope), cells were harvested under non-sterile conditions. This procedure involved the addition 
of 5.0ml of trypsin to 25cm2 flasks and lOml of trypsin to 75cm2 flasks, followed by incubation at 
37°C until cells had lifted off flask surfaces. The resulting cell suspensions were centrifuged at 3 OOOg 
for 10 minutes and cell pellets resuspended in 1.0ml of PBS unless otherwise stated. Cells were 
counted using a haemocytometer. These cell counts were used as a reflection of cell growth and 
enabled the effects of vitamin E succinate supplementation on growth of cells to be determined. The 
cells were then used for further analysis. 
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2.2.4 THE EFFECT OF SUCCINIC ACID AND VEHICLE TREATMENT ON CELL 
GROWTH 
2.2.4.1 Cell culture procedure 
3x105 BL6 or LLCMK cells were seeded into 6 sets of 5 75cm3 flasks. To 5 sets,of tl1ese flasks was 
added 10ml of MEM basal medium containing 10% (v Iv) FCS, varying levels of succinic acid (0.19-
1.89jLg/ml) and 0.1 % final concentration of ethanol. The sixth set of flasks received lOml of medium 
containing 10% (v/v) FCS and 0.1 % final concentration of ethanol. All flasks were incubated at 37°C 
for the duration of the experiment with one change of medium, and cells harvested as described in 
section 2.2.3.2. 
2.2.5 THE EFFECT OF COMBINED 3H-VITAMIN E SUCCINATE AND VITAMIN E 
SUCCINATE SUPPLEMENTATION ON CELL GROWTH 
2.2.5.1 Cell culture procedure 
5x105 BL6 or LLCMK cells were seeded into 7 sets of three 75cm2 tissue culture flasks. To five of 
these flasks, 30ml of MEM basal medium containing 10% (v/v) FCS and varying levels of vitamin 
E succinate (l-lOjLg/ml) were added. The sixth set of flasks received 30ml of medium containing 
0.1 % final concentration of ethanol and were referred to as control cultures OE, while the 7th-set of 
flasks received 30ml of MEM basal medium containing 10% (v/v) FCS and were referred to as 
control culture (0). All the flasks were incubated at 37°C with one change of medium. During media 
change, O.ljLCi of 3H-Vitamin E acid succinate was added to control culture OE and all vitamin E 
succinate supplemented flasks. Control cultures (0), received 30ml ofMEM basal medium containing 
10% (v/v) FCS. The flasks were incubated at 37°C for the duration of the experiment and the cells 
harvested as described in section 2.2.3.2. The above experimental procedure is relevant to 
experiments 3.3 in chapter 3. 
2.2.6 STATISTICAL ANALYSIS 
Results obtained were analysed using a One Way Analysis of Variance (ANOVA) followed by a 
Student Newmans-Kuels Multiple Range Test. 
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2.2.7 RESULTS 
-
2.2.7.1 The effect of vitamin E succinate supplementation on BL6 and LLCMK cell·growth 
The effect of varying levels (1-1O{tg/ml) of vitamin E succinate on the in vitro growth of malignant 
BL6 and non-malignant LLCMK cell lines, is shown in tables 1A and 1B respectively .. Results shown 
in these tables are relevant to the individual experiments described in chapters 3 and 4, and will be 
discussed relative to these studies at a later stage. Of relevance to the discussion in this chapter, is 
the overall mean growth inhibition results for all the experiments. 
The overall mean growth inhibitory effects of vitamin E succinate supplementation on BL6 cell 
growth indicate that supplementation of 1 and 3{tg/ml vitamin E succinate results in no significant 
change in growth, as compared with control cultures OE, while at 5, 7 and lO{tg/ml respectively a 
significant (p:::;; 0.001) decrease in growth occurred. LLCMK cells on the other hand showed no 
significant increase or decrease in growth over the vitamin concentration tested, although a slight but 
non-significant decrease was observed at 5, 7 and lO{tg/ml vitamin E succinate supplementation. 
However, LLCMK cell growth in certain individual experiments ie Exp's 3.3, 4.1, 4:2 and'4.8, were 
significantly inhibited by high concentrations of vitamin E succinate, while in others non-significant 
(Exp's 3.2.2; 3.2.3; 4.5) and significant (Exp's 4.4; 4.7) increases in LLCMK growth occurred 
following vitamin E succinate supplementation. 
2.2.7.2 The effect of succinic acid and vehicle treatments on cell growth 
The overall effects of vehicle (ethanol) and combined succinic acid:ethanol treatments on BL6 and 
LLCMK cell growth are shown in tables 2A, 2B and 3 respectively. In these studies, supplementation 
with 0.1 % ethanol resulted in a marked although non-significant increase in BL6 growth (table 2A) 
and a non significant decrease in LLCMK growth (table 2B) as compared with control cultures (0), 
although effects varied considerably within individual experiments. Supplementation with varying 
levels of succinic acid and equivalent amounts of ethanol (both BL6 and LLCMK cell lines) (table 3) 
resulted in no significant increase or decrease in growth compared with control cultures OE, although 
succinic acid at certain concentrations was shown to stimulate BL6 and LLCMK growth. 
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Table IA: The effect of Vitamin E succinate supplementation on BL6 cell growth. (Values recorded in the tahle represent the mean of 3# or 5· cultures ± 
SEM). 
Vitamin E 
succinate 
(I'g/ml) 
OE 
I 
3 
5 
7 
10 
a= p:S;O.OOI: 
b= p:s;O.OI: 
c= p:s;0.05: 
Exp' Exp' Exp· 
3.2.2 3.2.3 3.3 
100 100 100 
±6.1 ±6.2 ±9.6 
74.4c 96.7 108.8c 
±5.21 ± 11.3 ±6.1 
148.3a 90.4 67.2b 
±9.6 ±4.5 ±4.0 
66.3b 43.1:1 66.5b 
±6.3 ±3.1 ±0.47 
42.77a 53.5:1 69.7b 
±2.4 ±S.9 ±3.2 
33.3a 27.8:1 21.9:1 
±7.5 ± 1.8 ±O.IS 
) Relative to control cultures OE 
) 
Exp· 
4.1 
100 
±1O.6 
83.1 
± 19.3 
56.5 
± 16.1 
73.4 
±5.S 
63.2 
±2.6 
75.9 
±1O.9 
BL6 cells 
Growth Inhibition (% of untreated control,OE) 
Exp· Exp . Exp . Exp . Exp . Exp . Exp . Exp . MEAN 
4.2 4.3 4.4 4.5 4.6.2 4.6.4 4.7 4.8 
100 100 100 100 100 100 100 100 100 
± 16.1 ±2.9 ±32.4 ±2.3 ±2S.1 ±9.0 ± 19.8 ±8.2 ±3.43 
7.7:1 77.3c 266.2:1 91.9b 112.8 103.3 154.7b 85.5 101.1 
±0.l3 ±4.5 ± 12.4 ±3.8 ±9.1 ±4.8 ±2.0 ±4.3 ±9.2 
8.9:1 47.9b 286.4a 83.7b 112.6 78.6 182.2a 81.8 ," 100.2 
±0.17 ±8.8 ±27.5 ±3.2 ±9.7 ±2.6 ±15.0 ±7.0 ±f1.4 
7.8a 41.5a 25.lc 56.2~ 109.9 83.8 34.2a 57.1 63.1:1 
±0.34 ±3.4 ±2.8 ±1.4 ±5.1 ±6.0 ±0.8 ±6.6 £4.S 
34.1:1 64.0b 12.0c 37.4a 97.4 89.3 29.6b 80.4 55.0a 
±5.4 ±9.9 ±1.4 ±0.78 ±14.9 ±4.9 ±3.4 ±6.8 ±3.9 
6.9a 57.5b 11.5c 24.0a 79.9 71.4c 14.3a 7S.l b 39.la 
±O.li ±9.5 ±t.4 ± 1.0 ±6.8 ±1.5 ±1.0 ±4.7 ±4.0 
,\ 
~ 
Q 
--
--~ 
o §. 
VI 
o 
Table I B: The effect of Vitamin E succinate supplementation on LLCMK cell growth. (Values recorded in the table represent the mean of 3' or 5· 
cultures ± SEM). 
-
~ ~-
Vitamin E 
succinate 
(Jlg/ml) 
OE 
I 
3 
S 
7 
10 
01= p=':;O.OOI: 
b= p:50.01: 
c= p=':;O.OS: 
-- _ .. - ----- ----.- .. -----~-
EXJl' Ex!,' EXJI . 
3.2.2 3.2.3 3.3 
100 100 100 
±II.I ± 10.2 ±4.6 
137.4 .98.9 99.7 
±8.3 ±13.3 ±1O.8 
129.2 100.9 87.6 
H.8 ± 13.6 ± 1.4 
·37.2b 104.9 86.S 
±5.5 ±6.2 ±2.8 
102.1 118.3 63.7h 
±13.2 ±3.4 ±6.7 
126.1 IOJ.I 63.Sc 
±30.3 ± 13.0 ±5.3 
) Relative to control cultures OE 
) 
----~.--.-- - .. _--
LLCMK cells 
Growth Inhibition (% of untreated control OE) 
Ex(, . Exp . Exp· EXJl . Exp . EXJl . Ex!, . MEAN 
4.1 4.2 4.3 4.4 4.5 4.7 4.8 
100 100 100 100 100 100 100 100 
±4.6 ±7.7 ± 10.3 ±7.4 H.S ±8.2 ±II.O ±2.S 
94.7 122.7c 122.4 IS6.1c 86.7 137.3a 83.8 112.1 
±S.S ±1O.8 ±IS.8 ±12.5 ±13.1 ±1O.8 ±1.0 ±4.7 
97.0 7S.Sc 98.6 145.9c 110.9 121. 7a 85.4 106.0 
±1O.6 H.l ±9.7 ±6.8 ±IS.6 ± 1.7 ±3.8 ±4.3 
104.S 70.8c 94.4 164.2c 101.1 120.2a 80.9 91.3 
±2.9 ±3.6 ±B.2 ±14.0 ±3.4 ±3.2 ±3.9 ±S.S 
80.4 29.4b 49.7c 163.7c 99.7 12S.5a 75.9 90.2 
±4.9 ±1.3 ±2.S ± 17.8 ±5.8 ±14.9 ±4.4 ±6.1 
I 
57.3" 
I 
70.6c 43.811 66.4 116.0 118.0 IOS.711 88.6 I 
±3.9 .. ±3.2 ±8.S ±7.2 ±15.8 ±8.7 :1:3.2 ±6.5 I 
II 
!'-> 
Q 
:::::: 
st 
9 §. 
Table 2;\: Effect of vehicle supplementation on BL6 cell growth. (Values recorded in the tahle are the mean of 3# and 5' cultures ± SEM). 
BL6 cells 
Treatments' Growth Inhibition (% of untreated controls 0) 
Exp' Exp' Exp' Exp' Exp 
, 
Exp' Exp' Exp' Exp' Exp , Exp' Exp , MEAN 
3.2.2 3.2.3 3.3 4.1 4.2 4.3 4.4 4.5 4.6.2 4.6.4 4.7 4.8 
0 100 100 100 100 100 100 100 100 100 100 100 100 100 
±6.6 ±5.5 ±4.4 ±5.7 ±12.8 ± 1.4 ±17.2 ± 1.9 ±6.S ±7.1 ±16.6 ±9.9 ±2.2 
OE 90.6 99.6 103.7 89.6 197.9 70.5 239.0 146.1 IS6.6 236.3 96.S 130.1 132.9 
±5.S ±6.2 ±1O.0 ±29.0 ±S.7 ±7.2 ±38.3 ±3.4 ±28.0 ±20.? ±19.2 ±1O.? ±9.7 
VI 
...... a= Cells cultured in presence OE or ahsence (0) of ethanol. 
Table 2n: Effect of vehicle supplementation on LLCMK cell growth. (Values recorded in the tahle are the mean of 3' and 5' cultures ± SEM). 
LLCMK cells 
Treatments' Growth Inhibition (% of untreated controls 0) 
Exp' Exp' Exp , Exp , Exp 
, 
Exp , Exp , Exp' Exp , Exp , MEAN 
3.2.2 3.2.3 3.3 4.1 4.2 4.3 4.4 4.5 4.7 4.S 
0 100 100 100 100 100 100 100 100 100 100 100 
±7.2 ±5.0 ±9.7 ±5.7 ±1O.9 ±12.2 ± 1.4 ±1O.2 ±4.4 ±5.0 ±2.1 
,\ 
OE 86.1 92.7 S1.3 66.7 103.6 130.5 70.4 91.6 89.8 100 90.0 
±9.5 ±9.5 ±3.8 ±4.9 ±10.7 ±1O.1 ±7.2 ±4.1 ±?3 ±II.O ±3.7 
a= Cells cultured in presence OE or ahsence (0) of ethanol. 
~ 
Q 
.... 
.... 
~ 
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Table 3: The effect of succinic acid and vehicle treatment on BL6 and LLCMK cell growth. (Each 
value in the table represents the mean 10 determinations ±SEM) 
-
Succinate Vehicle Growth'Inhibition (% of untreated controls OE) 
(ltg/ml) concentration 
(%) BL6 LLCMK 
0 0.1 100 100 
±2.8 ~± 14.8 
- 0.19 0.1 119.1 107.4 
±3.0 ±9.2 
0.32 0.1 115.6 75.8 
±3.1 ±1O.1 
0.89 0.1 95.5 100.4 
±1O.1 ±17.2 
1.32 0.1 107.4 114.7 
±1O.9 ±15.0 
1.89 0.1 124.8 117.3 
±9.1 ±15.4 
2.2.7.3 The effect or combined 3H-vitamin E succinate and vitamin E succinate 
supplementation on BL6 and LLCMK growth. 
Supplementation of BL6 and LLCMK cells with varying levels (l-lO/1-g/ml) of vitamin E succinate 
and O.l/1-Ci of 3H-vitamin E succinate (table 4) resulted in a significant decrease in BL6 groWth 
compared with control cultures OE, while LLCMK cells showed a non-significant increase at 1, 5 and 
7/1-g/ml vitamin E succinate, and non-significant decrease at lO/1-g/ml. 
Treatment of BL6 and LLCMK cells with O.l/1-Ci 3H-vitamin E succinate and 0.1 % ethanol resulted 
in an overall non-significant increase in growth compared with untreated controls (0) (table 5). 
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Table 4: The effect of combined 3H-vitamin E succinate and vitamin E succinate supplementation on 
BL6 and LLCMK cell growth. (Each value in the table represents the mean of 3 determinations ± 
S~~ -
VitaminE Ethanol 3H-vitamin E Growth Inhibition 
succinate concentration succinate (% of untreated controls OE) 
(JLg/ml) (%) (JLCi) 
BL6 cells LLCMK cells 
,- - ~ 
OE 0.1 0.1 100 100 
±2.2 ±11.7 
1 0.1 0.1 54.2a 103.5 
±4.5 ±7.9 
3 0.1 0.1 59.3a 100.2 
±5.6 ±12.7 
5 0.1 0.1 66.6a 106.6 
±6.4 ±6.9 
7 0.1 0.1 66.5a 116.9 
±7.4 ±6.9 
10 0.1 0.1 63.3a 90.7 
±6.6 ±3.8 
a= p::;;;O.OI: Relative to BL6 control cultures OE. 
Table 5: The effect of combined 3H-vitamin E succinate and vehicle supplementation on BL6 and 
LLCMK cell growth. (Each value in the table represents the mean of 3 determinations ± SEM). 
Growth Inhibition 
Treatment (% of untreated controls 0) 
BL6 cells LLCMK cells 
0 100 100 
±4.6 ±31.7 
OEa 106.3 120.7 
±8.7 ±14.1 
a= Control cultures containing 0.1 % ethanol and O.IJLCi 3H-vitamin E succinate 
2.3 DISCUSSION 
Of all the various forms of vitamin E tested for their ability to inhibit tumour cell growth, vitamin 
E succinate has proven to be the most potent form in vitro (42,397). This vitamin has been found to 
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have several unique biochemical properties both in vitro and in vivo (398), and is believed to induce 
differentiation (42,398,399) and inhibit growth and survival (42,110,123, 126, 127,397-399) of various 
tumour cell lines in vitro-. In this study supplementati<:>n of 5, 7 and 1O/Lg/ml vitamin E 'succinate, 
resulted in a significant decrease in BL6 cell growth. Numerous other studies (42,124,127,399) have 
shown similar inhibition of BL6 cell growth following supplementation with 5-1O/Lg/ml vitamin E 
succinate. Furthermore treatment of these cells with vitamin E succinate has beeJl.-shewn to result in 
morp~ological changes (42,399), with the cells resembling their non-malignant counterparts (42). 
Apart from its growth inhibitory effects on BL6 cells, vitamin E succinate supplementation has been 
shown to inhibit the growth of various other tumour cell lines in vitro such as human tongue 
carcinoma (Scc-25) (110,123), mouse neuroblastoma (NPB2), rat glioma (127), human neuroblastoma 
(397) and avian retrovirus-transformed immature lymphoid tumour (C4#1) cells (126). 
Although several studies have investigated the effects of vitamin E succinate supplementation on 
tumour cell growth and proliferation, very few have investigated the in vitro effects of vitamin E 
succinate supplementation on normal or non-transformed cells (126). Studies by Helson and co-
workers (397), have shown that supplementation of 40/Lg/ml d-a-TOH polyethylene glycol succinate 
(vitamin E-TPGS) to normal human skin fibroblasts in culture resulted in a 50% reduction f~growth, 
while Prasad and Edwards-Prasad (399), studying the effects of vitamin E succinate supplementation 
on growth and differentiation of mouse fibroblasts in culture (L-cells), showed that 1O/Lg/ml vitamin 
E succinate inhibited L-cell growth by 50%. In addition to this, Kline et al (126) showed that vitamin 
E succinate at 5 and 1O/Lg/ml respectively was cytotoxic to lymphocytes from the spleen, th¥mus, 
bursa and peripheral blood of normal chickens, while lower concentrations (O.l-l/Lg/ml) of vitamin 
E succinate enhanced cell growth. 
Supplementation of non-malignant LLCMK cells with 1 and 3/Lg/ml vitamin E succinate in this study 
resulted in an overall marked increase in growth, while at 5, 7 and 1O/Lg/ml respectively, a non-
significant decrease in LLCMK growth occurred. However, in certain experiments (Exp's 3.3; 4.1, 
4.2; 4.8) (table lB), LLCMK growth was significantly decreased upon supplementation of vitamin 
E succinate, while in other experiments both significant (Exp's 4.4; 4.7) and non-significant (Exp's 
3.2.2; 3.2.3; 4.5) increases in LLCMK growth occurred. The reason for these varying effects on 
LLCMK growth in individual experiments is unclear, although the possibility exists that vitamin E 
succinate may have varied effects within the same cell line, a common occurrence in cell culture 
systems. 
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In an attempt to eliminate the possibility that the observed effects of vitamin E succinate 
supplementation on LLCMK and BL6 growth were due to the vehicle used, or the succinic acid 
component of the vitamin E succinate molecule, control experiments using equivalent amounts of 
ethanol (table 2A and 2B) and succinic acid with an equivalent amount of ethanol (table 3) were set 
up. In LLCMK cells, supplementation with ethanol or combined succinic acid and ethanol resulted 
in no significant increase or decrease in LLCMK growth, while BL6 cells showed..-a marked although 
non-significant increase in growth. Numerous studies with BL6 cells (42,126,399) have shown that 
supplementation with succinic acid, with an equivalent amount of ethanol, results in no significant 
change in growth or morphology of these cells. Thus it is reasonable to assume that the observed 
effects of vitamin E succinate supplementation on LLCMK and BL6 growth are the result of the 
vitamin E succinate molecule as a whole rather than the vehicle used or the succinic acid component 
of the vitamin. 
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VITAMIN E SUCCINATE UPTAKE, METABOLISM AND ROLE IN FREE RADICAL 
'. . 
FORMATION AND LIPID PEROXIDATION 
3.1 INTRODUCTION 
Reactive oxygen species such as the superoxide (S02-)' hydroxyl (OR), organic peroxide radicals, 
hydrogen peroxide (H20 2) and singlet oxygen, are continuously generated intracellularly in aerobic 
organisms (400), and if allowed to react uncontrollably are capable of causing extensive damage to 
macromolecular components within the cell such as DNA, carbohydrates, proteins and lipids 
(69,119,121,159). More recently, reactive oxygen species have beensuggested to play an important 
role in the stimulation of cell division (400). The close relationship between free radical activity and 
malignancy has been well documented (reviewed in 71), and at present the basic assumption appears 
to be that free radical mediated disturbances may play an important role in triggering the 
transformation of non-malignant cells to malignant cells (71,135). 
In normal cells, highly effective antioxidant defence mechanisms have been developed to protect 
against lipid peroxidation, toxic products of lipid peroxidation and free radical species 
(65,119,235,400). These protective mechanisms or antioxidant defences can be classified into two 
main categories, namely the enzymatic defence mechanisms, which include the superoxide dismutase, 
catalase and glutathione peroxidase enzymes (8,65,72,75,235), and the non-enzymatic cellular 
antioxidants which include the minerals selenium, copper, zinc and magnesium, and the vitamins A, 
E and C (60,65, 72,75,119,235,401). Under normal conditions, these antioxidant defence mechanisms 
provide adequate protection from free radical attack and lipid peroxidation, but, the possibility exists 
that under certain circumstances the effectiveness of these mechanisms may be decreased or even 
completely overwhelmed (401). Tumour cells are believed to have defective enzymatic antioxidant 
defences (139,400). Compared with their normal cell counterparts, it has been found that tumour cells 
are always low in superoxide dismutase, catalase (8,70,71,159,402) and glutathione peroxidase 
activity (8,71,159,402). Apart from antioxidant enzymes, tumour cells may be deficient in antioxidant 
vitamins and minerals. Numerous studies on the relationship between serum vitamin E and incidence 
of cancer have suggested an inverse relationship between the levels of vitamin E and risk of cancer 
development (52,54,60,119). As a result, one would expect tumour cells to have higher free radical 
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and lipid peroxidation levels than their normal counterparts {71, 159). 
Results from growth studies in section 2.2.3 have shown that vitamin E succinate supplementation 
significantly reduced the growth of BL6 cells in culture. The actual mechanism by which vitamin E 
succinate inhibits growth is at present unknown (126). Studies by Rama and Prasad (127) have 
suggested that the growth inhibitory effects of vitamin E succinate are mediated~ in part by its 
antio~idant properties. Vitamin E succinate, however, is a non-physiological antioxidant which 
requires esterase activity in order to liberated the free alcohol, a-TOH, with antioxidant properties 
(126,398,403,404). To date no species specific hydrolysis of vitamin E succinate has been 
demonstrated in murine melanoma cells. Researchers have suggested that esterified forms of vitamin 
E may undergo hydrolysis via a number of non-specific esterases associated with hydrophobic 
membranes and membranous structures present in most cells, such as the mitochondria, endoplasmic 
reticulum and nucleus (404). Concerning the uptake of vitamin E succinate, it appears that vitamin 
E esters are absorbed into the cell via an unknown transfer mechanism (405). 
Since it is unclear whether the growth inhibitory effect of vitamin E succinate on BL6 cells was 
mediated via an antioxidant mechanism, and because no species specific hydrolysis of vitamin E 
succinate has been demonstrated in BL6 or LLCMK cells, attempts were made to determine the effect 
of vitamin E succinate supplementation on free radical and lipid peroxidation levels in BL6 and 
LLCMK cells, as well as the relative uptake and metabolism of vitamin E succinate by these cells. 
3.2 EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON FREE RADICAL 
FORMATION AND LIPID PEROXIDATION LEVELS 
3.2.1 MATERIALS 
Trichloroacetic Acid (98%) (TCA) and glacial acetic acid (99.5%) were obtained from Holpro 
Chemical Co., South Africa. Butylated Hydroxy toluene (BHT), Nitroblue Diformazan (NBD), 
Nitroblue Tetrazolium (NBT) and 2-Thiobarbaturic acid (98 %) (TBA) were purchased from Sigma 
Chemical Co., USA. 1,1,3,3, -tetramethoxy-propan (98 %) (malondialdehyde-tetramethylacetal) was 
obtained from Fluka AG, Switzerland. 
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3.2.2 EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON FREE RADICAL 
FORMATION 
METHODS 
3.2.2.1 Cell culture procedure 
Methods described in sections 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were 
resuspended in 1.0ml PBS (PH 7.4). 
3.2.2.2 Nitroblue tetrazolium assay 
This is a simple and reliable technique for determining superoxide and other free radicals (406,407). 
The principle of the assay is based on the ability of free radicals to reduce NBT to insoluble 
diformazan, which can be extracted with glacial acetic acid and read at 560nm. A modified method 
of Sagar et al (406) and Das et al (407) was used for this assay. 1.0ml cell suspensions were 
incubated with O.4ml of 0.1 % NBT for two hours at 37°C. Termination of the assay and ~xtraction 
of reduced NBT was achieved by addition of 0.6ml glacial acetic acid. The absorbance of the reduced 
NBT was measured at 560nm and the resulting absorbance was converted to nmol diformazan using 
a standard curve (appendix 1) generated from NBD. Final results were expressed as nmol 
diformazanll06 cells. 
3.2.3 EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON LIPID 
PEROXIDATION LEVELS 
METHODS 
3.2.3.1 Cell culture procedure 
Methods described in sections 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were 
resuspended in 1.0ml 0.9% (w/v) saline solution (PH 7.6). 
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3.2.3.2 Thiobarbaturic acid assay 
The TBA assay is one of the most widely used methods for the determination of lipid peroxidation 
in biological samples (408,409). The principle of the assay is based on the reaction of MDA 
equivalents with TBA to form a pink complex which can be extracted with butanol and read at 
532nm. A modified method of Sagar et al (406) and Draper and Hardley (408) ~as used. To 1.0ml 
cell suspensions, 1.0ml of 25% TCA and O.5ml of BHT were added. Cell suspensions were 
centrifuged at 2 OOOg for 20 minutes to remove insoluble protein. Following centrifugation, 2.0ml 
of supernate was removed, and 0.25ml of 0.33% TBA added. Supernatant fractions were boiled for 
an hour at 95°C. Tubes were allowed to cool and the corresponding pink TBA-MDA complex was 
extracted with 2.0ml of butanol and read at 532nm. The absorbance values obtained were converted 
to nmol MDA from a standard curve generated with 1,1,3,3-tetramethoxypropane (appendix 2). Final 
results were expressed as nmol MDA/106 cells. 
3.2.4 STATISTICAL ANALYSIS 
The results obtained were analysed using a One Way Analysis of Variance (ANOVA), foflowed by 
a Student Newmans-Kuels Multiple Range test. Data in all subsequent sections of this chapter were 
similarly analyzed. 
3.2 .5 RESULTS 
The effect of vitamin E succinate supplementation on free radical levels in BL6 and LLCMK cells 
is shown in table 6. 
In BL6 cells, there was no significant increase or decrease in free radical levels at vitamin E succinate 
concentrations of 1, 3 and 5/Lg/ml compared with control cultures OE, while at 7 and lO/Lg/ml, a 
marked increase in free radical levels occurred, with a significant (p ~ 0.005) increase occurring at 
lO/Lg/ml. Analysis of lipid peroxidation levels in BL6 cells revealed a similar trend to that observed 
for free radical levels. At vitamin E succinate concentrations of 1 and 3/Lg/ml, no significant increase 
or decrease in MDA levels occurred, while at 5, 7 (p~0.OO5) and lO/Lg/ml (p~0.001) respectively, 
a significant increase in MDA levels occurred, compared with control cultures OE. 
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Table 6: The effect of vitamin E succinate supplementation on free radical formation and lipid 
peroxidation levels in BL6 and LLCMK cells respectively. (Values in the table are the mean of 5 
deterlllinations ± SEM). 
Vitamin E 
succinate 
(ltg/mI) 
-
OE 
1 
3 
5 
7 
10 
a= p~0.001: 
b= p~0.005: 
c= p~0.001: 
d= p~0.05: 
e= p~0.001: 
BL6 cells 
Free radical Lipid peroxidation 
formation(nmol (nmol MDA/I06 
diformazanl106 cells) 
cells) 
2.52 0.91 
±0.23 ±0.08 
2.96 0.48 
±0.38 ±0.11 
2.22 1.01 
±0.37 ±0.18 
2.98 3.37b 
±0.43 ±0.34 
3.58 3.28b 
±0.22 ±0.54 
4.52b 4.86a 
±0.41 ±0.88 
Relative to respective control cultures OE. 
Relative to BL6 control cultures OE. 
LLCMK cells 
Free radical Lipid peroxidation 
formation (nmol (nmol MDA/I06 
diforamzanl106 tellsf 
cells) 
5.68c 0.72 
±0.47 ±0.12 
2.92a 0.61 
±0.17 ±0.17 
4.04 0.59 
±0.31 ±0.14 
4.44 1.05e 
±0.32 ±0.14 
5.08 1.07e 
±0.50 ±0.15 ,> 
> •• 
6.50d O.92e 
±0.99 ±0.1O 
Relative to free radical levels in BL6 control cultures OE. 
Relative to free radical levels in BL6 cells supplemented with 10ltg/ml vitamin E suceinate. 
Relative to lipid peroxidation levels in BL6 cells in relevant groups. 
The LLCMK cells on the other hand (table 6) showed a general decrease in free radical formation 
at 1, 3, 5 and 7 jLg/ml vitamin E succinate, with a significant (p ~ 0.00 1) decrease occurring at 
1jLg/ml, while at lOjLg/ml vitamin E succinate, a non-significant increase in free radical levels 
occurred. Supplementation of LLCMK cells with 5, 7 and lOjLg/ml vitamin E succinate resulted in 
a non-significant increase in lipid peroxidation levels. 
Comparing free radical formation and lipid peroxidation levels in BL6 and LLCMK cells, it was 
evident that lipid peroxidation levels were generally higher in BL6 cells, significantly so at 5, 7 and 
lOjLg/ml vitamin E succinate. Free radical levels on the other hand were found to be generally higher 
in LLCMK cells, with significantly higher levels occurring in the control (p ~ 0.001) and lOjLg/ml 
(p ~ 0.05) supplemented cultures. 
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3.3 3H-VITAMIN E SUCCINATE UPTAKE IN BL6AND LLCMK CELLS. 
3.3.1 MATERIALS AND METHODS 
MATERIALS 
Emulsifier scintillator plus TM scintillation cocktail and scintillation vials were purchased from Packard 
Company. USA. Refer to section 2.2 for the remainder of materials used. 
METHODS 
3.3.1.1 Cell Culture procedure 
Refer to section 2.2.5.1 for method used. 
3.3.1.2 Homogenisation and separation into membrane and stroma fractions 
After cell enumeration, cell suspensions were poured into a dounce homogeniser and homogenised 
with 30 plunges of a tight plunger. The dounce homogeniser was rinsed with 1.0ml PBS, pH 6.6. 
Resulting homogenates were separated into membrane and stroma fractions by differential 
centrifugation. Cell homogenates were centrifuged (Beckman model 12-21) at 480g for 20 minutes 
at 4°C to remove undisrupted cells. Supernatant phase from step one was retained and further 
centrifuged at 4 OOOg for 20 minutes at 4°C. The supernatant was again retained and separated into 
membrane (pellet) and stroma (supernate) fractions by centrifugation at 20 OOOg for 30 minutes at 
4°C. The pellet was resuspended in 2.0ml of PBS pH 6.6. 
3.3.1.3 Determination of vitamin E succinate uptake 
Duplicate aliquots of membrane and stroma fractions were removed and added to scintillation vials 
containing lOml of scintillation cocktail. The radioactivity in membrane and stroma fractions was 
determined by counting in a Beckman (model LS2800) scintillation counter. 
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3.3.2 RESULTS 
Uptake of 3H -vitamin R succinate by BL6 and LcCMK cells (combined membrane arid stroma 
fractions) is shown in figure 13. The levels of 3H-vitamin E succinate in control cultures of LLCMK 
cells were found to be significantly (p::; 0.01) higher than the levels in BL6 control cultures OE. 
Supplementation of LLCMK cells with 3, 5, 7 and lOJLg/ml vitamin E succinate resulted in a 
significant (p::; 0.05) decrease in vitamin E succinate uptake compared with control cultures OE, while 
in BL6 cells, supplementation of 1 through to lOJLg/ml vitamin E succinate resulted in a significant 
(p::; 0.05) increase in vitamin E succinate uptake. 
OE 3 5 7 10 
Vitamin E succinate (1-l9/ml) 
• BL6 cells ~ LLCMK cells 
Figure 13: Comparison of total 3H-vitamin E succinate uptake in BL6 and 
LLCMK cells, and the effect of vitamin E succinate supplementation on 
these levels. (Each point on the graph represents the mean of 3 
determinations ± SEM). 
Table 7 shows the relative uptake of 3H-vitamin E succinate in membrane and stroma fractions ofBL6 
and LLCMK cells respectively. Supplementation of BL6 cells with l-lOJLg/ml vitamin E succinate, 
resulted in an overall increase in 3H -vitamin E succinate uptake in both membrane and stroma 
fractions when compared to their respective control cultures OE. However, 3H-vitamin E succinate 
uptake in LLCMK stroma fractions was significantly (p::;0.05) decreased following supplementation 
with 3, 5, 7 and lOJLg/ml vitamin E succinate, while in the membrane fractions uptake was 
significantly decreased at 3, 7 (p::; 0.01) and lOJLg/ml (p::; 0.05) respectively. 
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Table 7: The effect of vitamin E succinate supplementatiQn on 3H-vitamin E succinate uptake in 
membrane and stroma fractions of BL6 and LLCMK cells respectively. (Each value in the table 
represents the mean of 3 determinations ± SEM). 
VitaminE 
succinate 
(I'g/ml) 
OE 
-
1 
3 
5 
7 
10 
a= p:S;O.OOI: 
b= p:S;O.OI: 
c= p:S;0.05: 
d= p:S;0.05: 
e= p:S;O.OI: 
f= p:S;0.05: 
3H-vitamin E 3H-vitamin E succinate uptake (cpmJI0' cells) 
succinate (I'g/ml) 
Membrane fraction Stroma fraction 
BL6 cells LLCMK cells BL6 cells 
- -
J.,LCMK cells 
0.1 13.81 12.56a 15.96 73.42 
±1.42 ±0.28 ±0.43 ±9.50 
0.1 29.47 12.72a 23.22 71.68 
±3.00 ±0.87 ±3.16 ±8.51 
0.1 35.72 8.28be 25.31 36.28d 
±4.48 ±1.14 ±3.26 ±8.20 
0.1 36.69 9.82a 36.07 45.22d 
±7.18 ±0.60 ±8.33 ±3.55 
0.1 35.42 7. 84ce 35.62 30.77d 
±6.19 ±0.65 ±7.5 ±7.06 
0.1 39.03 9. 24bf 19.93 41.59d 
±8.32 ±0.83 ±2.64 ±3.1 
Relative to 3H-vitamin E succinate levels in LLCMK stroma fractions in relevant groups. 
Relative to 3H -vitamin E succinate levels in LLCMK stroma fractions in relevant groups. 
Relative to 7l'g/ml vitamin E succinate supplemented LLCMK stroma fraction. 
Relative to LLCMK stroma control cultures OE. 
Relative to LLCMK membrane control cultures OE. 
Relative to LLCMK membrane control cultures OE. 
Comparing uptake of 3H-vitamin E succinate between membrane and stroma fractions of these cells, 
non-significant differences were observed in BL6 cells. In contrast, 3H-vitamin E succinate uptake in 
membrane fractions of LLCMK control and vitamin E succinate supplemented cultures, was 
significantly lower than the uptake in the corresponding stroma fractions. 
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3.4 METABOLISM OF VITAMIN E SUCCINATE IN BL6 AND LLCMK CELLS 
-
3.4.1 MATERIALS AND METHODS 
MATERIALS 
Nitric acid (HN03) and Potassium Chloride (KCl) were purchased from Holpro Chemical Co., South 
Africa. High Performance Liquid Chromatography (HPLC) grade methanol, acetonitrile, hexane and 
ethanol were supplied by BDH Chemicals Ltd, England. Neostigmine, ascorbic acid (reduced-99%), 
iminodiacetic acid and (±) a-TOH (95%) were purchased from Sigma Chemical Co., USA. A 
reverse phase Bondaclone 10 C18 HPLC column (300rnrn x 3.9rnrn) was purchased from Phenomex, 
USA. Guard-Pak precolumns (5/-tm,ODS) were obtained from Metachemicals, USA. Sodium 
dihydrogen orthophosphate was supplied by Unilab, SAARCHEM, South Africa. 
METHODS 
3.4.1.1 Glassware preparation 
All glassware was treated by a modified method of Buettner (cited in 410). This procedure involved 
soaking glassware in 25% (v/v) HN03 for 48 hours followed by another 48 hour soak in milli-Q water 
containing 5g/1 of the chelating resin iminodiacetic acid. 
3.4.1.2 Preparation of calcium and magnesium free phosphate buffered saline 
In order to minimise TOH loss, trace amounts of adventitious catalytic transition metals such as Ca2 + 
and Mt+ were omitted from the assay buffer. This buffer was prepared as described in Kelly et al 
(410) with the exception that neostigmine (lOnM), an esterase inhibitor, was included in the buffer. 
3.4.1.3 Cell culture procedure 
Procedures described in section 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were 
resuspended in 1.0ml of calcium and magnesium free PBS, containing 10nM neostigmine. 
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3.4.1.4 Extraction of vitamin E and vitamin E succinate 
Extraction of vitamin E and vitamin E succinate wa£ carried out using a modified method of Kelly 
et al (410). Following cell enumeration, cell suspensions were centrifuged (Eppendorf 5403 
centrifuge) at 750g for 10 minutes at 4°C, supernatant discarded and the wash repeated with 
equivalent amounts of PBS and ascorbic acid. To pellets from the final wash was a,dded 1.0ml of PBS 
buffer, followed by vortex mixing and incubation on ice for 2 minutes. Cell suspensions were then 
transferred to a precooled dounce homogeniser containing O.5ml of 95% (v/v) ethanol, vortexed and 
homogenised 30 times with a tight plunger. The resulting cell homogenates were poured into 
precooled centrifugation tubes containing ice cold hexane, and the homogeniser rinsed with 0.5ml PBS 
buffer. Samples were vortex mixed for 1.0 minute, then centrifuged at 300g for 3 minutes to separate 
the hexane layer. The hexane layer was then transferred by glass pasteur pipette to storage vials. The 
head space was replaced with nitrogen and the vials stored at-70°C until required. 
3.4.1.5 Vitamin E and vitamin E succinate determination 
Extracted samples were analysed by Reverse-Phase HPLC, using a modified method of Scalia et al 
(411). Hexane extracts were dried under a stream of nitrogen and reconstituted in 100jll of mobile 
phase containing methanol: acetonitrile (60:40 (v/v)). Separations were performed on a Bondaclone 
10 CI8 column fitted with a Guard-Pak precolumn (5jlm, ODS) and eluted isocratically at a flow rate 
of l.5mllmin. 50jll aliquot volumes of the extracts were injected onto the column. Vitamin Kand 
vitamin E succinate were detected using a UV -visible spectrophotometer (Beckman, System Gold 
programmable detector module, model 166, USA). The identities of the separate compounds were 
determined by co-chromatography with authentic standards «±) a-TOH and vitamin E succinate), 
and the relative quantities of these compounds in the extracts were determined using peak areas and 
the standard curve shown in appendix 3. 
3.4.2 RESULTS 
The effect of vitamin E succinate supplementation on cellular vitamin E and vitamin E succinate 
content in BL6 and LLCMK cells is shown in table 8. Supplementation ofBL6 cells with l-lOjlg/ml 
vitamin E succinate resulted in a marked increase in vitamin E succinate levels being detected, with 
significant increases occurring at 3, 5 (p:-s:; 0.05), 7 and lOjlg/ml (p:-s:; 0.001) respectively, compared 
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with IjLg/ml vitamin E succinate supplemented cultures. In,contrast, vitamin E levels in BL6 cells 
supplemented with l-lOjLg/ml vitamin E succinate, ~ere marginally increased but showed no 
- -
significant trend compared with IjLg/ml supplemented, cultures. In LLCMK cells, supplementation 
with 3-lOjLg/ml vitamin E succinate resulted in no significant change in the levels of vitamin E 
succinate compared with IjLg/ml sample. However, with respect to the vitamin E levels in LLCMK 
cells, vitamin E succinate supplementation resulted in a general increase when .compared with the 
IjLg/ml group, with a significant (p ~ 0.001) increase occurring at lOjLg/ml. 
Table 8: The effect of vitamin E succinate supplementation on vitamin E and vitamin E succinate 
levels in BL6 and LLCMK cells respectively. (Each value in the graph represents the mean of 3 
samples ± SEM). 
Vitamin E Vitamin E succinate Vitamin E 
succinate (nmol/106 cells) (nmol/106 cells) 
(fLg/ml) 
BL6 cells LLCMK cells BL6 cells LLCMK cells 
OE ND ND ND 
1 0.294 0.203e 0.075 
±0.069 ±0.048 ±0.018 
3 1.149bc 0.048 0.235 
±0.129 ±0.007 ±0.121 
5 0.922bd 0.229 0.143 
±0.1Q4 ±0.075 ±0.056 
7 2. 152ac 0.452e 0.055 
±0.234 ±0.233 ±0.004 
10 4.09ac 0.168 0.159 
±0.277 ±0.032 ±0.037 
ND= Not detectable 
a= p:5:0.001: Relative to IfLg/ml vitamin E succinate supplemented BL6 cells. 
b= p:5:0.05: Relative to Ip.g/ml vitamin E succinate supplemented BL6 cells. 
c= p:5:0.001: Relative to vitamin E levels in BL6 cells in the relevant groups. 
ND 
0.016 
-' 
±0.OO2 
0.073f 
±0.035 
0.091 
±0.031 
. "'" -
0.107 
±0.01Q 
0.156g 
±0.034 
d= p:5:0.01: Relative to vitamin E levels in 5fLg/ml vitamin E succinate supplemented BL6 cells. 
e= p:5:0.01: Relative to vitamin E levels in LLCMK cells in the relevant groups. 
f= p :5:0.05: Relative to vitamin E succinate levels in 3fLg/ml supplemented LLCMK cells. 
g= p:5:0.01: Relative to IfLg/ml vitamin E succinate supplemented BL6 cells. 
Comparison of vitamin E succinate and vitamin E levels in BL6 cells supplemented with l-lOjLg/ml 
vitamin E succinate, revealed generally higher levels of vitamin E succinate in these cells, 
significantly so at 7 and lOjLg/ml. In LLCMK cells a similar trend to BL6 cells was observed, with 
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significant increases occurring at 1 and 7 j.tg/ml. The only exception was that recorded at 3j.tg/ml, 
where significantly higher levels of vitamin E were det~cted. 
3.5 DISCUSSION 
Studies by Fariss on vitamin E succinate-mediated cytoprotection against cadmium--induced (412) and 
oxygen-induced (413) toxicity in freshly isolated rat hepatocytes showed that vitamin E succinate 
supplementation significantly reduced lipid peroxidation levels. In addition, studies by Pascoe and 
Reed (cited in 404,405) have shown that vitamin E succinate was more effective than vitamin E in 
inhibiting the toxic effects of free radical-generating drugs such as adriamycin. The actual mechanism 
by which vitamin E succinate acts as an antioxidant, quenching free radicals and preventing lipid 
peroxidation, is unclear, although it has been suggested that vitamin E succinate may act as a carrier 
for vitaI11in E, enabling the uptake, release and accumulation_of vitamin E at a unique and critical 
cellular site within the cell (404,405,412,413). 
In BL6 and LLCMK cells used in this study, however, supplementation of vitamin E su~~inate 
resulted in a marked increase in lipid peroxidation levels, with a significant increase ()ccurrIng in the 
BL6 cells. The free radical levels in BL6 cells followed a similar trend to that of lipid peroxidation, 
while in the non-malignant LLCMK cells, an initial decrease in free radical levels occurred, followed 
by a general increase in free radical levels. One possible explanation for the ineffectiveness of vitamin 
E succinate in preventing free radical and lipid peroxidation in BL6 and LLCMK cells is that different 
forms of vitamin E exhibit varied intracellular compartmental distribution patterns (126), which may 
be cell specific. This is suggested by findings in BL6 and LLCMK uptake studies, which clearly show 
that vitamin E succinate was taken up by these cells, and furthermore that in BL6 cells, equivalent 
amounts of vitamin E succinate were located in both the cytosolic and membrane fractions, while in 
LLCMK cells the majority of vitamin E succinate was located in the cytosolic portion of the cell. 
The theory that vitamin E succinate acts as a carrier for vitamin E, enabling the uptake and release 
of vitamin E at a unique site within the cell, is not supported by data from these studies. In BL6 cells, 
supplementation with increasing concentrations of vitamin E succinate did not result in a marked 
increase in cellular vitamin E content, but rather a cellular accumulation of the intact vitamin E 
succinate molecule. LLCMK cells showed a general increase in vitamin E levels with increasing 
concentrations of vitamin E succinate, although the levels of vitamin E succinate were generally 
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higher than vitamin E levels. These results suggest that the inability of vitamin E succinate 
supplementation to reduce free radical and lipid peroxiqation levels in BL6 and LLCMK cells, may 
be due to the absence of various esterase enzymes in these cells, capable of removing the succinate 
component of the vitamin E succinate molecule, and liberating free vitamin E with antioxidant 
properties. 
Vitamin E succinate may have numerous other potential roles within the cell, such as alteration in 
membrane stability or function through the direct interaction of the lipophilic TOll moiety with 
unsaturated fatty acids and the ionic succinate moiety with polar phospholipid regions of the 
membranes (412,413). Several reports indicate that vitamin E succinate supplementation stabilises 
membranes (414) and alters membrane-bound enzyme activities (124,415,416). In order to explain 
the lack of antioxidant effect of vitamin E succinate found in this study, alternative pathways needed 
to be investigated. Since vitamin E has been suggested to playa role in the direct modulation of 
regulatory proteins in signal transduction pathways, as well as modulating the activity of key 
regulatory enzymes in the eicosanoid pathway (135,417,418), the effect of vitamin E succinate 
supplementation on the eicosanoid pathway and its relevant metabolites associated with cell growth 
were subsequently investigated in BL6 and LLCMK cells. ' 
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VITAMIN E SUCCINATE SUPPLEMENTATION AND SECONDARY MES,SENGER 
METABOLISM 
Studies reported in chapter 2 have shown that supplementation of vitamin E succinate significantly 
r - -
reduced BL6 cell growth while having minimal effects on LLCMK cell growth. Although 
numerous researchers working with BL6 cells have reported similar growth inhibitory effects upon 
supplementation of vitamin E succinate (42,124,127,399), the actual mechanism by which vitamin 
E succinate inhibits growth is unclear. This study initially considered the possibility that toxic 
effects of vitamin E succinate supplementation on tumour cell growth were mediated to a certain 
extent through the antioxidant properties of the vitamin. Studies reported in chapter 3 however 
revealed no antioxidant role for vitamiri E succinate in BL6 or LLCMK cells, but rather a 
prooxidant role, increasing free radical formation and lipid peroxidation levels within these cells. 
Since lipid peroxidation (159,235) and free radical formation (235) has been linked to COX and 
LOX activity, and vitamin E is believed to be active in a number of aspects of the eicosanoid 
metabolism (135,417,418), it was necessary to determine the effect of vitamin E ,&uccinate 
supplementation on various enzymes and metabolites associated with this pathway (figure 4), as 
well as the various factors influencing the pathway. 
4.1 VITAMIN E SUCCINATE SUPPLEMENTATION AND CALCIUM LEVELS 
4.1.1 INTRODUCTION 
Although characterised only by its charge, coordination number and unhydrated radius (263), Ca2+ 
ions acquire a specific ability to modulate many cellular functions when bound to calcium-dependant 
regulatory proteins such as calmodulin (263,264,419). Ca2+ ions exert a variety of effects on 
biological processes and are known to participate in membrane-associated functions such as regulation 
of enzyme activities (145,275,277,419,420), transduction of hormonal information, stimulus secretion 
coupling, transport systems, neuronal conduction and muscular contraction (145). The ability ofCa2+ 
to regulate metabolic processes within a cell, is believed to be due to the "sticky" nature of Ca2+ions, 
which enables them to bind to a variety of ligands such as proteins and phosphate groups (264). The 
69 
4. Secondary Messenger Metabolism 
availability of Ca2+ within a cell is believed to be a key regulator of cell proliferation in multicellular 
organisms. Defects in Ca2+ control processes are a. common determinant of unrestrained cell 
proliferation (278,279), and this is believed to be a' major factor contributing to tumour mortality 
(284). Since Ca2+ levels play an important role in modulating cell proliferation, and earlier studies 
(chapter 2) have shown significant inhibition of malignant BL6 cell growth following vitamin E 
succinate supplementation, it was necessary to determine the levels of Ca2+ in malignam: BL6 and non-
malignant LLCMK cells, as well as the effect of vitamin E succinate supplementation on intracellular 
-
Ca2+ levels. 
4.1.2 MATERIALS AND METHODS 
MATERIALS 
A GBC 909 model Atomic Absorption Spectrophotometer was used for Ca2+determinations. Calcium 
Chloride (CaCI2) standard was purchased from Merck, Darmstadt Germany. 
METHODS 
4.1.2.1 Glassware preparation 
Refer to section 3.4.1.1 for method used. 
4.1.2.2 Cell culture procedure 
Methods described in section 2.2.3.1 and 2.2.3.2 were repeated, except that cell pellets were 
resuspended in 1.0ml of Tris-HCI buffer pH 7.4. 
4.1.2.3 Acid digestion and calcium determination 
On completion of cell enumeration, suspensions were centrifuged at 3 OOOg for 10 minutes. The 
resulting supernatant solutions were discarded and the wash repeatedly with 1.0ml of Tris-HCI buffer. 
The supernatant fraction was discarded and centrifugation tubes were drained. Cell pellets were 
resuspended in 0.2ml concentrated HCI and boiled at 100°C for two hours. Following acid digestion, 
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0.3ml of milli-Q water was added to cell pellets to give a final volume of 1.0mI. This was followed 
by centrifugation at 3 OOOg for 10 minutes to remove d~bris. Caz+ levels in supernatant phases were 
detennined using flame atomic absorption spectroscQPY, using a GBC model atomic absorption 
spectrophotometer. The fuel source was nitric oxide:acetylene; slit width was O.5nm; wavelength set 
at 422.7nm; and current 3mA. The absorbance values obtained were converted to jLM 
Caz+concentrations from a standard curve (appendix 4) generated from standard CaClz solution. 
4.1.3- STATISTICAL ANALYSIS 
The results obtained were analysed using a One Way Analysis of Variance (ANOVA) followed by 
the Student Newmans-Kuels Multiple Range Test. Data in all subsequent sections of this chapter were 
analysed by this method. 
4.1.4 ·RESUL TS 
Supplementation of BL6 cells with 1-1OjLg/ml vitamin E succinate (table 9) resulted in a non-
significant increase in Caz+ levels at 1-7 jLg/ml respectively, while at 10jLg/ml supplementation, a non-
significant decrease occurred compared with control cultures OE. 
In LLCMK cells, supplementation with 1 and 3jLg/ml vitamin E succinate resulted in a marked 
increase in Caz+ levels compared with control cultures OE, with a significant (p:::;; 0.05) increase 
occurring at 3jLg/mi. In contrast, supplementation of 5, 7 and 1OjLg/ml vitamin E succinate re_sulted 
in a general decrease in Caz+levels, with a significant (p:::;; 0.001) decrease occurring at 7 and 1OjLg/ml 
respectively. The Caz+ levels in BL6 control and vitamin E succinate-supplemented cultures were 
generally lower than the levels of Caz+ found in the LLCMK control cultures, significantly so in the 
control and 1-5jLg/ml vitamin E succinate-supplemented cultures. 
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Table 9: The effect of vitamin E succinate supplementation on calcium levels in BL6 and LLCMK 
cells respectively. (Each value in the table represents the mean of 3 determinations ± SEM) . 
. 
Vitamin E succinate Calcium concentration (ltg/lO' cells) 
(ltg/ml) 
OE 
1 
3 
5 
7 
10 
a= p=:;;O.OOl: 
b= p=:;;0.05: 
c= p=:;;O.OOl: 
d= p=:;;0.05: 
4.1.5 DISCUSSION 
BL6 cells LLCMK cells 
8.24a 103.80 
±1.57 ±60.83 
11.30c 226.83 
±6.00 ± 115.11 
1O.lOc 404.80b 
±3.60 ±134.09 
9.79d 84.92 
±3.35 ±31.51 
9.68 1O.84a 
±1.44 ±1.82 
7.30 8.96a 
±3.30 ±1.29 
Relative to LLCMK control cultures OE. 
Relative to LLCMK control cultures OE. 
Relative to calcium levels in LLCMK cells in the corresponding groups. 
Relative to Ca2+ levels in 5ltg/ml supplemented LLCMK cultures. 
Cancer is associated more frequently with hypocalcaemia than with hypercalcaemia (421). Pancreatic 
acinar carcinoma cells have been shown to have lower levels of free Ca2+ than their normal cell 
counterparts (cited in 422). In contrast, other tumour cells have higher levels of Ca2+ than their 
normal cell counterparts (285,287). In this study malignant BL6 control cultures were found to have 
significantly lower levels of Ca2+ than non-malignant LLCMK control cultures. Coman (cited in 285 
and 287) postulated that the local invasiveness and ability of tumour cells to metastasis were due to 
decreased adhesiveness between tumour cells as a result of decreased ability of these cells to bind 
Ca2+. If this hypothesis were valid, one would expect lower levels of free Ca2+in malignant cells than 
in non-malignant cells. In another study on BL6 cells, the amount of soluble Ca2+ in most cases was 
below 50% of the total Ca2+ within the cell (287). 
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Changes in the distribution and levels of intracellular Ca2+ are believed to play an important role in 
the development of neoplasia (422). In BL6 cells used in this study, supplementation of 1 through to 
7 jLg/ml vitamin E succinate resulted in a general although non-significant increase in intraceiIular Ca2+ 
levels compared to control cultures, while at lOjLg/ml, a slight decrease in Ca2+levels occurred. The 
ability of vitamin E succinate to alter the physical properties of membranes through their 
physicochemical interaction with membrane lipids (412,413), could account for the "Observed changes 
in Ca:+ levels, since the only mechanism available for causing large scale changes in intracellular 
Ca2+ levels involves movements across the plasma membranes (264). In non-malignant LLCMK cells, 
an inconsistent trend in Ca2+ levels was found following supplementation with vitamin E succinate. 
As far as can be ascertained, the effect of vitamin E succinate supplementation on Ca2+ levels in 
LLCMK cells has not been reported to date. As Ca2+ levels play an important role in modulating 
PLA2 activity (270-277,420), and since marked changes in intracellular Ca2+ levels have been shown 
to occur in BL6 and LLCMK cells supplemented with varying levels of vitamin E succinate, it was 
necessary to study the effect of vitamin E succinate supplementation on PLA2 activity in BL6 and 
LLCMK cells. 
4.2 VITAMIN E SUCCINATE SUPPLEMENTATION AND PHOSPHOLIPASE Az 
ACTIVITY 
4.2.1 INTRODUCTION 
All mammalian cell membranes consist of a lipid bilayer composed primarily of phospholipids and 
cholesterol (146). Phospholipids constitute the major structural components of cell membranes and 
playa key role in a number of biological functions such as signal transduction, secondary messenger 
generation, cell membrane integrity (146,423,424) and activity of membrane-bound enzymes 
(146,423-425). The fatty acid AA, present at the one and two position on the phospholipid molecule 
(423) is an important precursor of PG and leukotriene biosynthesis (426-428) in its non-esterified 
form (429). The release of AA from the Sn2 position of phospholipids moieties occurs primarily 
through the activation of PLA2 enzymes (424-427,430-432). These enzymes are a structurally diverse 
group, which include low MW Ca2+ -dependant and independent intracellular forms (420). Of interest 
to this study is the membrane-bound 85KDa PLA2 (cPLA), which is specific for AA at the Sn2 
position, and regulated by intracellular Ca2+ levels. This enzyme is activated and becomes membrane-
associated at levels of Ca2+ found intracellularly (291,293,295,297,299,311,420). Furthermore studies 
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by Lin et al (311) have demonstrated that cPLA2 activity can be triggered by the activation of cell 
surface receptors, and tl!at receptor-mediated activation of cPLA2 requires synergistic actions of 
.< 
intracellular Ca2+ and a phosphorylation of enzyme. 
The calcium-dependant PLA2 enzyme plays a crucial role in the eicosanoid pathway, where it 
functions to produce rate-limiting precursor substrates for 5-LOX and COX enzymes (273,292-
297,299,304). Since this study considered the effect of vitamin E succinate supplementation on the 
eicosanoid pathway (figure 4), and prostaglandin synthesis is regulated acutely by PLA2 activity, and 
indirectly by changes in intracellular Ca2+ levels, the effect of vitamin E succinate supplementation 
on PLA2 in BL6 and LLCMK cells was determined. 
4.2.2 MATERIALS AND METHODS 
MATERIALS 
1-Palmitoyl-2-(1-CI4)-Arachidonyl-sn-Glycero-3 -Phosphotidylcholine(1-CI4-PC) was suppli~clby New 
England Nuclear Products, Boston, USA. Taurocholic acid, fatty acid free Bovine Serum Albumin 
(BSA) and Phosphatidyl Choline (PC) were purchased from Sigma Chemical Co., USA. Chloroform 
was obtained from BDH Chemicals LTD, England, while Folin-Ciocalteau reagent, Copper Sulphate 
(CuS04"5H20) and sodium tartrate were purchased from Unilab, SAARCHEM, South Africa. Silica 
gel 60 aluminium Thin Layer Chromatography (TLC) plates were supplied by Merck, Darmstadt, 
Germany. 
METHODS 
4.2.2.1 Cell culture procedure 
Methods described in 2.2.3.1 and 2.2.3.2 were repeated except that cell pellets were resuspended in 
1.0ml ofO.1M Tris-HCI buffer pH 7.4. 
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4.2.2.2 Homogenisation and separation of membrane arid stroma fractions. 
The method described in section 3.3.1.2 was used with'the following change. The pellet (membrane) 
fraction was retained and resuspended in 2.0ml of O.IM Tris-HCI buffer pH 7.4. 
4.2.2.3 Protein determination 
Protein determinations were performed using a modified method of Lowry et al (cited in 433). The 
absorbance values obtained were converted to mg/ml protein from a standard curve (appendix 5) 
generated from BSA. 
4.2.2.4 Phospholipase A2 assay 
A modified method of Krumhardt and Dupont (425) and Ballou and Cheung (303) was used to 
determine membrane PLA2 activity. 
A 200jLI aliquot of membrane suspension was incubated for 10 minutes at 37°C with 50jLI of a 
reaction mixture containing O.IM Tris-HCI buffer pH 7.5, 50mM taurocholic acid, 20mM CaCI2 , 
0.05% (w/v) BSA and 0.03jLCi of l-C14-PC. Following a 10 minute incubation period, a l00jLl aliquot 
of this solution was spotted on a silica gel 60 TLC plate. Plates were developed in a solvent system 
of chloroform:methanol:water (65:25:4 v/v/v). AA and PC were used as markers. Silica geIlii the 
regions corresponding to the AA and PC were scraped off into scintillation vials containing lOml of 
emulsifier scintillation plus TM scintillation cocktail and counted in a Beckman scintillation counter 
(Model LS 2800). PLA2 activity was determined as net l-C14-AA released from l-C14-PC substrate, 
and was expressed as pmol AA released per minute per mg membrane protein. 
4.2.3 RESULTS 
PLA2 activity in BL6 control and vitamin E succinate-supplemented cultures were significantly 
(p::;;0.001) lower than the levels of PLA2 activity in LLCMK cultures (table 10). Supplementation 
of vitamin E succinate resulted in a significant increase in PLA2 activity in BL6 cells at 1 (p::;; 0.05), 
3 (p ::;;0.001) and 5jLg/ml (p ::;;0.05) respectively, while at 7 and 10 jLg/ml vitamin E succinate, a non-
significant increase in PLA2 activity was observed compared to control cultures OE. 
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Table 10: The effect of vitamin E succinate supplementation on Phospholipase Az activity in BL6 and 
LLCMK cells respectively. (Each value in the table repr~sents the mean of 3 determinations ± SEM). 
Vitamin E succinate Phospholipase A2 activity (pmol AA/minlmg protein) 
(JLg/ml) 
OE 
1 
3 
5 
7 
10 
a= p:s;O.OOI: 
b= p:s;0.05: 
c= p:s;O.OOI: 
BL6 cells 
2A8c 
±0.15 
3.80bc 
±0.14 
4.98ac 
±OA9 
4.25bc 
±0.51 
3.25c 
±0.12 
3.38c 
±0.07 
Relative to BL6 control cultures OE. 
Relative to BL6 control cultures OE. 
LLCMK cells 
13.94 
±2.f9 -
12.46 
±1.18 
13.53 
±1.38 
13.99 
±0.29 
14.27 
±0.87 
13.05 
±1.75 
Relative to PLA2 activity in LLCMK cells in corresponding groups. 
Supplementation of LLCMK cells with l-IO/Lg/ml vitamin E succinate resulted in no significant 
increasing or decreasing trend in PLAz activity compared to control cultures OE, except at 74-tg/ml 
vitamin E succinate, where an increase in PLAz activity was observed. 
4.2.4 DISCUSSION 
The mobilisation of AA is primarily initiated by physiological and/or pharmacological agonists which 
function to activate one or more intracellular or extracellular PLAz enzymes. In unstimulated cultured 
cells, the basal turnover of phospholipids by PLA2 exhibits no particular fatty acyl specificity. In 
contrast, agonist-stimulated fatty acid mobilisation is remarkably specific for AA and a few 
structurally unrelated PUPAs. Many of the agonists which stimulate AA mobilisation also increase 
the levels of intracellular free Ca2+ (299). The 85KDa PLAz enzymes exhibit many prerequisite 
characteristics for involvement in intracellular signal transduction pathways (299), such as selectivity 
towards phospholipids containing AA at Sn2 position, and its activation and translocation to 
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membranes in response to physiological (submicromolar) concentrations of Ca2+ (291,293,295,297, 
299). 
The activities of PLA2 assessed in tumour and normal tissue have generally shown increased PLA2 
in tumour tissue compared to normal tissue (427,428). Comparing membrane bound PLA2 activity 
in BL6 and LLCMK control cultures in this study, revealed that PLA2 activity was 'Significantly lower 
in the_ malignant BL6 cell line. Since this study was concerned with a Ca2+ -dependant PLA2 enzyme, 
and earlier studies reported in section 4.1 have shown significantly lower levels of Ca2+in BL6 cells 
compared to LLCMK cells, it is reasonable to assume that the lower levels of PLA2 in BL6 control 
cultures may be due to lower intracellular Ca2+ levels. In addition to this, tumour cells have been 
reported to have altered essential fatty acid (EF A) compositions compared to their normal cell 
counterparts (423,434,435). In particular, the levels of PUFA AA have been found to be generally 
lower in tumour cells (434,435). Thus, limited availability of AA required for membrane-bound PLA2 
activity (299,311,420), could also account for the lower PLA2 activity observed in BL6 cells. 
Supplementation of BL6 cells with increasing levels of vitamin E succinate resulted in a general 
,--
increase in PLA2 activity relative to control cultures. These increases correlate positively with the 
corresponding slightly increased intracellular Ca2 + levels which were found in earlier studies, 
suggesting that PLA2 activity in BL6 cells may be mediated in part by the intracellular Ca2+ levels. 
An exception was at lOj.tg/ml supplementation, which showed a marked increase in PLA2 activity and 
decrease in Ca2+ levels. Since tumour cells are believed to have altered membrane fluidities-(i59-
161), and vitamin E succinate supplementation has been suggested to alter membrane fluidity 
(413,414), it is proposed that the observed increase in membrane bound PLA2 activity in BL6 cells 
at lOj.tg/ml vitamin E succinate supplementation, could be due to changes in the membranes physical 
properties, although the role of vitamin E succinate in modulating membrane fluidity at 1-7j.tg/ml 
vitamin E succinate may also influence PLA2 activity at these levels of supplementation. While PLAz 
activity increased with vitamin E succinate supplementation in BL6 cells, LLCMK cells showed 
marginal increases in PLA2 at 7 j.tg/ml vitamin E succinate only. The reason for this lack of effect in 
LLCMK cells is unclear, although one factor to consider is that the physical and chemical properties 
of non-malignant cell membranes are essentially "normal" compared to those of malignant cells, and 
as a result membrane-bound enzymes are more stable in normal cells and less likely to be affected 
by vitamin E succinate supplementation. The dependence of 5-LOX and COX activity on Ca2+ (276) 
and AA levels within a cell, and the finding that vitamin E succinate supplementation markedly 
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altered intracellular Ca2+ levels and PLA2 activity in BL6 cells, led to further investigations of both 
the activities of 5-LOX and COX in BL6 and LLCMK cells. 
4.3 VITAMIN E SUCCINATE SUPPLEMENTATION ANDLIPOXYGENASE ACTIVITY. 
4.3.1 INTRODUCTION 
AA is a precursor of a large variety of potent physiological effectors. This PUPA is the branch point 
leading to two important pathways, namely the COX pathway which functions to synthesise PGs and 
thromboxanes, and the LOX pathway which synthesises various leukotrienes and lipoxins (436). To 
date, three animal LOXs have been identified, and are referred to as 5-, 12- and 15-LOX depending 
on where oxygen is inserted on the AA moiety (437). Both the 12- and 15-LOX enzymes have been 
shown to have broad substrate specificities, whereas the 5-LOX enzymes predominantly react with 
C20 fatty acids such as AA. LOX enzymes are non-heme, non-sulphur iron dioxygenases which react 
with fatty acid substrates containing one or more 1,4-z,z-pentadiene moieties to yield z,e-conjugated 
hydroperoxides (436,438,439). These hydroperoxides are precursors of specific regulatory molecules, 
' .. 
such as leukotrienes and lipoxins in animals (436,439), and jasmonic acid and traumatin in plants 
(439). Leukotrienes are a group of potent biological mediators which act at nanomolar concentrations 
in intracellular communications, signal transduction and more importantly host immune defence (440). 
Since the LOX pathway synthesises many products which affect cell proliferation (159,235), and the 
recent findings that metabolism of AA by LOX enzymes is a major source of free radical (235) and 
lipid peroxidation levels within a cell (159,235), the possibility exists that the observed increase in 
free radical and lipid peroxidation levels in BL6 and LLCMK cells (see section 3.2) supplemented 
with varying levels of vitamin E succinate were due to an increased LOX activity in these cells. 
Hence this study was undertaken to determine the effect of vitamin E succinate supplementation on 
5-LOX activity in malignant BL6 and non-malignant LLCMK cells. 
4.3.1.1 MATERIALS AND METHODS 
MATERIALS 
ATP and 5 (s )-Hydroperoxy-(6E,8Z, llZ, 14Z)-Eicosatetranoic acid (5-HPETE) were purchased from 
Sigma Chemical Co., USA. Calcium Chloride (CaCI2) was purchased form Merck, Darmstadt, 
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Germany, while sucrose was obtained from Unilab, SAARCHEM, South Africa. 
METHODS 
4.3.1.2 Cell culture procedure 
The methods described in 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were resuspended 
in 1.0rn! of lOmM Tris-HCI buffer (PH 8.0) containing ImM EDTA and 0.25M sucrose. 
4.3.1.3 Homogenisation and enzyme preparation 
Enzyme preparation was carried out using a modified method of Soberman (441). Following cell 
enumeration, cell suspensions were poured into a dounce homogeniser and homogenised 30 times with 
a tight plunger. The homogeniser was rinsed with 1.0ml of Tris-HCI buffer. Resulting cell 
homogenates were poured into precooled centrifugation tubes and centrifuged at 10 OOOg for 10 
minutes at 4°C. Supernatant solutions were retained and stored at -70°C until required. 
4.3.1.4 5-Lipoxygenase assay 
For routine assay of 5-LOX activity, a modified method of Soberman (441) and Furukawa et at (442) 
was used. The principle of this assay is based on the addition of 3H-AA to the enzyme preparation, 
separation of product 5-HPETE from substrate 3H-AA by TLC and quantification and determination 
of radioactive product formed by scraping the relevant sections of the TLC plates. Standard reaction 
mixtures containing lOmM Tris-HCI (PH 8,0), 4mM ATP, 2mM CaCI2, 20ILM 15-3H AA and enzyme 
solution (75ILI) in 200ILI final volume, were allowed to react for 10 minutes at room temperature, and 
terminated by the addition of 500ILI of ethyl ether:methanol:2N citric acid (30:4: 1 v/v/v). Terminated 
samples were centrifuged at 3 OOOg for 5 minutes at 4°C. A 100ILI aliquot of upper organic layer was 
removed, spotted onto precoated silica gel F254 aluminium TLC plates, and dried under a stream of 
nitrogen. AA and 5-HPETE standards were used as markers. Plates were developed in ethyl 
ether:petroleum ether:acetic acid (50:50: 1 v/v/v) at 4°C. Silica gel in the regions corresponding to 
AA and 5-HPETE were scraped off into scintillation vials containing lOml of emulsifier scintillator 
plus™ scintillation cocktail and counted in a Beckman counter (Model LS 2800). Final results were 
expressed as pmol 5-HPETE formed per 106 cells. 
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4.3.2 RESULTS 
The effect of vitamin E succinate supplementation on .5-LOX activity in BL6 and LLCMK cells is 
shown in table 11. In BL6 cells, supplementation with 3-1Oj.tg/ml vitamin E succinate resulted in a 
general increase in 5-LOX activity compared with control cultures OE, with a significant (p:S;0.001) 
increase occurring at lOj.tg/ml. Supplementation of LLCMK cells with l-lOj.tg/ml vitamin E succinate 
resulted in no significant increase or decrease in 5-LOX activity at 1, 3 and 5j.tg/ml vitamin E 
-
succinate, while at 7 and lOj.tg/ml respectively, a significant (p:S;0.001) increase in 5-LOX activity 
occurred. When comparing the levels of 5-LOX activity in control cultures of BL6 and LLCMK cells, 
lower levels of 5-LOX activity were detected in BL6 cells. 
Table 11: The effect of vitamin E succinate supplementation on 5-lipoxygenase activity in BL6 and 
LLCMK cells respectively. (Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate 5-lipoxygnease activity (pmol 5-HPETE fonnedl106 cells) 
(ltg/ml) 
OE 
1 
3 
5 
7 
10 
a= p::;;O.OOI: 
b= p::;;O.OOI: 
4.3.3 DISCUSSION 
BL6 cells 
0.23 
±0.02 
0.15 
±0.03 
0.31 
±0.03 
0.28 
±0.03 
0.33 
±0.04 
0.85a 
±0.03 
Relative to BL6 control cultures OE. 
Relative to LLCMK control cultures OE. 
LLCMK cells 
0.28 
±0.06 
0.29 
±0.06 
0.17 
±0.02 
0.41 
±0.05 
l.07b 
±0.15 
l.07b 
±0.1O 
The 5-LOX (EC 1.13.11.34) enzyme catalyses the first two steps in Ieukotriene formation (443-446). 
80 
4. Secondary Messenger Metabolism 
These two steps involve the oxygenation of AA to form 5-hydroperoxy acid (5HPETE) and 
subsequent conversion of 5-HPETE to leukotrie_ne A4 (LTA4) (442,443,446-448). 5-LOX activity in 
the BL6 control and vitamin E succinate-supplemented cultures in this study, were found to be 
markedly lower than that in the LLCMK control cultures, which supports evidence that malignant 
cells generally have lower 5-LOX (449). 
Resul1s from this study also indicate that vitamin E succinate supplementation stimulates 5-LOX 
activity in BL6 and LLCMK cells. Other studies (439,450) however, have suggested that chain 
breaking antioxidants such as vitamin E inhibit LOX activity, and furthermore that these inhibitory 
effects occur at high doses of vitamin E. Vitamin E succinate, however, is a non-physiological 
antioxidant which exhibits no antioxidant properties in its esterified form (126,398,403,404). Since 
no significant cleavage of vitamin E succinate was shown to occur in BL6 cells (section 3.4), it is 
proposed that the observed effects of vitamin E succinate supplementation on 5-LOX activity in BL6 
cells did not involve antioxidant properties. 5-LOX enzymes exhibit a specific requirement for mM 
Ca2+concentrations (438,442,443,446), lipid hydroperoxide activators (438,449,451) and precursor 
fatty acids AA (438) during catalytic activity. This suggests that the observed effects of vitamin E 
succinate supplementation on BL6 and LLCMK 5-LOX activity may be mediated through changes in 
the levels of one or more of these cofactors. However, earlier studies on intracellular Ca2+ in 
LLCMK cells have shown significant decreases in Ca2+ levels at 7 and 10f.tg/ml vitamin E succinate, 
while in BL6 cells, marked decreases occurred at lOf.tg/ml supplementation. These decreases in 
intracellular Ca2+ levels were inversely related to 5-LOX activity, and suggests that 5-LOX aCtivity 
in these cells was independent of intracellular Ca2+ levels at high concentrations of vitamin E 
succinate. 
4.4 VITAMIN E SUCCINATE SUPPLEMENTATION AND CYCLOOXYGENASE 
ACTIVITY 
4.4.1 INTRODUCTION 
The cyclooxygenase enzyme is a membrane-bound multi-enzyme complex (176) located on the smooth 
ER (170,172-174,195). This enzyme metabolises AA to various eicosanoids (see section 1.5.4 and 
1.5.5) and is found in both normal and neoplastic tissues (452). As previously mentioned, vitamin 
E and other lipid-soluble antioxidants are believed to modulate the eicosanoid pathway at a number 
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of different points (417,418). It has been suggested that antioxidants either inhibit, stimulate or have 
no effect on COX activity (417). These effects however depend largely on the type and concentration 
of the- antioxidant used (453) as well as the system 15eing studied (417). In addition to their general 
role in eicosanoid metabolism, the COX enzymes are believed to be major sources of free radical 
(235) and lipid peroxidation levels within a cell (159,235). Since preliminary studies outlined in 
chapter 3 have shown significant increases in free radical and lipid peroxidation 1evels in BL6 cells 
follo~ing supplementation with vitamin E succinate, this study was undertaken to determine the 
effects of vitamin E succinate supplementation on COX activity in malignant BL6 and non-malignant 
LLCMK cells. 
4.4.2 MATERIALS AND METHODS 
MATERIALS 
AA, Prostaglandin Bz (PGBz) and Protoporphyrin IX were purchased from Sigma Chemical Co., 
USA. Tris (Hydroxymethyl)-aminomethane was purchased from Boehringer Mannheim. Preooated 
,--
Silica gel 60 FZ54 aluminium TLC plates were supplied by Merck, Darmstadt, Germany, while citric 
acid was obtained from H.W.O. Chemical Co., South Africa. 15-3H AA was purchased from 
Amersham International, England. Petroleum ether, ethyl ether and anhydrous Sodium Sulphate (Naz 
S04) were obtained from Unilab, SAARCHEM, South Africa. 
METHODS 
4.4.2.1 Cell culture procedure 
The methods described in 2.2.3.1 and 2.2.3.2 were used, except that the cell pellets were resuspended 
in 1.0ml of Tris-HCI buffer, and final pellets (membrane fraction) resuspended in 2.0ml of Tris-HCI 
buffer. 
4.4.2.2 Homogenisation and separation into membrane and stroma (ractions 
The method described in section 3.3.1.2 was used except that cell pellets (membrane fractions) were 
resuspended in 2.0ml 0.1M Tris-HCI buffer pH 7.4. 
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4.4.2.3 Cyclooxygenase assay 
A modified method of Yamamoto (4S4) was used to'determine COX activity. The principle of this 
assay is based on the addition of a radioactive substrate CH-AA) to the enzyme preparation and 
separation of reaction product PGG2 by thin layer chromatography (TLC) based upon their affinity 
for a non-polar solvent. A reaction mixture containing 70jLI of 0.2M Tris-HCI bUffer pH 8.0, lOjLI 
of 40pM manganese protoporphyrin IX, SjLI of Snmol AA and SjLI of 15-3H AA (0.42pmol) was 
vortex mixed to disperse AA. A 10jLI aliquot of the membrane suspension was added to the reaction 
mixture, and allowed to react for 2 minutes at room temperature. Termination of the reaction was 
carried out by addition of 300jLI of a mixture of ethyl ether:methanol:0.2M citric acid (30:4:1 v/v/v) 
precooled to -20°C. The terminated reaction mixture was transferred to an ice bath, where O.Sg of 
anhydrous sulphate was added with gentieshaking. A 150jLI aliquot of the upper organic phase was 
removed using a graduated capillary tube, spotted onto precoated silica gel 60 F254 aluminum TLC 
plates and dried under a stream of nitrogen. AA and PGB2 standards were used as markers since 
PGG2 is not available commercially. Plates were developed in TLC tanks containing ethyl 
ether:petroleum ether:acetic acid (85:1S:0.1 v/v/v) in a fridge at 4°C. AA and PGB2 markers were 
visualised with iodine vapours and product PGG2 located between these two markers (455). Silica gel 
in the regions corresponding to AA, and PGG2 were scraped off into scintillation vials containing 
lOml of emulsifier scintillator plus TM scintillation cocktail and counted in a Beckman scintillation 
counter (Model LS 2800). Final results were expressed as pmol PGG2 formed per 106 cells. 
4.4.3 RESULTS 
At vitamin E succinate concentrations of 1 and 3jLg/ml, no significant increase or decrease in COX 
activity in BL6 cells (table 12) was detected, compared with control cultures OE, while at S,7 and 
10jLg/ml, a marked increase in COX activity occurred, with significant increases occurring at 7jLg/ml 
(p::;;0.02S) and lOjLg/ml (p::;;0.001) respectively. 
Treatment of LLCMK cells with varying levels of vitamin E succinate (l-lOjLg/ml) resulted in 
significant decreases in COX activity at 1 (p::;; 0.001), S (p::;; 0.01) and 7 jLg/ml (p::;; O.OS) respectively, 
while at lOjLg/ml, a non-significant increase in COX activity occurred when compared with control 
cultures OE. Comparing the levels of COX activity in BL6 versus LLCMK cultures (table 12), the 
trend revealed was that of substantially higher levels of COX activity in BL6 cells. 
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Table 12: The effect of vitamin E succinate supplementation on cyclooxygenase activity in BL6 and 
LLCMK cells respectively. (Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate Cyclooxygenase activity (pmol PGG2 formedl106 cells) 
(/Lgiml) 
OE 
1 
3 
5 
7 
10 
a= p~O.OOI: 
b= p~0.025: 
c= p~O.OOI: 
d= p~O.OI: 
e= p~0.05: 
f= p~O.OI: 
g= p~O.OOI: 
h= p~0.05: 
4.4.4 DISCUSSION 
BL6 cells 
0.248f 
±0.086 
0.579f 
±0.020 
0.018h 
±0.005 
0.826g 
±0.61O 
1.641 bg 
±0.188 
3.785ag 
±0.460 
Relative to BL6 control cultures OE. 
Relative to BL6 control cultures OE. 
Relative to LLCMK control cultures OE. 
Relative to LLCMK control cultures OE. 
Relative to LLCMK control cultures OE. 
LLCMK cells (xlOZ) 
0.5~)2 -
±0.055 
0.293c 
±0.017 
0.504 
±0.020 
0.402d 
±0.045 
0.428e 
±0.034 
0.669 
±0.131 
Relative to COX activity in LLCMK cells in corresponding groups. 
Relative to COX activity in LLCMK cells in corresponding groups. 
Relative to COX activity in 3/Lg/ml supplemented LLCMK cultures. 
' .. 
--
As previously mentioned, vitamin E is believed to be active in modulating the activity of a number 
of key regulatory enzymes in the eicosanoid pathway, such as the COX enzyme (417,418). In this 
study, supplementation of BL6 cells with 1, 3 and 5JLg/ml vitamin E succinate did not significantly 
affect COX activity. However, as the vitamin supplementation was increased to 7 and lOJLg/ml, a 
significant increase in COX activity was detected. Although the role of vitamin E in COX reactions 
has been disputed for some time, it is suggested that vitamin E stimulates COX activity by protecting 
the enzyme from inactivation resulting from autooxidation (417). In BL6 cells however, vitamin E 
succinate supplementation was shown to exhibit no antioxidant properties in BL6 cells (see section 
3.2). One possible role for vitamin E succinate in modulating the activity of the COX enzyme is 
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through its physicochemical interaction with and stabilisation of biological membranes (412,413). 
Membranes as compartmentalizing structures _not only bring together molecules taking part in 
metabolic reactions (98), but also regulate the activities of various membrane-bound enzymes 
(98,455). In diseased states (eg neoplastic states), lipid structures are usually altered, resulting in 
changes in membrane fluidity and consequent enzyme activities (159,161). Studies by Lai et al (414) 
have shown that vitamin E succinate supplementation stabilises membranes. 
In LLCMK cells, a significant decrease in COX activity occurred at vitamin E succinate 
concentrations of 1, 5 and 7 JLg/ml respectively. Antioxidants are believed to inhibit COX activity by 
lowering the concentration of oxygen-centred radicals necessary for COX activity (417). Although 
vitamin E succinate exhibits no antioxidant properties in its esterified form (126,403,404), earlier 
studies (see section 3.4) have shown that supplementation of vitamin E succinate to LLCMK cells 
results In marked increases in cellular (X-TOH content. This increase in free (X-TOH could account 
for the observed decrease in LLCMK COX activity. Comparing levels of COX activity in BL6 and 
LLCMK cells, the activity of the COX enzyme was shown to be significantly higher in BL6 cells. 
As previously mentioned, neoplastic transformation is believed to alter lipid structures and ty.~I1ibrane 
fluidity in a number of tissues (159,161). Since the COX enzyme is membrane-bound (170,172-
174,195,196), such changes in membrane physical properties may account for the differences in COX 
activity in BL6 and LLCMK cells. 
4.5 VITAMIN E SUCCINATE SUPPLEMENTATION AND PROSTAGLANDIN E2 LEVELS 
4.5.1 INTRODUCTION 
PGs are a group of closely related 20-carbon compounds, derived both enzymatically and non-
enzymatically from the PUFA AA (203,205,207,209). PG synthesis is initiated when active and 
specific phospholipases release AA from various phospholipid and glyceride stores (165,166,209,417). 
These compounds are believed to play a regulatory role in a number of systems such as the 
reproductive, neural and cardiovascular systems (207). More recently PGs have been implicated as 
modulators of tumour metastasis (205,207,209,231-235), tumour promotion (205,207,209-211 ,234-
236), host immunoregulation(205,206,211,233-235,237) and cell proliferation (205,209,211,218,221, 
222,234,237-241). Of particular interest to this study were the levels ofPGEz, since PGE2 has been 
shown to inhibit the growth of various tumour cell lines in vitro (247-251) and in vivo (252,253), 
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through activation of an AC-cAMP linked system (205,248). Tumour cells synthesise and secrete 
large quantities ofPGs, in particular E series PGs (205-207,209,210,234,241-244). Increased PGE2 
levels were found in tumours induced by Maloney' sarcoma virus in mouse leg muscle tissue 
compared to normal leg muscle tissue in the same animal (209,210,241). Untransformed baby hamster 
kidney (BHK) and balb/c 3T3 fibroblasts in culture were shown to secrete low quantities of PGs into 
the media, whereas transformation of these cells with polyoma virus resulted in a sigIiificant increase 
in PQE2 release into the media (210). 
Vitamin E succinate supplementation has been shown to increase both PLA2 (section 4.2) and COX 
(section 4.4) activity in BL6 cells, and to inhibit COX activity in LLCMK cells. Since the rate of 
synthesis and net production of PGs is controlled by the activities of the PLA2 and COX enzymes 
respectively (166,168), it was necessary to study the effect of vitamin E succinate supplementation 
on PGE2 levels in malignant BL6 and non-malignant LLCMK cells. 
4.5.2 MATERIALS AND METHODS 
MATERIALS 
PG~ _p25 radio-immunoassay kit was obtained from Amersham Life Science, Inc, PIc., England. 
Methyl formate was supplied by Sigma Chemical Co., USA, while Sep-Pak ct8-Octadecyclsilyl (ODS) 
silica cartridges were obtained from Waters Association, USA. 
METHODS 
4.5.2.1 Cell culture procedure 
Methods described in 2.2.3.1 and 2.2.3.2 were repeated, except that cell pellets were resuspended 
in 2.0ml of PBS buffer pH 7.0. 
4.5.2.2 Homogenisation and preparation of samples 
After cell enumeration, cell suspensions were poured into a dounce homogeniser and homogenised 
with 30 plunges of a tight plunger. The dounce homogeniser was rinsed with 2.0ml of water to give 
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a final volume of 4.0ml homogenate (2.0ml PBS and 2.0ml·of water). Resulting homogenates were 
centrifuged at 1 OOOg for 10 minutes at 4°C to remove precipitated proteins. 
4.5.2.3 Extraction of prostaglandin E2 
Extraction and isolation of PGE2 was carried out using a modified method of Power (456,457) and 
Nig~ (458). Following centrifugation, the supernatant solution were poured into 15ml of cold 
absolute ethanol and shaken for one minute. The pH of the solutions was adjusted to 3.0 with IN 
HCl. Sep-Pak C18 cartridges were pretreated with 20ml of 80% ethanol, followed by 20ml of distilled 
water to remove excess ethanol. Acidified samples were passed through the Sep-Pak C18 cartridges. 
Contaminating materials such as inorganic salts and neutral lipids were removed by passing 10ml of 
water and lOml of distilled petroleum ether through the columns. PG extracts were eluted using 5.0ml 
of methyl formate, and dried under a stream of nitrogen at 25°C. 
4.5.2.4 Determination of prostaglandin E2 levels 
" 
The principle of this assay is based on the competition between unlabelled methyl-oximate derivative 
(PG~-MOX) and a fixed quantity of 125I-Iabelled PGE2 methyl-oximate derivative for binding sites 
on a PGE2 antibody, which is specific for the methyl-oximate (459). Prior to their analysis with PG~­
J125 assay kit, PG extracts were converted to methyl oximate derivatives. Dried PGE2 extracts were 
reconstituted in 100J..t1 of PBS buffer pH 7.0. To reconstituted samples were added 100J..t1 of methyl 
oximate reagent, followed by vortex mixing and incubation at 60°C for one hour. Followingriiethyl 
oximation, samples were diluted to a final volume of 500J..t1 with PBS (PH 7.0) and assayed as 
described in the assay protocol. To appropriately labelled tubes was added 100J..t1 of sample and 100J..t1 
of tracer followed by 100J..t1 of antiserum. Tubes were briefly vortex mixed and incubated for two 
hours at room temperature. After incubation, 250J..t1 of amerlex-M second antibody reagent was added 
to each tube. The tubes were incubated for a further 15 minutes at room temperature before separating 
the antibody-bound fraction by centrifugation at 1500g for 10 minutes at 4°C. Following 
centrifugation, the supernatant solution was discarded and radioactivity in each sample was determined 
using a Packard Auto-Gamma scintillation counter. Picograms of PGE/tube were determined from 
a PGE2 standard curve (appendix 6). Final results were expressed as pg PG~/106 cells. 
4.5.3 RESULTS 
The levels of PGE2 in BL6 and LLCMK cells supplemented with 1-10J..tg/ml vitamin E succinate are 
87 
4. Secondary Messenger Metabolism 
shown in table 13. In BL6 cells supplemented with 1, 3 and 5JLg/ml vitamin E succinate, no 
significant increase or decrease in PGE2 levels occurred compared with control cultures OE. As the 
vitamin concentrations were increased to 7 and 1 <>,:tg/ml respectively, a marked increaSe in PGE2 
levels occurred, with a significant (p ~ 0.01) increase occurring at lOJLg/ml. 
Table 13: The effect of vitamin E succinate supplementation on prostaglandin E7-le~els in BL6 and 
LLCMK cells respectively. (Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate PGE2 levels (pg/106 cells) 
(pg/ml) 
OE 
1 
3 
5 
7 
10 
a= pSO.Ol: 
b= pSO.05: 
BL6 cells LLCMK cells 
9.60b 33.11 
±0.31 ±2.63 
1O.80b 44.70 
±0.81 ±7.60 
8.20b 18.30 
±0.90 ±1.90 
8.90b 18.00 
±0.66 ±3.1O 
12.0b 23.00 
±0.58 ±5.50 
13.53ab 20.00 
±0.56 ±2.70 
Relative to BL6 control cultures OE. 
Relative to PG~ levels in LLCMK cells in corresponding groups. 
Supplementation of LLCMK cells with 1-10JLg/ml vitamin E succinate resulted in a non-significant 
increase in PGE2 levels at 1 JLg/ml , followed by a non-significant decrease at 3-lOJLg/ml. The PGE2 
levels in BL6 control and vitamin E succinate-supplemented cultures were generally lower than PGEz 
levels in LLCMK cultures. 
4.5.4 DISCUSSION 
Vitamin E is believed to p lay an important role in several aspects of eicosanoid metabolism (417,418). 
Depending on the system, vitamin E may have no effect or may enhance PG synthesis (417). In one 
study (cited in 417), it was found that microsomes isolated form vitamin E-supplemented animals 
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synthesised far greater amounts of PGs than microsomes isolated from vitamin E-deficient animals. 
In this study supplementation of malignant BL6 cells. with 1, 3 and 5p.g/ml vitamin E succinate 
resulted in no significant increase or decrease in PG~ levels, while at 7 and lOp.g/ml vitamin E 
succinate, marked increases in PGE2 levels occurred relative to control cultures. Studies by El Attar 
and Lin (460) have shown that supplementation of Scc-25 oral squamous carcinoma cells with 1 and 
10p.M vitamin E succinate stimulates PGE2 synthesis, and furthermore suggest that lhese effects of 
vitamin E on endogenous PGE2 levels were a reflection of the activities of both the PLA2 and COX 
enzymes. This suggests that the observed increase in PG~ levels in BL6 cells following vitamin E 
succinate supplementation could be due to increased PLA2 and COX activity observed in earlier 
sections of this study (see section 4.2 and 4.4). In non-malignant LLCMK cells on the other hand, 
supplementation of 3-10p.g/ml vitamin E succinate resulted in a general decrease in PGE2 levels 
compared to control cultures OE. This decrease was positively correlated with a decrease in LLCMK 
COX activity (section 4.4), providing further evidence for a direct link between PGE2 levels and COX 
activity. Human gingival fibroblasts supplemented with 10 and 100p.M vitamin E succinate also 
showed significant decreases in PGE2 formation (460). 
' .. 
Over the past few years evidence has been put forward which suggests that increased PG synthesis 
may be responsible for increasing both the tumorigenicity and metastatic potential of various tumour 
cells (205,207,210,211,232,236). The precise role of PG~ in tumorigenicity is at present unclear 
(232), although its presence in most tumour cells is believed to contribute to the ability of these cells 
to metastasise (232,236,239,461). Researchers have suggested that the metastatic potential of BL6 
cells is inversely related to the ability of these cells to synthesise PGE2 (209,232,250,252,255), and 
furthermore that the highly metastatic BL6-FI0 popUlation, as used in this study, synthesise far less 
PGE2 than the less metastatic Fl population (233,255). Since the quantity and type of PG produced 
by a given cell is vital to its metabolic effect, elucidation of the various PGs produced by a cell is of 
paramount importance in understanding the metabolic regulation in that cell (213). In terms of 
eicosanoid biology the BL6 melanoma cells are unusual in that PGD2 is the major PG produced, while 
PGE2 and F2o< are synthesised in smaller amounts (232,256,257). It is therefore important to determine 
the extent of production of the AA metabolites PGD2, PGF2o< and PGI2 in BL6 cells, and the effect 
of vitamin E succinate supplementation on the levels of these PGs. The above-mentioned PGs are the 
major ones produced by BL6 cells (232,233,255). No quantitation of these PGs was carried out in 
LLCMK cells, since vitamin E succinate supplementation was shown to have little effect on cell 
growth, and indeed decreased the activity of the COX enzyme, a critical determinant in controlling 
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PG synthesis (165,166,213). In view of these factors, and the cost of obtaining the assay kits, PGI2, 
F2Ci and D2 assays were not performed in LLCMK cells. 
4.6 VITAMIN E SUCCINATE SUPPLEMENTATION AND PROSTAGLANDIN D2, F2,. 
AND 12 LEVELS IN BL6 CELLS 
4.6.1 INTRODUCTION 
Mammalian tissues do not store PGs to any great extent (203,208-212), but rapidly synthesise them 
upon stimulation (208,209,212). Induction of PG synthesis occurs when a hormone or protein 
interacts with specific receptors or protein targets on the cell surface (166). This interaction results 
in the release of AA and subsequent oxidation by PGH synthase enzyme to endoperoxide PGH2 (208) 
(see section 1.5.4). The product of the PGH synthase enzyme, PGH2, is an important intermediate 
as it occupies a pivotal position in the divergent pathways which lead to the synthesis of various PGs 
and thromboxanes (165,167,169,173,208,209). The aim of this part of the study was to quantitate and 
compare the levels of PGD2, PGF2Ci and PGI2 in BL6 cells with previously determined PGE2 levels, 
as well as the effect of vitamin E succinate supplementation on the levels of these PGs. 
4.6.2 THE EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON 
PROSTAGLANDIN D2 AND F2,. FORMATION IN BL6 CELLS 
4.6.2.1 MATERIALS AND METHODS 
MATERIALS 
3H-PGD2 and 3H-PGF2Ci radio-immunoassay kits were obtained from Amersham Life Science, Int., 
England. 
METHODS 
4.6.2.2 Cell culture procedure 
Methods described in 2.2.3.1 and 2.2.3.2 were repeated except, that cell pellets were resuspended 
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in 2.0ml of PBS pH 7.0. 
4.6.2.3 Homogenisatiori and preparation of samples 
Refer to section 4.5.2.2 for method used. 
4.6.2.4 Extraction of prostaglandin D2 and F2a 
Isolation and extraction of PGDz and PGFza was carried out using the method described in section 
4.5.2.3 with the following changes. The dried PG extracts were reconstituted in 500JLI of assay buffer 
and duplicate 100JLI aliquots used for PGDz and PGFza determination. 
4.6.2.5. Determination of prostaglandin D2 levels 
The principle of this assay is based on the competition between unlabelled PGDz and a fixed quantity 
of 3H-PGDz for binding to a fixed quantity of antibody which is both specific and has a high a,ftinity 
for PGDz (462). A 100JLI aliquot of sample was pipetted into appropriately labelled rubes. One 
hundred microlitres of tracer was added to each vial, followed by a 100JLI of antiserum and 100JLI of 
assay buffer. All tubes were vortex mixed and incubated overnight at 2-8°C. Following incubation 
period, 500JLI of charcoal suspension was added to each tube. The tubes were vortex mixed and 
allowed to incubate in an ice bath for 10 minutes before centrifuging at 2 OOOg for 10 minutes. <IJA.oC. 
Resulting supernatant solutions were decanted into scintillation vials containing lOml of emulsifier 
scintillator plus TM scintillation cocktail. Radioactivity in each sample was determined using a Beckman 
(Model LS 2800) scintillation counter. The concentration of unlabelled PGDz in the sample was 
determined from a PGDz standard curve (appendix 7), and final results expressed as pg PGDz per 106 
cells. 
4.6.2.6 Determination of prostaglandin F2a levels 
The principle of this assay is based upon competition between unlabelled PGFza and a fixed quantity 
of 3H-PGFza for binding to a fixed quantity of an antibody which has high specificity and affinity for 
PGFza (463). A 100JLI aliquot of sample was pipetted into appropriately labelled tubes. One hundred 
microlitres of tracer was added to each tube, followed by 100JLI of assay buffer. All tubes were vortex 
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mixed and incubated overnight at 2-8°C. After incubation, 500/LI of charcoal suspension was added 
to each tube. The tubes were vortex mixed and allow~d to incubate in an ice bath for 10 minutes, 
- -
before centrifuging at 2 OOOg for 10 minutes at 4°C;< Resulting supernatant solutions were decanted 
into scintillation vials containing lOml of emulsifier scintillator plus TM scintillation cocktail. 
Measurement of radioactivity in each sample was determined using a Beckman (model LS 2800) 
scintillation counter. The concentration of unlabelled PGF2a in the samples was ,determined from a 
PGF2a standard curve (appendix 8), and final results expressed as pg PGF2a per 106 cells. 
4.6.3 RESULTS 
The levels of PGD2 and PGF2a in BL6 cells supplemented with 1-1O/Lg/ml vitamin E succinate are 
shown in table 14. PGD2 levels in BL6 cells were found to be significantly (p::;; 0.05) decreased at 
vitaminE succinate concentrations of 3, 5, 7 and lO/Lg/ml. compared with control cultures OE, while 
PGF2a levels were significantly (p::;;0.001) decreased at all levels of vitamin E succinate 
supplementation. 
Table 14: The effect of vitamin E succinate supplementation on prostaglandin Dz and prostaglandin 
F2a levels in BL6 cells. (Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate Prostaglandin levels (pg/106 cells) 
("g/ml) 
PGD2 Levels PGF2a Levels 
OE 26.80 10.10 
±4.31 ±0.58 
1 20.41 6.50a 
±l.30 ±0.35 
3 13.80b 5.20a 
±2.30 ±0.64 
5 13.30b 5.20a 
±1.40 ±0.42 
7 15.70b 4.1Oa 
±2.90 ±0.95 
10 15.40b 4.20a 
±l.82 ±0.34 
a= p:S;O.OOl: 
b= p:S;0.05: 
Relative to PGF2,. levels in control cultures OE. 
Relative to PGD2 leveis in control cultures OE. 
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4.6.4 THE EFFECT OF VITAMIN E SUCCINATE SUPPLEMENTATION ON 
PROSTAGLANDIN 12 LEVELS IN BL6 CELLS 
4.6.4.1 MATERIALS AND METHODS 
MATERIALS 
Sulphuric acid (H2S04) was obtained from Holpro Chemical Co., South Africa, while a 6-Keto-PGF1a 
enzyme immunoassay kit was purchased from Amersham Life Science, Int., England. 
METHODS 
4.6.4.2 Cell culture procedure 
The methods described in section 2.2.3.1 and 2.2.3.2 were used except that cell pellets were 
resuspended in 2.0ml of PBS buffer pH 7.0. 
4.6.4.3 Homogenisation and preparation of samples 
Refer to section 4.5.2.2 for the method used. 
4.6.4.4 Extraction of prostaglandin 12 
Extraction ofPGI2 was carried out using the method described in section 4.5.2.3, with the following 
change. Dried PG extracts were resuspended in 500jLI of assay buffer, and duplicate 50jLI aliquots 
were used for PGI2 determination. 
4.6.4.5 Determination of prostaglandin 12 levels 
Prostacyclin (PGI2) is an unstable vinyl ether which undergoes spontaneous hydrolysis to 6-Keto-
PGF1a • The quantification of 6-Keto-PGF1a is accepted as a measure of PGI2 formation (464,465). 
This assay is based on the competition between 6-Keto-PGF1a and a fixed quantity of peroxidase-
labelled 6-Keto-PGF1a for binding sites on a 6-Keto-PGF1a specific antibody (464). Preparation of 
samples for PGI2 determination was carried out as described in the 6-Keto-PGF1a assay kit. A 50jLI 
93 
4. Secondary Messenger Metabolism 
aliquot of sample was pipetted into appropriate wells in a microtitre plate. Fifty microliters of 
antiserum was added to each well followed by shaking for 30 minutes on a microtitre plate shaker at 
room temperature. After incubation, 50j-t1 of 6-Keto:"PGF1ct peroxidase conjugate was added to each 
well and microtitre plate further shaken for one hour at room temperature. Thereafter, all wells were 
aspirated and rinsed four times with 400j-t1 of was buffer. To the washed wells was added 150j-t1 of 
enzyme substrate followed by incubation for 10 minutes at room temperature. ';fermination of the 
reactism was carried out by the addition of a 100j-t1 of 1.0M H2S04, and the resultant colour read at 
450nm in a EAR 400 plate reader. The concentration of unlabelled 6-Keto-PGF1ct was determined 
from a 6-Keto-PGF1ct standard curve (appendix 9), and final results were expressed as pg PGI2 per 
106 cells. 
4.6.5 RESULTS 
In BL6 cells supplementation of 1, 3, 5 and 7j-tg/ml vitamin E succinate resulted in no significant 
increase or decrease in PGI2 levels (table 15), compared with control cultures OE, while at lOj-tg/ml, 
a significant increase in PGI2 levels was observed. 
Table 15: The effect of vitamin E succinate supplementation on prostaglandin 12 levels in BL6 cells. 
(Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate PGlz levels (pg/106 cells) 
(ltg/mI) 
OE 0.39 
±0.07 
1 0.34 
±0.02 
3 0.37 
±0.01 
5 0.38 
±0.02 
7 0.29 
±0.05 
10 0.57a 
±0.07 
a= p:::;0.05: Relative to control culture OE. 
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4.6.6 DISCUSSION 
In section 4.4, supplementation of BL6 cells with' l--lOj.tg/ml vitamin E succinate resulted in a 
significant increase in COX activity. Since the COX enzyme forms an integral part of the PGH 
synthase enzyme, which functions to catalyse the conversion of AA to PGH2 (166-169,171,173-179), 
any increase in COX activity would be expected to increase the overall levels of varif)US PGs within 
a cell. Results from this study have shown that supplementation of vitamin E succinate to BL6 cells 
results in a significant increase in PGEz and PGI2 levels at lOj.tg/ml concentrations, while PGD2 and 
PGF2a levels were significantly decreased at 3,5,7 and lOj.tg/ml vitamin E succinate. Synthesis of 
various biologically active eicosanoids from precursor PGH2, occurs via the action of PG synthase 
enzymes specific for each PG (165,169), although the amount and type of PG produced depends 
largely on the cell or tissue type (165,166~169,200,205,207,209,213), which could account for the 
fact that an increase in PGD2 and F2a was not found. 
A comparison of PGD2 , PGF2a, PGEz and PGI2 levels in BL6 control cultures is shown in figure 14. 
As previously mentioned, BL6 cells are unusual in terms of eicosanoid biology in that they 
predominantly synthesise PGD2 (232,256,257), while PGE2 and PGF2a are produced in smaller 
amounts (232,233,255). From this graph, it is evident that BL6 cells convert AA primarily to PGD2 , 
and also PGF2a , PGE2 and PGI2 in descending order of magnitude. 
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Figure 14: Comparison of prostaglandin levels in control cultures of BL6 
cells. Each bar on the graph represents the mean of 3 determinations ± 
SEM. 
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Although most PG-producing cells predominantly synthesise one type of PG due to the existence of 
a single PGH2 metabolising enzyme (165,169), in BL6.cells it is clear that the stimulatory effect of 
vitamin E succinate on COX activity (see section 4.4), "an enzyme closely related to the PG synthase 
enzymes, mainly influences PGE2 and PGI2 and not PGD2 and PGF2a synthesis. Studies by Toivanen 
(415) and Chan et al (466,467), have shown that in various experimental models vitamin E affects 
PGI2 synthesis. PGI2 levels in BL6 cells were found to be significantly lower than the revels of PGD2 , 
PGF2a, and PGE2 • PGI2 synthase activity is believed to be inactivated by a variety of lipid 
hydroperoxides (169,176,215-217) and hydroperxide intermediates of PG synthesis (215). Since 
earlier studies have shown markedly higher levels of lipid peroxidation (section 3.2.3) and COX 
activity (section 4.4) in malignant BL6 cells compared to non malignant LLCMK cells, this may 
explain the low PGI2 concentrations in the BL6 cells. 
The synthesis of PGF2a is believed to be linked to PGE2 synthesis, and studies with neonatal mouse 
calvaria cells have shown that PGF2a stimulates the synthesis of PGE2 via the release of AA from 
membranes (468). This suggests that any change in the levels of PGF2a would result in similar 
changes in PGE2 levels within the cell. In BL6 cells however, vitamin E succinate supplementation 
resulted in a significant decrease in PGF2a levels, while PGE2 levels remained unchanged over vitamin 
concentrations of 1-5j1g/ml, followed by a significant increase at 7 and lOj1g/ml respectively. One 
factor to consider in this regard is that vitamin E succinate supplementation may modulate the activity 
of PGE2 and PGF2a synthase enzymes differently. 
Of particular interest to this study were PGE2 (248,334,345,347,365,366) and PGI2 (333,334,351), 
since their actions within a cell are believed to be mediated via a cAMP-AC linked system. Since 
vitamin E succinate supplementation has been shown to increase both PGE2 and PGI2 levels in BL6 
cells, and decreases PGE2 levels in LLCMK cells, it was of interest to this study to determine the 
effect of vitamin E succinate supplementation on AC activity and cAMP levels in BL6 and LLCMK 
cells respectively. 
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4.7 VITAMIN E SUCCINATE SUPPLEMENTATION, ADENYLATE CYCLASE 
ACTIVITY AND CYCLIC ADENOSINE MONOPHOSPHATE FORMATION. 
4.7.1 INTRODUCTION 
Changes to the membrane intracellular signalling systems are frequently implicated)11 tbe development 
of neoplasia, and possibly the acquisition of a metastatic phenotype (422,469). One major intracellular 
signalling system identified to date is the AC-cAMP linked system (422). This system is membrane-
bound (157,321), and composed exclusively of intrinsic membrane-bound proteins (145,157,265). 
Like many membrane-bound enzymes, the activity of the AC system is influenced by the nature of 
its membrane lipid environment (145,149,157). This sensitivity to alterations in membrane fluidity 
is believed to be due to changes in the conformational flexibility of intrinsic proteins (149,157) as well 
as alterations in the efficacy of the interaction of various components of the AC system 
(145,149,157). Transformation of normal cells to tumour cells is usually accompanied by dramatic 
changes in the lipid structural organisation of membranes (159,247). Numerous studies 
(352,356,373,360,374,376,384,386,387,470) have shown an inverse relationship between intrac~llular 
levels of cAMP and tumour cell growth. Since intracellular levels of cAMP are regulated byAC and 
PDE activity (325,378,379) alterations in the activities of either of these enzymes, possibly through 
changes in membrane fluidity, could account for the lower intracellular levels of cAMP observed in 
tumour cells. 
In addition to membrane fluidity, AC activity is influenced by various PGs (154,342) as well as by 
intracellular Ca2+ levels (266,275,277). Since vitamin E succinate supplementation has been shown 
to influence the cellular concentrations of both PGEz (section 4.5) and to a lesser extent Ca2+(section 
4.1) in BL6 cells, the aim of this part of the study was to determine the effects of vitamin E succinate 
supplementation on AC activity and cAMP levels in these cells and to compare this with effects on 
non-malignant LLCMK cells. 
4.7.2 MATERIALS AND METHODS 
MATERIALS 
3-Isobutyl-1-Methylxanthine (IBMX), cAMP and ATP disodium salts were purchased from Sigma 
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Chemical Co., USA. Triethanolamine and aluminium oxide 90 (Woelm N active-neutral) were 
obtained from Merck, Darmstadt Germany. (2,S',8-3H)-ATP ammonium salt and 3H-cAMP assay kit 
was supplied by Amersham Life Sciences, Int., England. Creatine-Phosphate-Naz,4H20 (Creatine 
Phosphate) and creatine-kinase were purchased from Boehringer Mannheim Gmbh, Germany. 
METHODS 
4.7.2.1 Cell culture procedure 
The methods described in section 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were 
resuspended in 1.0ml of O.lM Tris-HCI buffer pH 7.5 containing 4mM EDTA. 
4.7.2.2' Homogenisation and preparation of samples 
The method described in section 3.3.1.2 was used with the following changes. The dounce 
homogeniser was rinsed with 1.0ml of Tris HCI buffer pH 7.5. Following centrifugation, the 
supernatant fractions were retained for cAMP determination and membrane fractions (pellet) 
resuspended in 2.0ml of Tris-HCI buffer pH 7.S for determination of adenylate cyclase activity. 
4.7.2.3 Protein determination 
Protein determinations of membrane and stroma fractions were carried out using a modified method 
of Lowry et al (cited in 433) and absorbance values converted to mg/ml protein from the standard 
curve in appendix S. 
4.7.2.4 Adenylate cyclase assay 
Adenylate cyclase activities of membrane samples were determined using the method of Schultz and 
Jakobs (321) and Salomon (471). In this assay, the formation oeH-cAMP from 3H-ATP is measured. 
GTP and forskolin were omitted from the reaction mixture and were substituted with 20jLI of O.lM 
Tris-HCI buffer pH 7.S to obtain the desired volume. The standard component reaction mixture 
contained SOOjLI 1M triethanolamine buffer, SOOjLI 100mM Mg2Cl2 solution, 1ml lOmM 3-IBMX 
(PDE inhibitor), 100jLI lOmM cAMP solution, 100jLI lOmM ATP solution, 16.4mg creatine-
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phosphate, 4mg creatine kinase, lOmg BSA and 500/LI of water, to give a final volume sufficient for 
100 assays. Constant time course assays were performed over a period of 10 minutes to determine 
optimal incubation period~. Maximal AC activity was detected after a 2 minute incubation p~riod. The 
AC activity related to the mass of protein (specific activity), was expressed as the formation of 1pmol 
cAMP per minute per mg protein. 
4.7.2...5 Cyclic adenosine mono phosphate assay 
Following protein determinations, the remaining supernatant fractions were boiled for 5 minutes to 
precipitate proteins, and centrifuged at 3 OOOg for 3 minutes. The resulting pellet (protein) was 
discarded and supernatant fractions retained for cAMP determination using a commercially available 
3H-cAMP assay kit. 
The principle of this assay is based on the competition between unlabelled cAMP and a fixed quantity 
oPH-cAMP for binding to a protein which has high specificity and affinity for cAMP (472). The 
tubes, as required, were placed in racks in an ice bath. Fifty microliters of the samples we~e'(ldded 
to the appropriate assay tubes. To these tubes was added 50/LI of labelled cAMP and 100/Llofbinding 
protein. All tubes were vortex mixed for 5 seconds, followed by transfer to an ice bath in a cold room 
at 4°C, where they were incubated for 2 hours. At least 15 minutes prior to the end of incubation, 
20ml of ice cold milli-Q water was added to charcoal reagent and stirred continuously during use. 
After incubation, a 100/LI ofthe charcoal suspension was added to all tubes and centrifuged at 3 OOOg 
for 4 minutes. Following centrifugation, and without disturbing the charcoal sediment, 200/LI of 
supernatant phase was removed and placed into scintillations vials containing lOml of scintillator 
plus TM scintillation cocktail. Radioactivity in each sample was determined by counting in a Beckman 
(LS 2899) scintillation counter. The amount of unlabelled cAMP in the assay sample was determined 
from a standard curve (appendix 10), and final results were expressed as pmol cAMP/mg protein. 
4.7.3 RESULTS 
LLCMK cells (Table 16) supplemented with 1-lO/Lg/ml vitamin E succinate showed no significant 
increase or decrease in AC activity or cAMP levels, compared with control cultures OE. BL6 cells 
on the other hand showed no significant increase or decrease in AC activity at vitamin E succinate 
concentrations of 1, 3 and 5/Lg/ml, but at 7 (p ~ 0.01) and 10 (p ~ 0.001), a significant increase in AC 
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activity occurred. Supplementation of BL6 cells with 1 and 3 j.tg/ml vitamin E succinate resulted in 
a decrease in cAMP levels, with a significant decrease (p:::;; 0.01) occurring at 3j.tg/ml. As the vitamin 
- -
- -
concentration was increased to 5 (p:::;;0.05), 7 and'1Oj.tg/ml (p:::;;0.001) respectively, a significant 
increase in cAMP levels was noted. 
Table 16: The effect of vitamin E succinate supplementation on adenylate cyclase-activity and cyclic 
adenosine monophosphate levels in BL6 and LLCMK cells respectively. (Each value in the table 
represents the mean of 3 determinations ± SEM) 
VitaminE 
succinate 
(Jtg/m1) 
OE 
1 
3 
5 
7 
10 
a= p::;;;O.OOI: 
b= p::;;;O.OI: 
c= p::;;; 0.05: 
d= p::;;;O.OI: 
e= p::;;;0.05: 
f= p::;;;O.OOI: 
BL6 cells LLCMK cells 
Adenylate cAMP Levels Adenylate 
cyclase activity (pmol/mg protein) cyclase activity 
(U/mg protein) (U/mg protein) 
66.09 30.84 
±1.87 ±0.09 
73.64 24.97 
±1.37 ±1.75 
67.05d 14.51 b 
±1.47 ±1.44 
70.01e 40.2c£ 
±2.89 ±4.94 
81.41 b 61. 48a£ 
±2.60 ±1.65 
84.00a 52.27a£ 
±0.77 ±5.35 
Relative to respective BL6 control cultures OE. 
Relative to respective BL6 control cultures OE. 
Relative to cAMP levels in BL6 control cultures OE. 
85.98 
±4.01 
90.92 
±3.37 
103.32 
±4.40 
105.13 
±19.04 
72.29 
±3.10 
67.10 
±1.15 
Relative to AC activity in 3Jtg/ml supplemented LLCMK cultures. 
Relative to AC activity in 5Jtg/ml supplemented LLCMK cultures. 
Relative to cAMP levels in LLCMK cells in respective groups. 
cAMP Levels 
(pmol/mg protein) 
24.96 
±1.17 
24.98 
-' 
±2.16 
17.85 
±2.58 
21.47 
±2.98 
. "'" -
20.94 
±0.21 
18.42 
±0.35 
Comparing the levels of AC activity in BL6 and LLCMK cells, the observed trend was that of lower 
AC activity in the control, 1, 3, and 5j.tg/ml vitamin E succinate supplemented BL6 cultures, while 
at 7 and 1Oj.tg/ml, AC activity was markedly higher in BL6 cultures. cAMP levels in BL6 cells were 
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also significantly higher in the 5, 7 and lOj.tg/ml vitamin E succinate supplemented cultures, while at 
1 and 3j.tg/ml, lower levels of cAMP were detected. 
4.7.4 DISCUSSION 
The AC enzyme is a membrane-bound enzyme (157,321,323) whose function in the cell is to catalyse 
the cQnversion of ATP to cAMP (265,321). Comparing the basal levels of AC activity in BL6 and 
LLCMK cells, the trend observed was that of higher AC activity in LLCMK cells. Studies by Emmelot 
and Bos (323) on plasma membranes isolated from liver tumours (rat hepatoma 484A) have shown 
decreased basal AC activity compared with their normal cell counterparts. Decreased AC activity was 
also reported in various cell lines transformed by polyoma virus (380). 
Supplementation ofBL6 cells with 1-10j.tg/ml vitamin E succinate resulted in a general increase in AC 
activity, with a significant increase occurring at 7 and lOj.tg/ml respectively. Like many integral 
membrane-bound enzymes, the activity of the AC enzyme is modulated by the nature of its membrane 
lipid environment (143,146,147,149,157). Hence the ability of vitamin E succinate to alter membrane 
' .. 
fluidity through its physicochemical interaction with membranes (412,413), could account for the 
observed increase in AC activity in BL6 cells following vitamin E succinate supplementation. In 
LLCMK cells on the other hand, a general increase in AC activity occurred at 1, 3 and 5j.tg/ml vitamin 
E succinate, followed by a non-significant decrease at 7 and 10j.tg/ml respectively. In addition various 
PGs are known to influence the activity of the AC enzyme (154,310). Studies reported in section 4.5, 
have shown that supplementation of vitamin E succinate, particularly at higher concentrations, results 
in a significant increase in PGE2 levels in BL6 cells, while in LLCMK cells, a decrease in PGE2 
levels occurs. These changes in PGE2 levels in BL6 and LLCMK cells were positively correlated with 
changes in AC activity. 
Since the intracellular levels of cAMP are controlled in part by the activity of the AC enzyme 
(380,473), any change in AC activity would be expected to bring about similar changes in cAMP 
levels. In this study supplementation of BL6 cells with 5, 7 and lOj.tg/ml vitamin E succinate resulted 
in a significant increase in cAMP levels, compared with control cultures OE. This increase was 
positively correlated with an increase in AC activity in BL6 cells (table 16). In contrast, cAMP levels 
in LLCMK cells were generally unaffected by vitamin E succinate supplementation, which correlated 
with the non-significant effect of vitamin E succinate supplementation on AC activity in these cells. 
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Another finding was that cAMP levels in control cultures of BL6 cells were marginally higher than 
the levels in LLCMK control cultures. If cAMP levels were regulated by AC activity, one would have 
- -
- -
in fact expected lower cAMP levels in BL6 cells:' Numerous studies with tumorigenic and non-
tumorigenic cell lines have shown also markedly higher levels of cAMP in non-tumorigenic cells 
compared to tumorigenic cells (352,355,356,360,372,373,375,384,386,387). One factor to consider 
is that the levels of intracellular cAMP are determined in large part by its rate ofrsynthesis, catalyses 
by A~ enzyme, and its rate of hydrolysis catalyses by PDE enzymes (325,378,379,473). A lower PDE 
activity in malignant compared to non-malignant cells could therefore account for the higher levels of 
cAMP observed in control cultures of BL6 cells. Studies by Chatterjee and Kim (473) have in fact 
shown that spontaneously metastasising rat mammary tumours have higher levels of cAMP than non-
metastasising tumours, and they suggested that this increase in cAMP was due to decreased PDE 
activity in non-metastasising tumours. 
Since a close relationship exists between AC, cPDE activity and cAMP levels (378), it was therefore 
relevant to determine the effect of vitamin E succinate supplementation on PDE activity in BL6 and 
LLCMK cells. 
4.8 VITAMIN E SUCCINATE SUPPLEMENTATION AND PHOSPHODIESTERASE 
ACTIVITY 
4.8.1 INTRODUCTION 
PDEs are a group of hydrolytic enzymes which function to catalyse the hydrolysis of the 3' bond of 
cyclic nucleotides to a non-cyclic product 5'-monophosphate derivative (473). Although numerous 
forms of the PDE enzyme are believed to exist in cells from various sources (324), it is now believed 
that two distinct forms of PDE occur, namely a low Km PDE and a high Km PDE (326,371). Both 
the low Km membrane-bound or particulate (PPDE) and high Km soluble PDE (sPDE) enzymes play 
an important role in regulating the intracellular levels of cAMP, although the pPDE is the major 
enzyme involved in controlling cAMP levels (370). 
Various hormones as well as intracellular activators such as cAMP are known to stimulate the activity 
ofthe low Km form of the enzyme (326,370,372). As changes in the membrane intracellular signalling 
systems are frequently implicated in the development of neoplasia (159,247), it is reasonable to assume 
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that the levels ofPDE activity would also be altered in tumourigenic cells. SV40 transformed 3T3 cells 
exhibit low Km PDE activity only, while non-transfor~ed 3T3 cells were found to contain both low 
and hIgh Km PDE activity (325). Perkins et al (474}.studying particulate and soluble PDEactivity in 
malignant human glial tumour cells found that the activities of these enzymes were markedly lower 
than those found in normal cells. The aim of this part of the study was to determine the activity of 
both the low Km and high Km forms of the PDE enzymes in malignant BL6~and non-malignant 
LLCMK cells, as well as the effect of vitamin E succinate supplementation on the activities of these 
enzymes. 
4.8.2 MATERIALS AND METHODS 
MATERIALS 
Ethylene-bis (oxy-ethylenenitrilo) Tetraacetic Acid (EGT A), leupeptin, phenylmethylsulfonylflouride, 
pepstatin, triton X-100, brij 30 (polyethylene 4-Lauryl ether) and snake venom (Naja hannah, King 
Cobra) were purchased from Sigma Chemical Co., USA. Ion exchange resin Super Q-650c was 
obtained from TOSOH Corp., Japan. ' 
METHODS 
4.8.2.1 Preparation of homogenising buffers A and B. 
Homogenising buffers A and B were prepared as described in Elks and Manganiello (475). 
4.8.2.2 Preparation of anion exchange resin 
Anion exchange resin was prepared as described in Elks and Manganiello (475). 
4.8.2.3 Cell culture procedure 
The method described in section 2.2.3.1 and 2.2.3.2 were used, except that cell pellets were 
resuspended in 1.0ml of homogenising buffer A. 
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4.8.2.4 Homogenisation and preparation of soluble and particulate phosphodiesterase enzymes 
Preparation of soluble and particulate fractions -of PDE were carried out using a modified method of 
Elks and Manganiello (475). After cell enumeration, suspensions were poured into a dounce 
homogeniser and homogenised with 30 plunges of a tight plunger. The dounce homogeniser was rinsed 
with 1.0ml of buffer A. Following homogenisation, cell homogenates were ce!ltrifuged (Beckman 
model L8-80M) at 100 OOOg for 40 minutes at 4°C. Supernatant fractions (sPDE fractions) were 
-
retained and stored at -70°C until required. Resulting pellet fractions were resuspended in 2.0ml of 
homogenising buffer B and incubated overnight at 4°C, followed by centrifugation at 100 OOOg for 4 
minutes at 4°C. Supernatant fractions (pPDE fractions) were retained, and stored at -70°C until 
required. 
4.8.2.5. Phosphodiesterase assay 
The principle of this assay involves the conversion of 3H-cAMP to 3H-5'-AMP by PDE in the presence 
of an excess of 5'-nucleotidase to produce 3H-adenosine as the final product (474). Soluble and 
particulate PDE activity was determined using a modified method of the one step assay-procedure 
described by Thompson et al (476). Standard reaction mixtures containing 5j.LI of a 100mM Tris-HCI 
buffer pH 8.0 containing O.Ij.LCi 8-3H-cAMP, 1.2 j.Lmole MgCI2, 20j.LI of a cAMP solution calculated 
to alter total cAMP concentrations from O.Ij.LM to O.lmM, 5j.LI of PDE preparation (soluble or 
particulate), and 5j.LI of King Cobra venom (A nucleotidase which functions to convert 5'-AMP !qrmed 
by PDE to 3H-adenosine) were allowed to react for 10 minutes at 30°C. Reactions were terminated by 
addition of 0.8ml of anion exchange resin slurry and allowed to stand for 10 minutes. Following the 
10 minute equilibration period, samples were centrifuged at 2 OOOg for 10 minutes. 0.5ml aliquot of 
supernatant liquid was removed and counted by liquid scintillation using lOml of emulsifier scintillator 
plus™ scintillation cocktail. Assay blanks were prepared with heat inactivated enzyme. PDE activity 
was expressed as pmoles 3H-adenosine per 106 cells. 
4.8.3 RESULTS 
The effect of vitamin E succinate supplementation on PDE activity (combined soluble and particulate 
fractions) is recorded in figure 15. In BL6 cells supplementation of l-lOj.Lg/ml vitamin E succinate did 
not result in any significant increase or decrease in total PDE activity compared to control cultures OE 
104 
4. Secondary Messenger Metabolism 
La 
.!!! 
Qj 
u 0.8 
10 
9 
...... 
QJ 0.6 c 
.jji 
0 
C 
QJ 
0.4 -0 
c<: 
I 
f'l 
I 
0 
E 
C>-
aE 3 5 7 10 
Vitamin E succinate ().lg/mt) 
• BL6 cells ~ LLCMK cells 
Figure 15: Total phosphodiesterase activity in BL6 and LLCMK cells 
respectively. Each bar on the graph represents the mean of 3 
determinations ± SEM. 
Table 17: The effect of vitamin E succinate on phosphodiesterase activity in soluble and particulate 
fractions of BL6 and LLCMK cells respectively. (Each value in the table represents the mean of 3 
determinations ± SEM). 
VitaminE 
succinate 
(pg/ml) 
OE 
1 
3 
5 
7 
10 
a= p::;0.05: 
b= p::;O.OOI: 
c= p::;0.05: 
d= p::;0.05: 
e= p::;0.05: 
Particulate PDE activity (xl~) 
(pmol 3H-Adenosine/106 cells) 
BL6 cells LLCMK cells 
7.67 95.80e 
±2.44 ±21.2 
5.64 20.10 
±2.88 ±8.1O 
1.31 58.90 
±1.08 ±29.1O 
3.64 142.7 
±2.38 ±33.60 
5.98 396.40b 
±1.1O ±41.50 
19.00ad 200.00c 
±4.53 ±7.28 
Relative to BL6 control cultures OE. 
Relative to LLCMK control cultures OE. 
Relative to LLCMK control cultures OE. 
Soluble PDE activity (xl~) 
(pmoI 3H-Adenosine/106 cells) 
BL6 cells LLCMK cells 
5.31 50.50 
±1.67 ±2.64 .- -
5.95 54.30 
±2.46 ±23.40 
5.08 69.70 
± 1.01 ±25.70 
3.83 148.50 
±2.50 ±54.80 
6.77 453.00c 
±2.29 ±37.50 
6.57 385.20c 
±4.05 161.20 
Relative to sPDE activity in BL6 cells supplemented with lOpg/ml vitamin E succinate. 
Relative to sPDE activity in LLCMK control cultures OE. 
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(figure 15), while LLCMK cells on the other hand showed a general increase in PDE activity at 5,7 
and lOj.tg/ml vitamin E succinate, with a significant increase occurring at 7 (p::::;;0.001) and 10 j.tg/ml 
(p ::::;;0~01) respectively. PDE activity in BL6 control Gultures was found to be significantly-(p ::::;;0.01) 
lower than the PDE activity in BL6 control cultures. 
Comparing PDE activity in soluble and particulate fractions (table 17) of BL6 ~d_ L.LCMK control 
cultures, it is apparent that the trend is towards higher levels of PDE activity in particulate fractions, 
-
significantly so in LLCMK control cultures. This trend was in general reversed as a result of vitamin 
E succinate supplementation. BL6 cells, supplemented with 7 and lOj.tg/ml vitamin E succinate 
showed a non-significant increase in sPDE activity compared to control cultures OE. In respect of 
pPDE activity in BL6 cells, supplementation with 1-7j.tg/ml vitamin E succinate resulted in an overall 
decrease in activity, while at lOj.tg/ml a significant (p ::::;; 0.05) increase in pPD E activity occurred. 
Supplementation of LLCMK cells with l-lOj.tg/ml vitamin E succinate resulted in a non-significant 
decrease in pPDE activity at 1 and 3j.tg/ml respectively, compared to control cultures OE. As the 
vitamin concentration was increased to 5, 7 and lOj.tg/ml, a marked increase in pPDE activity 
occurred, with a significant increase occurring at 7 (p::::;;0.001) and lOj.tg/ml (p::::;;0.05) respectively. 
sPDE activity was generally increased in LLCMK cells supplemented with 1-10j.tg/ml vitamin E 
succinate, however this increase was significant at 7 and lOj.tg/ml supplementation only. 
4.8.4 DISCUSSION 
cAMP is believed to regulate many basic biological processes within a cell, suggesting that any 
alteration in the intracellular levels of these compounds might disrupt normal physiological functions 
and in turn lead to a diseased state (371). Many of the abnormal properties of transformed cells are 
believed to be due to changes in intracellular cAMP levels (325,378,379). 
The PDE enzymes playa key role in regulating intracellular levels of cAMP (325,378,379). A 
comparison of total PDE activity in BL6 and LLCMK cells revealed that PDE activity of the BL6 
control cultures was significantly lower than PDE activity in LLCMK control cultures. Studies on 
PDE activity in normal and malignant cells have generally found lower levels of PDE activity in 
tumour cells (325,361). The transformation of normal cells to tumour cells is believed to alter the 
ratio of the pPDE to sPDE enzymes (374,473). This may have important consequences for the cell, 
106 
4. Secondary Messenger Metabolism 
since the pPDE enzyme is believed to regulate intracellular levels of cAMP (326). Studies by Clarke 
et al (cited in 379 and 473), reported that neoplastic cells have higher ratios of pPDE to sPDE 
activity, compared to their normal counterparts. Results from this study however indicate that BL6 
control cultures have lower ratios of pPDE to sPDE activity compared to LLCMK control cultures. 
The reason for this is at present unclear. 
Of interest to this study was the pPDE activity due to its ability to regulate intracellular cAMP levels 
and respond to various hormones and intracellular cAMP levels. Supplementation of BL6 cells with 
vitamin E succinate resulted in a non-significant decrease in pPDE activity compared to control 
cultures OE. An exception was at 1OJLg/ml supplementation, where a significant increase in pPDE 
occurred. pPDE is a membrane-bound enzyme (369,370) and since tumour cell membranes generally 
have altered physical and chemical properties (159,161,247,436), and the fact that vitamin E succinate 
has been shown to stabilise membranes (414), it is proposedthat the observed decreases in pPDE 
activity following vitamin E succinate supplementation, could be due to changes in the physical 
properties of the tumour cell membranes. However, it is important to remember that alterations in 
PDE activity may be more complicated than merely altering the physical properties of membranes, 
since PDE enzymes form part of an extremely complex system of enzymes the characteristics of 
which differ from one tissue to another and even between cell types (371). In LLCMK cells, 
supplementation of vitamin E succinate resulted in a marked increase in pPDE activity at 5, 7 and 
1OJLg/ml, with a significant increase occurring at 7 and 1OJLg/ml respectively. A similar increase in 
sPDE activity was observed in LLCMK cells supplemented with 5, 7 and 1OJLg/ml vitarp.!n E 
succinate, although this increase was significant at 7JLg/ml only. The reason for this increase in sPDE 
and pPDE activity in LLCMK cells is unclear, although factors to consider are the intracellular levels 
of cAMP and Ca2+ (263,266,275) both of which are known to regulate PDE activity. 
When relating AC activity (section 4.7) and total PDE activity (figure 15) to cAMP levels in BL6 
cells, it was clear that the observed increase in cAMP levels detected in BL6 cells (see section 4.7) 
supplemented with 5, 7 and 1OJLg/ml vitamin E succinate was due to marked increases in AC activity 
rather than to changes in PDE activity, since supplementation of 5-1OJLg/ml vitamin E succinate 
resulted in a marked increase in AC activity, significantly so at 7 and 1OJLg/ml supplementation, while 
having no stimulatory effect on PDE activity. In LLCMK cells on the other hand, supplementation 
of 3-1OJLg/ml vitamin E succinate resulted in a non-significant decrease in cAMP levels. This decrease 
in cAMP levels at 7 and 1OJLg/ml vitamin E succinate in LLCMK cells was positively correlated with 
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a decrease in AC activity and inversely related to PDE activity. This suggests that in LLCMK cells, 
the observed decrease in cAMP levels at 7 and 1 O/Lg/~l vitamin E succinate was due to increased 
- -
PDE activity and decreased AC activity in these cells.-
4.9 Summary 
Of main concern in this chapter was the effect of vitamin E succinate supplementation on the 
metabolism of the AA cascade pathway in BL6 and LLCMK cells that is outlined in figure 4. In BL6 
cells, supplementation of l-lO/Lg/ml vitamin E succinate resulted in a general increase in PLAz 
activity. Calcium, a known regulator of membrane-bound PLAz activity, was positively correlated 
with changes in PLAz activity, suggesting a possible link between the activity of this enzyme and 
intracellular Caz+ levels in BL6 cells. Analysis of 5-LOX and COX activity in BL6 cells revealed 
significant increases in COX activity at 7 and lO/Lg/ml vitamin E succinate supplementation, while 
5-LOX activity was increased significantly at lO/Lg/ml only. This increase in COX activity at 7 and 
lO/Lg/ml vitamin E succinate correlated with an increase iIi the levels of PGEz, AC activity and 
cAMP. Furthermore, this increase in COX activity was positively correlated with an increase _~n free 
radical formation and lipid peroxidation levels in BL6 cells (chapter 3). A similar relationship between 
5-LOX activity, free radical formation and lipid peroxidation levels was observed in BL6 cells 
supplemented with 10/Lg/ml vitamin E succinate. Another factor considered in these studies was the 
role of PDE in regulating intracellular cAMP levels following vitamin E succinate supplementation. 
Results from these studies revealed no significant increase or decrease in PDE activity in BL{) _cells 
supplemented with 1-IO/Lg/ml vitamin E succinate, suggesting that intracellular cAMP levels in BL6 
cells were regulated in part by AC activity and not PDE activity. 
Supplementation of LLCMK cells with l-lO/Lg/ml vitamin E succinate resulted in no significant 
increase or decrease in PLAz activity, while intracellular Caz+levels were increased at 1, 3 and 5/Lg/ml 
vitamin E succinate and decreased at 7 and lO/Lg/ml supplementation. COX activity in LLCMK cells 
was decreased at vitamin E succinate concentrations of 1-7/Lg/ml, while at 10/Lg/ml a non-significant 
increase in activity was observed. 5-LOX activity on the other hand was significantly increased at 5, 
7 and lO/Lg/ml vitamin E succinate. This increase in 5-LOX activity correlated with increased free 
radical formation and lipid peroxidation levels in these cells (chapter 3). In LLCMK cells, PGEzlevels 
were decreased at all levels of vitamin E succinate supplementation. This decrease in PGEz levels 
correlated with a decreased in COX activity, with the exception of the lO/Lg/ml vitamin E succinate 
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supplementation, where a non-significant increase in COX activity occurred. Supplementation of 
LLCMK cells with 1-1Oj.tg/ml vitamin E succinate resu~ted in a general increase in AC activity at 1, 
3 ana 5j.tg/ml vitamin E succinate, followed bya .non-significant decrease at 7 and 1Oj.tg/ml 
respectively. This decrease in AC activity was inversely related to PDE activity in LLCMK cells, 
suggesting that the observed decrease in intracellular cAMP levels at 7 and 1Oj.tg/ml vitamin E 
succinate supplementation in LLCMK cells was due to a decreased AC activity and increased PDE 
activity within these cells. 
The effect of vitamin E succinate supplementation on free radical and lipid peroxidation levels 
(chapter 3) as well as its effects on the levels of secondary messengers and metabolites (chapter 4) 
will now be discussed in relation to its possible effects on cell growth (chapter 2). 
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VITAMIN E SUCCINATE SUPPLEMENTATION IN RELATION TO CELL 
OXIDATION STATE, SECONDARY MESSENGERS AND CELL GROWTH 
The geographical distribution of various cancers, the changing patterns in migrant p{)pulations, and 
the v~rying incidence of specific tumours in various socioeconomic groups, all point to diet and 
nutrition as important factors in the possible control and prevention of human cancers (46,105). The 
human diet contains a wide variety of naturally occurring mutagens and carcinogens, as well as 
numerous antimutagens and anticarcinogens (477). As already discussed (section 1.2.6.6), one dietary 
nutrient receiving recent attention as a possible anticarcinogen is vitamin E. Numerous 
epidemiological studies (52,54,55,105,119-121,130) over the past few years have revealed a link 
between dietary levels of vitamin E and tumour incidence. Since vitamin E' s discovery, exaggerated 
claims have made about its possible role in human health, although no single primary role for this 
vitamin has as yet been discovered. It has been suggested that vitamin E's action within a cell may 
be secondary to its primary role as an antioxidant (26,32,57,58). Of interest to this study was the 
, .. 
effect of vitamin E succinate supplementation on cell growth and free radical and lipid peroxidation 
levels in BL6 and LLCMK cells, as well as its effects on the AA cascade (figure 4), and the various 
metabolites affecting this pathway. 
In chapter 2 the effect of vitamin E succinate supplementation on BL6 and LLCMK cell growth 'was 
determined, while chapter 3 investigated the effect of vitamin E succinate supplementation on free 
radical and lipid peroxidation levels in these cells. Finally chapter 4 investigated the effects of vitamin 
E succinate supplementation on various AA metabolites and secondary messengers shown in figure 
4. In this chapter an attempt will be made to relate the effects of vitamin E succinate supplementation 
on BL6 and LLCMK cell growth, to free radical and lipid peroxidation levels as well as to the levels 
of various secondary messengers and factors influencing the AA pathway. Due to some variability 
in the effect of vitamin E succinate supplementation on cell growth in the different experiments 
performed, the relationship between various metabolites relative to cell growth will be discussed for 
each individual experiment. Furthermore, since supplementation of vitamin E succinate to LLCMK 
cells resulted in variable and less significant effects on cell growth and non-significant trends or 
relationships between various metabolites and secondary messengers in the AA pathway (figure 4), 
emphasis in this chapter was placed on the BL6 cell line. It must be noted however, that although 
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studies have consistently shown significant decreases in BL6 cell growth at 5-10{tg/ml vitamin E 
succinate, the effects at 1 and 3{tg/ml were inconsistent, with some studies showing inhibitory and 
others stimulatory effects: The reason for this variability is unclear although results from various other 
studies have shown that the effective concentration range of vitamin E succinate in BL6 cells lies 
between 5 and lO{tg/ml respectively (42,127). 
Lipid peroxidation, a consequence of free radical attack on PUF As, has been linked to events 
promoting carcinogenesis (138,139). Recently however, numerous studies (235,478-482) have 
suggested an inverse relationship between lipid peroxidation levels and cell growth. The prime 
concern of this study was to establish whether such an inverse relationship existed between free 
radical formation, lipid peroxidation levels and cell growth following vitamin E succinate 
supplementation. In LLCMK cells, supplementation of vitamin E succinate resulted in a general 
although non-significant increase in growth, with the exception of the 5{tg/ml supplemented cultures, 
where a significant decrease in growth occurred. Free radical levels on the other hand were generally 
decreased at all vitamin concentrations tested when compared with control cultures OE. The only 
exception was that recorded in the lO{tg/ml supplemented cultures, where a marked increase in free 
' .. 
radical levels occurred. This decrease in free radical levels was inversely related to LLCMK cell 
growth at 1 and 3{tg/ml vitamin E succinate. 
When comparing free radical levels to BL6 cell growth (figure 16), the general trend that was 
apparent was that when BL6 cell growth was decreased, free radical levels were increased and vice 
versa. Studies by Yoshikawa et at (483) have also shown an inverse relationship between free radical 
levels and tumour cell growth. Vitamin E succinate supplementation did not significantly affect cell 
growth or lipid peroxidation levels in LLCMK cells but in BL6 cells, resulted in a significant decrease 
in growth and increase in lipid peroxidation levels at vitamin E succinate concentrations of 5, 7 and 
lO{tg/ml respectively (figure 17). Hence upon vitamin E succinate supplementation, free radical and 
lipid peroxidation levels found in the BL6 cells were inversely related to BL6 cell growth (484). 
Begin et at (478) studying the contribution of lipid peroxidation in killing breast carcinoma cells, also 
demonstrated an inverse relationship between intracellular levels of thiobarbaturic acid-reactive 
materials, and tumour cell growth. Further studies by Cheesman et at (481) have shown lower levels 
of lipid peroxidation in highly undifferentiated rapidly proliferating Novikoff hepatoma tissue, 
compared with normal rat liver tissue. 
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Figure 17: Effect of vitamin E succinate supplementation on lipid 
peroxidation levels and BL6 cell growth. 
Lipid peroxidation, can be initiated both enzymatically through the catalytic action of LOX and COX 
enzymes (159,235), or non-enzymatically as by products of free radical chain reactions (135,159, 
235). Since the catalytic action of COX and LOX enzymes are believed to contribute to free radical 
formation (235) and lipid peroxidation levels (159,235) in a cell, an investigation of the relationship 
between the activity of these enzymes and cell growth was necessary. Supplementation of LLCMK 
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cells with vitamin E succinate resulted in a significant decre.ase in COX activity, with the exception 
of the lO/Lgiml supplemented cultures, where a non-si~nificant increase occurred. This decrease in 
COX -activity was inversely related to LLCMK gf()wth. With respect to BL6 cells (figure 18), 
supplementation of vitamin E succinate resulted in a general increase in COX activity, with a 
significant increase occurring at 7 and lO/Lgiml respectively. The only exception was that recorded 
at 3/Lgiml supplementation, where a marked decrease in COX activity was det~ted. This general 
increase in COX activity was inversely related to BL6 growth at vitamin concentrations of 5, 7 and 
-
10/Lgiml respectively. 
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Figure 18: Effect of vitamin E succinate supplementation on cyclooxygenase 
activity and BL6 cell growth. 
,. 
Relevant to the 5-LOX studies, vitamin E succinate supplementation of BL6 and LLCMK cells 
resulted in an overall decrease in growth with a significant decrease occurring in the BL6 cells. 5-
LOX activity in LLCMK cells was generally increased following vitamin E succinate supplementation, 
significantly so at 7 and lO/Lgiml supplementation. In BL6 cells (figure 19), supplementation of 3-
lO/Lgiml vitamin E succinate resulted in a general increase in 5-LOX activity, with a significant 
increase occurring at lO/Lgiml supplementation. 
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Figure 19: Effect of vitamin E succinate supplementation on 5-lipoxygenase 
activity and BL6 cell growth. 
Thus 5-LOX activity was inversely related to BL6 andLLCMK growth and was enhanced by vitamin 
E succinate supplementation. As previously mentioned both 5-LOX and COX activity are thought to 
contribute to free radical and lipid peroxidation levels within a cell (235). Since vitamin E succinate 
supplementation significantly decreased COX activity and increased 5-LOX activity in LLCMK cells, 
it is reasonable to assume that the increase in free radical and lipid peroxidation levels in LLCMK 
cells following vitamin E succinate supplementation were due to an increase in 5-LOX activity. In 
BL6 cells on the other hand, increased free radical and lipid peroxidation levels correlated with an 
increase in both 5-LOX and COX activity. 
An additional factor which needed to be considered in these studies was the effect of vitamin E 
succinate supplementation on intracellular Ca2+ levels, since Ca2+ has been implicated as a key 
regulator of cell proliferation through its effects on the cell cycle (278,280,281). Furthermore Ca2+is 
believed to playa critical role in regulating the activity of the COX enzyme and LOX enzymes (276). 
Supplementation of LLCMK cells with vitamin E succinate did not result in any trend when 
comparing cell growth and intracellular Ca2+levels. The only exceptions were at vitamin E succinate 
concentrations of 7 and lOJ-tg/ml, where a marked decrease in both intracellular Ca2+levels and 
LLCMK cell growth occurred. 
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With respect to BL6 cells (figure 20), vitamin E succinate supplementation resulted in an overall 
increase in Ca2+levels, with the exception of lOjLg/ml supplementation cultures where a non-
significant decrease occurred. These changes in intracellular Ca2+ levels were inversely related to BL6 
cell growth. 
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Figure 20: Effect of vitamin E succinate supplementation on calcium levels 
and BL6 cell growth. 
Although intracellular Ca2+ levels are believed to regulate the activity of the COX and LOX enzymes 
(276), it may also affect the activation of the PLAz enzyme with consequent AA release, an important 
rate-limiting precursor of COX activity and eicosanoid synthesis (165,166,273,291-297,299,-.:304). 
Hence an additional factor which needed to be considered, was the effect of vitamin E succinate 
supplementation on PLA2 activity. With the exception of the IjLg/ml supplemented cultures, 
supplementation of vitamin E resulted in a significant decrease in LLCMK growth, while PLA2 
activity was neither significantly increased nor decreased. 
Vitamin E succinate supplementation significantly decreased BL6 cell growth, while PLA2 activity 
(figure 21) was generally increased in BL6 cells, significantly so at 1, 3 and 5 jLg/ml vitamin E 
succinate. Thus an inverse relationship again existed between PLA2 activity and BL6 cell growth. 
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Figure 21: Effect of vitamin E succinate supplementation on phospholipase 
~ activity and BL6 cell growth. 
Summarising the results obtained up to this point, it is clear that supplementation of vitamin E 
succinate significantly inhibits BL6 cell growth and furthermore that this decreases in growth was 
inversely related to free radical, lipid peroxidation and intracellular Ca2+levels, as well the'activities 
of the 5-LOX, COX and PLA2 enzymes. 
PG synthesis is regulated acutely via the activation of phospholipases and release of AA, while net 
PG production is dependant on COX activity (166). Since marked changes in the activities Bf the 
PLA2 and COX enzymes have been shown to occur in BL6 and LLCMK cells supplemented with 
varying levels of vitamin E succinate, it was important to determine the effects of vitamin E succinate 
supplementation on PG levels in these cells. LLCMK cells showed no significant increase or decrease 
in growth upon supplementation of vitamin E succinate, while PGE2 levels, with the exception of the 
1j-tg/ml supplemented cultures, were generally decreased at all vitamin concentrations tested. Although 
the precise role of PGE2 in tumour metastasis is unclear (232), studies with BL6 cells 
(209,232,250,252,255) have suggested that the metastatic potential of these cells is inverseiy related 
to the ability of BL6 cells to synthesis PGE2, and furthermore that the highly metastatic BL6F10 
population synthesise far less PGE2 than the lower metastatic FI population (233,255). 
In the experiment concerning the effect of vitamin E succinate supplementation on PGEz levels in BL6 
cells (figure 22), supplementation of l-lOj-tg/ml vitamin succinate resulted in a significant decrease 
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in growth. The general trend that was apparent was that as BL6 growth decreased, PGE2 levels 
increased and visa versa._ The only exception was that -recorded at 3j.tg/ml supplementation, where 
both cell growth and PGEz levels decrease. 
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Figure 22: Effect of vitamin E succinate supplementation on prostaglandin 
E2 levels and BL6 cell growth. 
Since the quantity and type of prostaglandin produced by a given cell is vital to the metabolic effect 
it has (213), and the fact that BL6 cells are unusual in terms of eicosanoid biology in that they 
synthesise more than one type of PG (232,256,257), it was of interest to this study to determine 
whether vitamin E succinate supplementation affected the levels of various other PGs in BL6 cells. 
Vitamin E succinate supplementation ofBL6 cells resulted in an overall decrease in PGD2 (figure 23), 
with a significant decrease occurring at 3 to lOj.tg/ml supplementation. This decrease in PGD2 levels 
at 7 and lOj.tg/ml respectively, correlated with a non-significant decrease in BL6 growth. Relevant 
to the PGF2a experiment (figure 24), supplementation of vitamin E succinate resulted in a significant 
decrease in PGF2a levels, at all vitamin E succinate concentrations tested. Comparing BL6 growth and 
PGF2a levels, the trend was that of increased growth with decreasing PGF2a levels at 1, 3 and 5j.tg/ml 
vitamin E succinate supplementation, while at 7 and lOj.tg/ml respectively, a decrease in PGF2a levels 
correlated with a decrease in cell growth. 
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Figure 23: Effect of vitamin E succinate supplementation on prostaglandin 
D2 levels and BL6 cell growth. 
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Figure 24: Effect of vitamin E succinate supplementation on prostaglandin 
F2a levels and BL6 cell growth. 
This suggests that at lower concentrations of vitamin E succinate, an inverse relationship exists 
between BL6 growth and the levels of PGD2 and PGF2a, while at higher concentrations of vitamin 
E succinate, the inhibitory effects on BL6 cell growth were positively correlated with a decrease in 
PGD2 and PGF2a levels. 
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In the experiment examining the effect of vitamin E succinate supplementation on PGI2 levels in BL6 
cells (Figure 25), 3-lOJLg~ml vitamin E succinate supplementation decreased the growth of these cells 
to a certain extent, significantly so at lOJLg/ml.' With respect to PGI2 levels in the cells, 
supplementation of 1-7 JLg/ml vitamin E succinate resulted in no significant increase or decrease in 
PGI2 levels while at lOJLg/ml a significant increase in PGI2 levels occurred. Thus, the growth 
inhibitory effects observed in BL6 cells at high concentrations of vitamin E succinafe were correlated 
in paR by increasing PGE2 and 12 levels, and decreasing PGD2 and F2a levels in these cells. 
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Figure 25: Effect of vitamin E succinate supplementation on prostaglandin 
lz levels and BL6 cell growth. 
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In general PG effects within a cell are believed to be mediated through activation of AC enzyme and 
cAMP synthesis (154,227,343,344). PGs are believed to mediate their effects on growth through 
changes in the intracellular levels of cAMP (205,248,334,347,364,367). PGs of the D, E and I series 
are capable of increasing cAMP levels in various systems (345). Since vitamin E succinate 
supplementation modulates intracellular levels ofPGEz, D2 and 12 in BL6 cells (485), and the fact that 
the AC enzyme is responsible for the synthesis of cAMP, it was relevant to this study to determine 
the effect of vitamin E succinate supplementation on both AC activity and cAMP levels. In LLCMK 
cells, supplementation of vitamin E succinate resulted in a significant increase in cell growth, with 
AC activity following a similar trend. The only exception was that recorded at 7 and 10JLg/ml 
vitamin E succinate, where an inverse relationship existed between cell growth and AC activity. With 
respect to cAMP levels, supplementation of 3-lOJLg/ml vitamin E succinate resulted in an overall 
decrease in cAMP levels in LLCMK cells, together with a significant increase in cell growth. This 
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suggests that intracellular levels of cAMP are negative regulators of LLCMK growth and furthermore 
that intracellular levels of cAMP in LLCMK ~ells at 7 and lOfLg/ml vitamin E succinate correlate 
positively with AC activity. 
Supplementation of BL6 cells with 1-lOfLg/ml vitamin E succinate resulted in a significant increase 
in AC activity (figure 26) at 7 and lOfLg/ml respectively. With respect to 'ELo cell growth, 
supplementation of 1 and 3fLg/mi vitamin E succinate significantly increased growth, while at 5, 7 
and lOfLg/ml respectively, a significant decrease in growth occurred. With the exception of 1fLg/mi 
supplemented cultures, the general trend that was apparent was that as AC activity increased, BL6 
growth decreased and visa versa. Hence an inverse relationship exists between AC activity and BL6 
cell growth. 
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Figure 26: Effect of vitamin E succinate supplementation on adenyl ate 
cyclase activity and BL6 cell growth. 
When comparing cAMP levels and BL6 cell growth (figure 27), cAMP levels were also inversely 
related to BL6 cell growth at all vitamin concentrations tested. Thus, supplementation of vitamin E 
succinate, significantly increases the levels of PGE2, AC activity and cAMP in BL6 cells, and 
furthermore these increases were inversely related to BL6 cell growth (486). 
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Figure 27: Effect of vitamin E succinate supplementation on cyclic adenosine 
monophosphate levels and BL6 growth. 
Apart from the AC enzyme, intracellular levels of cAMP are regulated in part by the activity of the 
PDE enzymes. These enzymes catalyse the hydrolysis of cAMP, and are the major physiological 
pathway for terminating the intracellular effects of cAMP (326). As a result, an investigation of the 
relationship between total PDE activity and cell growth was undertaken. 
Vitamin E succinate supplementation of LLCMK and BL6 cells resulted in an overall decrease in 
growth, significantly so at lOjLg/ml supplementation. PDE activity was generally increased in LLCMK 
cells, with a significant increase occurring at 7 and lOjLg/ml vitamin E succinate supplementation. 
This increase in PDE activity following vitamin E succinate supplementation could account for the 
significant decrease in cAMP levels observed in earlier studies with LLCMK cells. In the experiment 
concerning the effect of vitamin E succinate supplementation on PDE activity in BL6 cells (figure 28), 
the general trend was that as BL6 growth increased, PDE activity increased and visa versa. An 
exception was at lOjLg/ml supplementation where a significant increase in PDE activity was associated 
with a decrease in growth. 
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Figure 28: Effect of vitamin E succinate supplementation on 
phosphodiesterase activity and BL6 cell growth. 
r - ~ 
In conclusion, although some studies suggest an inverse relationship between LLCMK cell growth 
and the levels of various enzymes and secondary messengers shown in figure 4, no conc~~sion can 
be made since the magnitude of this relationship varied considerably from one experiment to another, 
while other experiments showed no such inverse relationship. In contrast, the inverse relationship 
between growth and secondary metabolites in BL6 cells was consistent with the same general trend 
being observed in the pathway studied, even though the magnitude of this relationship did vary 
marginally between experiments. 
Numerous in vitro studies (42,66,125-127) have shown that vitamin E in its esterified form acts as 
a potent inhibitor of tumour cell growth and development, although the mechanism(s) by which its 
inhibits tumour cell growth and development is at present unclear. One possible mechanism suggested 
was through its antioxidant properties associated with the vitamin E component of the vitamin E 
succinate molecule (66,127). In this study however, supplementation of vitamin E succinate resulted 
in a significant increase in free radical and lipid peroxidation levels. Since free radical formation 
(235) and lipid peroxidation (159,235) can be initiated enzymatically through the catalytic action of 
the COX and LOX enzymes, and the fact that vitamin E succinate supplementation results in an 
inverse relationship between BL6 growth and the levels of PGEz, AC activity and cAMP (486), it is 
proposed that vitamin E succinate inhibitory effects on BL6 growth were mediated via a PGEz, AC, 
and cAMP linked system. 
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In an attempt to demonstrate a relationship between the levels of free radicals, lipid peroxidation and 
the activity of the COX _enzyme in BL6 cells,_ as well- as provide further evidence that vitamin E 
. -
succinate mediates its growth inhibitory effects through a PGE2, AC and cAMP linked system, BL6 
cells were treated with COX inhibitor indomethacin. It must be noted that since supplementation of 
vitamin E succinate to LLCMK cells resulted in variable and less significant effects on cell growth 
and secondary messenger metabolism, with no real correlation between the two, llieie indomethacin 
studies were carried out on the BL6 cell line only. 
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INHIBITOR TREATMENT At"m BL6 CELL GROWTH 
6.1 EFFECT OF VITAMIN E SUCCINATE AND INDOMETHACIN SUPPLEMENTATION 
ON BL6 CELL GROWTH r - _ ... 
6.1.1 INTRODUCTION 
Numerous PG-synthesising inhibitors or non-steroidal anti-inflammatory drugs have been discovered, 
which markedly inhibit COX activity. These include aspirin, ibuprofen, piroxicam, sulindac and 
indomethacin (INDO) (487,488). The best known of these inhibitors and the one used in this study 
is INDO (figure 29). 
Figure 29: Structure of indomethacin (43). 
The mechanism by which INDO inhibits COX activity is at present unknown, although it has been 
suggested that an initial reversible binding between COX enzyme and INDO occurs, followed by a 
selective conformational change in PGH synthase which eventually leads to irreversible inactivation 
of the enzyme and tighter binding of the INDO (165,489). 
The inhibition of PG synthesis by indomethacin (INDO) results in growth inhibition of tumours both 
in experimental animals (205,233,490) and humans (491). These antitumour properties ofINDO are 
believed to be due to its ability to enhance immune responses by inhibiting the production of immune 
suppressive PGs, notably PGE2 (232,237,487,488). However, these beneficial effects of INDO must 
be interpreted with caution, since INDO supplementation has been shown to be ineffective (237) or 
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even stimulatory (232,256,488) to various tumour cell lines. The reason for this variable effect is at 
presel!t unclear, although studies by Furuta e~ al (237) suggest that different malignant tumours 
synthesise specific PGs, and furthermore that their response to INDO treatment was dependant on the 
expression of PGH synthase activity and the type of PG produced. The aim of this part of the present 
study was to determine the effect of INDO supplementation on the in vitro growth of malignant BL6 
cells. 
6.1.2 MATERIALS AND METHODS 
MATERIALS 
Indomethacin was purchased from Sigma Chemical Co., USA. Refer to section 2.2 for the remainder 
of materials used. 
METHODS 
6.1.2.1 Preparation of vitamin E succinate and indomethacin stock solutions 
Stock solutions of vitamin E succinate (2-20mg/ml) and indomethacin (O.3mM) were freshly prepared 
in absolute ethanol and diluted 0.5:1 000 in medium containing 10% (v/v) FeS to give a final 
concentration of 1, 3, 5, 7, lOjl.g/ml vitamin E succinate and 0.15jl.M INDO respectively in-O.1 % 
final volume of ethanol. The concentration of INDO required to inhibit COX activity in BL6 cells at 
all vitamin concentrations tested was determined by preliminary range finding experiments, and was 
shown to be most effective at 0.15jl.M INDO. 
6.1.2.2 Cell culture procedure 
In the experiments relevant to 7.2.2 and 7.2.3, for which further analytical procedures and data are 
described in chapter 7 (the numbering denoting the relevant experiments), 3x106 BL6 cells were 
seeded into 6 sets of 5 25cm2 flasks. To five sets of these flasks, 10ml of MEM basal medium 
containing 10% (v/v) FCS, 0.15jl.M INDO and varying levels of vitamin E succinate (l-lOjl.g/ml) was 
added. The sixth set of flasks (control cultures OE) received lOml of 10% (v/v) FCS medium 
containing 0.1 % final volume of ethanol and 0.15jl.M INDO. In experiments 7.3 and 7.4, 5x105 BL6 
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cells were seeded into 6 sets of 3 75cm2 flasks. To 5 of the 6 sets of flasks was added 30ml of 
mediu!ll containing 10% FCS (v/v) containing 0.15/-tM INDO and varying levels of vitamin E 
succinate (l-1O/-tg/ml). The sixth set of flasks received 30ml of medium containing 0.1 % ethanol and 
0.15/-tM INDO and were referred to as control cultures OE. All flasks were incubated at 37°C for the 
duration of the experiment with one medium change during this period. 
6.1.2~3 Harvesting of experiments 
Refer to section 2.2.3.2 for the method used. 
6.1.2.4 Statistical analysis 
The results obtained were analysed using a One Way Analysis of Variance (ANOVA) followed by 
the Student Newmans-Kuels Multiple Range Test. Data in all subsequent sections of this chapter were 
similarly analyzed. 
6.1.3 RESULTS 
The results of BL6 growth obtained in the relevant experiments, in which 1-1O/-tg/ml vitamin E 
succinate and 0.15/-tM INDO were supplemented, are shown in table 18. Relevant to the discussion 
in this chapter is the mean percentage growth inhibition of all the experiments. Growth inhibition 
results for each individual experiment will be discussed relative to cell metabolism in chapter 7. 
BL6 cells supplemented with 1 to 7/-tg/ml vitamin E succinate and 0.15/-tM INDO showed a general 
increase in growth compared with control cultures OE, with a significant (p ~ 0.05) increase occurring 
at 5/-tg/ml supplementation. At 1O/-tg/ml vitamin E succinate supplementation, a non-significant 
decrease in growth occurred. 
In individual experiments, combined vitamin E succinate and INDO supplementation resulted in 
similar trends to overall mean growth results, however the differences compared to controls were 
significant in certain experiments. 
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Table 18: The effect of vitamin E succinate and indomethacin supplementation on BL6 cell growth. 
(Values recorded in the table are the mean of 3# or 5* cultures ± SEM) . 
. 
Vitamin E succinate Growth Inhibition (% of untreated controls OE) 
(I'g/ml) 
Exp 7.2.1* Exp 7.2.2* 
OE 100 100 
±6.1 ±12.9 
- 1 182.7a 133.3 
±7.20 ±7.1 
3 191.3a 110.2 
±17.8 ±5.9 
5 21O.5a 125.7 
±13.6 ±1O.4 
7 199.4a 115.7 
±1O.8 ±8.7 
10 126.1 86.2 
±11.2 ±3.1 
) a= p:::;;O.OOI: 
b= p:::;;O.OI: 
c= p:::;;0.05: 
) Relative to control cultures OE. 
) 
6.1.4 DISCUSSION 
Exp 7.3# Exp 7.4# 
100 100 
r -
-
±12.4 ±4.4 
113.5 97.3 
±6.0 ±3.7 
70.7 ±102.0 
±3.8 ±6.2 
108.4 100.2 
±8.5 ±5.0 
106;93 101.2 
±8.9 ±0.6 
85.9 76.9b 
.. 
±7.2 ±3.6 
MEAN 
100 
±4.0 
131.8 
±8.3 
122.8 
±11.2 
137.2c 
±11.5 
130.7 
±1O.7 
93.7 
±5.6 
" 
In vitro supplementation of BL6 cells with vitamin E succinate results in a significant decrease in 
growth at 5, 7 and lOjLg/ml respectively (486). Other studies (42,127) with BL6 cells have shown 
similar decreases in growth when supplemented with l-lOjLg/ml vitamin E succinate. The 
supplementation ofBL6 cells with O.15jLM INDO and 1,3,5 and 7jLg/ml vitamin E succinate resulted 
in a general increase in growth compared with control cultures OE, with a significant increase 
occurring at 3jLg/ml. The only exception was that recorded at lOjLg/ml vitamin Esuccinate 
supplementation, where a non-significant decrease in growth occurred. 
Researchers (256,492) working with BL6 cells have shown that pretreatment of these cells with INDO 
also results in a significant increase in growth. This suggests that the growth inhibitory effects of 
vitamin E succinate supplementation on BL6 cells, was mediated in part by the activation of COX 
enzyme and increased PG synthesis. However one factor to consider is that inhibition of enzymatic 
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reactions through one pathway may enhance the activity of other pathways (488). For example, agents 
. which. block the COX pathway are believed to ~nhance -the activity of the LOX pathway (232,488). 
This pathway is believed to synthesise metabolites< which affect cell proliferation (232). Hence 
uncertainty exists as to whether the stimulatory effects of INDO supplementation on BL6 growth in 
these studies were as a result of decreased COX activity and PG synthesis, or as a result of increased 
5-LOX activity and leukotriene synthesis. ~. -
In an attempt to demonstrate that the stimulatory effects of INDO supplementation on BL6 cell growth 
were as a result of decreased COX activity rather than increased 5-LOX activity, the effects of 
combined nordihydroguaidaretic acid (NDGA) (5-LOX inhibitor) and INDO (COX inhibitor) 
supplementation on BL6 cell growth was determined. 
6.2 -EFFECT OF VITAMIN E SUCCINATE, INDOMETHACIN AND 
NORDIHYDROGUAIDARETIC ACID SUPPLEMENTATION ON BL6 GROWTH 
6.2.1 INTRODUCTION 
Studies by Lee et al (cited in 488), have shown that the inhibition of the COX enzyme with INDO 
stimulates the synthesis of leukotrienes in TMT -081 rat mammary tumour cells. At least two 
mechanisms could account for this, namely; a) inhibition of COX enzyme could shunt AA into the 
LOX pathway resulting in an increase in leukotrienes synthesis, or b) these drugs could directly 
stimulate LOX enzyme activity and leukotriene synthesis. Since the LOX enzymes synthesise products 
which affect cell proliferation, and the fact that inhibiting COX activity increases LOX activity 
(232,488), it was important to this study to determine whether the stimulatory effects of INDO 
supplementation on BL6 cell growth observed in chapter 6, were due to a decrease in COX activity 
or increase in LOX activity. Hence an investigation of the effect of combined INDO (COX inhibitor) 
and NDGA (5-LOX inhibitor) supplementation on BL6 cell growth was determined. The antioxidant 
NDGA (figure 30) is widely used in the inhibition of 5-LOX activity (449,451), and is of principle 
concern in this study. 
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Figure 30: Structure of nordihydroguaidaretic acid (43). 
6.2.2 MA TERIALS AND METHODS 
MATERIALS 
Nordihydroguaidaretic acid was purchased from ICN Biomedical Inc., South Africa. 
6.2.2.1 Preparation ofvitamin E succinate, indomethacin and nordighydroguaidaretic acid.stock 
solutions 
Stock solutions of vitamin E succinate (l-lOmg/ml) containing INDO (0. 15mM) and NDGA (5mM) 
were prepared freshly in absolute ethanol and diluted 1:1 000 in medium containing 10% (v/v) FCS 
to give a final concentration of 1,3,5, 7 and 1Ollg/ml vitamin E succinate, 0.151lM INDO and-¥M 
NDGA. (51lM concentrations of NDGA were fo~nd to be effective inhibitors of 5-LOX activity in 
various other studies (449,451». 
6.2.2.2 Cell culture procedure 
3xl05 BL6 cells were seeded into 6 sets of 5 25cm2 flasks. To five sets of these flasks, 10ml of MEM 
basal medium containing 10% (v/v) FCS, 0.151lM INDO, 51lM NDGA and varying levels of vitamin 
E succinate (l-lOllg/mI) was added. The sixth set of flasks received 10ml of 10% (v/v) FCS 
supplemented medium containing 0.1 % (v/v) final volume of ethanol and 0.151lM INDO, and were 
referred to as control cultures OE. All flasks were incubated at 37°C for the duration of the 
experiment with one medium change during this period. 
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6.2.2.3 Harvesting of experiments 
- -
The method used is described in section 2.2.3.2. 
6.2.3 RESULTS 
Supplementation of BL6 cells with varying levels of vitamin E succinate (l-lOJLg/ml), 0 . 15JLM INDO 
and O':SJLM NDGA, resulted in no significant increase or decrease in growth compared with control 
cultures OE (table 19). 
Table 19: The effect of indomethacin and nordihydroguaidaretic acid supplementation on BL6 cell 
growth. (Each value in the table represents the mean of S determinations ± SEM). 
Vitamin E succinate Growth Inhibition 
("g/ml) (% of untreated controls OE) 
OE 100 
±4.6 
1 119.4 
±4.4 
3 98.0 
±3.7 
5 103.2 
±5.1 
7 96.3 
±7.1 
10 102.0 
±6.1 
6.2.4 DISCUSSION 
In this study, inhibition of S-LOX activity resulted in no significant increase or decrease in BL6 cell 
growth. More importantly however, when comparing these results with mean growth results obtained 
following INDO supplementation alone (section 6.1), the trend was that of marginally decreased 
growth in combined NDGA and INDO treated cultures, with the exception of the 10JLg/ml, where a 
non-significant increase in growth occurred. This suggests that the observed increase in growth 
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following INDO supplementation was primarily due to inhibition of COX activity rather than changes 
in 5-LOX activity. 
Since COX activity is believed to contribute to free radical formation (235), lipid peroxidation levels 
(159,235) and net PG synthesis within a cell (166), the effect of INDO supplementation on free 
radical formation, lipid peroxidation levels and secondary messengers was detenniheO in BL6 cells. 
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EFFECT OF INDOMETHACIN AND NUTJlIENT SUPPLEMENTATION ON CELL 
OXIDATION STATE AND SECONDARY MESSENGER METABOLISM 
7.1 EFFECT OF VITAMIN E SUCCINATE AND INDOMETHACIN SUPPLEMENTATION 
.- - ~ 
ON FREE RADICAL FORMATION AND LIPID PEROXIDATION LEVELS IN BL6 
CELLS 
7.1.1 INTRODUCTION 
The mechanism(s) by which vitamin E succinate inhibits tumour cell proliferation is at present 
unclear, although it has been suggested that the anticarcinogenic effects of vitamin E may reside in 
their ability to scavenge free radicals and prevent lipid peroxidation (15,22,24,46,54,58,112,117-
122,127). Earlier studies described in section 3.2 have shown significant increases in free radical and 
lipid peroxidation levels in BL6 cells following vitamin E succinate supplementation. 
Since lipid peroxidation can be initiated enzymatically through the catalytic action of COX enzyme 
(159,235), and significant increases in COX activity have been shown to occur in BL6 cells 
supplemented with vitamin E succinate (see section 4.4), it is possible that the observed increases in 
free radical and lipid peroxidation levels in BL6 cells were as a result of increased COX acti~i!y in 
these cells. 
In an attempt to demonstrate a relationship between free radical formation, lipid per oxidation levels 
and COX activity, BL6 cells were supplemented with a COX inhibitor INDO. 
7.2 MATERIALS 
Refer to sections 3.2.1 and 6.1.2 for the materials used. 
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7.2.1 EFFECT OF VITAMIN E SUCCINATE AND INDOMETHACIN SUPPLEMENTATION 
ON FREE RADICAL FORMATION IN BL6 CELLS. 
METHODS 
7.2.1.1 Cell culture procedure 
Refer to section 6.1.2.2 for the method used. 
7.2.1.2 Harvesting of cells 
The method described in section 2.2.3.2 was repeated, except that cell pellets were resuspended in 
1.0mIPBS (PH 7.4). 
7.2.1.3 Nitroblue tetrazolium assay 
Refer to section 3.2.2.2 for the method used. 
7.2.2 EFFECT OF VITAMIN E SUCCINATE AND INDOMETHACIN SUPPLEMENTATION 
ON LIPID PEROXIDATION LEVELS IN BL6 CELLS 
METHODS 
7.2.2.1 Cell culture procedure 
Refer to section 6.1.2.2 for the method used. 
7.2.2.2 Harvesting of cells 
The method described in section 2.2.3.2 was repeated, except that cell pellets were resuspended in 
1.0ml 0.9% saline solution (PH 7.6). 
7.2.2.3 Thiobarbaturic acid assay 
Refer to section 3.2.3.2 for the method used. 
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7.2.3 STATISTICAL ANALYSIS 
The results obtained were analysed using a One Way Analysis of Variance (ANOVA) followed by 
the Student Newmans-Kuels Multiple Range Test. Data in all subsequent sections of this chapter were 
analysed by this method. 
7.2.4 RESULTS 
Supplementation ofBL6 cells (table 20) with 0.15JLM INDO and varying levels of vitamin E succinate 
(l-lOJLg/ml) resulted in a significant (p:::;;0.001) decrease in lipid peroxidation levels, compared with 
control cultures OE. The free radical levels on the other hand showed no significant increase or 
decrease when compared to control cultures. 
Table 20: The effect of indomethacin and vitamin E succinate supplementation on free radical 
formation and lipid peroxidation levels in BL6 cells. (Each value in the table represents the mean of 
5 determinations ± SEM) 
Vitamin E Free radical formation Lipid peroxidation 
succinate (ltg Iml) nmol diformazan/106 cells nmol MDA/I06 cells 
' .. 
OB 2.40 0.75 
±0.24 ±0.07 
1 2.14 0.16a 
±0.06 ±0.05 
3 1.99 O.lOa 
±0.014 ±0.03 
5 2.18 0.08a 
±0.16 ±0.02 
7 2.16 0.06a 
±0.11 ±0.01 
10 2.35 0.07a 
±0.16 ±0.02 
a= p:::;O.OOl: Relative to lipid peroxidation levels in control cultures OB. 
7.2.5 DISCUSSION 
Analysis of COX catalytic mechanism has revealed that the activity of this enzyme is dependant on 
the presence of lipid hydroperoxides and that these lipid hydroperoxides are continuously required 
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during catalysis (168,169,175,181,182). In addition to this, it was found that a wide variety of lipid 
hydroperoxides could stimulate COX activity, including the product of COX enzyme itself, PGG2 
(168,169,182). These lipid hydroperoxides can decompose into TBA reactive materials such as MDA 
(186,409,493,494). This suggests that any agent capable of increasing COX activity could indirectly 
increase MDA levels within the cells through the generation of lipid peroxides. 
The pG hydroperoxidase (PG-peroxidase) component of the PGH synthase enzyme complex, is 
believed to produce numerous oxygen-containing free radicals when catalyzing the conversion of 
PGG2 to PGH2 (168,176,186,235), hence any component capable of increasing COX activity would 
result in an increase in PGH synthesis activity and indirectly increase free radicals levels. In earlier 
experiments (section 4.4), vitamin E succinate supplementation of BL6 cells was in fact shown to 
stimulate COX activity and to increase the levels of free radicals and lipid peroxidation (section 3.2) 
in these cells. In the present experiment, supplementation of BL6 cells (table 20) with INDO and 
vitamin E succinate resulted in a significant decrease in lipid peroxidation levels compared with 
control cultures OE. The reason for this decrease is unclear, although one factor to consider is that 
inhibiting the COX enzyme may stimulate other enzymes within the cell which function to remove 
the MDA precursor lipid hydroperoxides. Free radical levels on the other hand showed no significant 
increase or decrease following INDO supplementation. More importantly, however, when comparing 
the effect of vitamin E succinate supplementation on free radical and lipid peroxidation levels in 
INDO treated cells versus untreated cells (see sections 3.2), a marked decrease in both free radical 
and lipid peroxidation levels occurred in the INDO treated cells. This suggests that the observed 
increase in free radical and lipid peroxidation levels in BL6 cells supplemented with vitamin E 
succinate (484), was due to an increase in COX activity in these cells. 
7.3 EFFECT OF VITAMIN E SUCCINATE AND INDOMETHACIN SUPPLEMENTATION 
ON PROSTAGLANDIN E2 LEVELS IN BL6 CELLS 
7.3.1 INTRODUCTION 
The COX inhibitor INDO, functions to irreversibly inhibit the COX activity of the PGH synthase 
enzyme (165,173,489,495), and has been widely used in the pharmacological intervention of PG 
biosynthesis (487,488,496). As discussed earlier, although reports have been conflicting regarding 
the exact role of PGs in tumour development and progression, evidence over the past few years has 
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suggested a possible link between cancer development, cancer progression, invasiveness and the levels 
of PGs. The use of various COX inhibitors ha~ contributed greatly to improving the understanding 
of the role of PGs in tumour growth and development (487,488). In this part of the study, the effect 
of INDO supplementation on PGE2 levels in BL6 cells supplemented with varying levels of vitamin 
E succinate was determined, since PGE2 has been shown to inhibit tumour cell growth in vitro (247-
251) and earlier studies in section 4.5 have shown marked increases in PGE2 revels in BL6 cells 
following supplementation with vitamin E succinate. 
7.3.2 MATERIALS AND METHODS 
MATERIALS 
Refer to sections 4.5.2 and 6.1.2 for the materials used. 
METHODS 
7.3.2.1 Cell culture procedure 
Methods described in 6.1.2.2 and 2.2.3.2 were repeated, except that cell pellets were resuspended 
in 2.0ml of PBS buffer pH 7.0. 
7.3.2.2 Homogenisation and preparation of samples 
Refer to section 4.5.2.2 for the method used. 
7.3.2.3 Extraction of prostaglandin Ez 
Refer to sections 4.5.2.3 for the procedure used. 
7.3.2.4 Determination of prostaglandin Ez levels 
PGE2 levels were determined using PGE2-F25 assay kit as described in section 4.5.2.4. 
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7.3.3 RESULTS 
The levels ofPGE2 in BL6 cells supplemented with O. iSj-tM INDO and l-lOj-tg/ml vitamin E succinate 
are shown in table 21. Supplementation with l-lOj-tg/ml vitamin E succinate resulted in no significant 
increase or decrease in PGE2 levels in BL6 cells compared with control cultures OE. 
Table 21: The effect of indomethacin and vitamin E succinate supplementation on prostaglandin E2 
levels in BL6 cells. (Each value in the table represents the mean of 3 determinations ± SEM). 
Vitamin E succinate PG~ levels (pg/106 cells) 
(lLg/ml) 
OE 4.90 
±1.03 
1 3.72 
±0.25 
3 3.69 
±1.42 
5 4.65 
±0.55 
7 2.93 
±0.26 
10 5.88 
±1.53 
7.3.4 DISCUSSION 
Various experimental and therapeutic studies have consistently shown that INDO significantly inhibits 
PG synthesis by inhibiting the enzymes which synthesise them (487). Le Duc et al (496) studying the 
effects of COX inhibition on eicosanoid synthesis in rats showed that INDO supplementation inhibited 
PGE2 synthesis by greater than 90% when compared to control animals. In this study supplementation 
of l-lOj-tg/ml vitamin E succinate and 0.15j-tM INDO to BL6 cells resulted in no significant increase 
or decrease in PGE2 when compared with control cultures OE. However, when comparing results 
obtained from vitamin E succinate treatment alone (section 4.5) to INDO treated cells, a marked 
decrease in PGE2 levels was observed in INDO treated cells. INDO supplementation therefore appears 
to inhibit the stimulatory effects of vitamin E succinate on PGE2 levels in BL6 cells as observed in 
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earlier studies (section 4.5). 
-
7.4 EFFECT OF - VITAMIN E SUCCINATE AND INDOMETHACIN 
SUPPLEMENTATION ON ADENYLATE CYCLASE ACTIVITY AND CYCLIC 
ADENOSINE MONOPHOSPHATE FORMATION 
7.4.1 INTRODUCTION 
As has been mentioned in earlier studies of this thesis, PGs are believed to exert their effects on 
tumour growth through a cAMP-mediated pathway (334,347,364,367). Both metastatic and non-
metastatic tumour cells in response to PGEz synthesis generate elevate levels of cAMP. These effects 
are believed to be mediated through a PGE2-receptor-AC-cAMP linked system (154,343,344). Hence 
any change in PGE2 levels would result in similar changes in AC activity and cAMP levels. Since in 
vitamin E succinate supplemented BL6 cells, a decreased PGEz synthesis was shown to occur as a 
result of treatment with INDO, this study was undertaken to determine what effect INDO treatment 
had on AC activity and intracellular levels of cAMP in BL6 cells. 
7.4.2 MATERIALS AND METHODS 
MATERIALS 
Refer to sections 4.7.2 and 6.1.2 for the materials used. 
METHODS 
7.4.2.1 Cell culture procedure 
The method described in 6.1.2.2 and 2.3.3.2 was repeated, except that cell pellet was resuspended 
in 1.0ml of Tris-HCI buffer pH 7.5 containing 4mM EDTA. 
7.4.2.2 Homogenisation and separation into membrane and stroma fractions 
The procedure used is described in section 3.3.1.2. 
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7.4.2.3 Protein determination 
Refer to section 4.7.2.3 for the method used. 
7.4.2.4 Adenylate cyclase assay 
The method described in 4.7.2.4 was used. 
7.4.2.5 Cyclic adenosine mono phosphate assay 
The method described in 4.7.2.5 was used. 
7.4.3 RESULTS 
Treatment of BL6 cells (table 22) with l-lOJ..tg/ml vitamin E succinate and 0.15 J..tM INDO resulted 
in no significant increase or decrease in AC activity or in the intracellular levels of cAMP ,>,when 
compared with control cultures OE. 
Table 22: The effect of indomethacin and vitamin E succinate supplementation on adenyl ate cyclase 
activity and cyclic adenosine monophosphate levels in BL6 cells. (Each value in the table represents 
the mean of 3 determinations ± SEM). 
. -
Vitamin E succinate Adenylate cyclase activity cAMP levels 
(ltg/m1) (U/mg Protein) pmol/mg protein 
OE 31.80 3.32 
±6.45 ±0.13 
1 25.60 3.28 
±1.44 ±0.075 
3 19.67 3.69 
±1.04 ±0.26 
5 29.71 2.89 
±2.69 ±0.06 
7 23.05 3.74 
±1.72 ±0.84 
10 25.33 3.50 
±1.98 ±0.15 
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7.4.4 DISCUSSION 
BL6 cells supplemented with vitamin E succinate and O.15pM INDO showed no significant increase 
or decrease in AC activity or cAMP levels when compared with control cultures OE. However, when 
comparing the levels of AC activity and cAMP in BL6 cells treated with vitamin E succinate alone 
(section 4.7) to the INDO treated cells, AC activity and cAMP levels were marJeedly lower in the 
IND~ treated cells. This suggests that this observed decrease in AC activity and cAMP levels in BL6 
cells following INDO supplementation was probably due to a decrease in PGE2 synthesis, since AC 
activity is known to be functionally linked to PG synthesis (154,343,344). In summary, results from 
this study provide further evidence that vitamin E succinate mediates its effects on malignant BL6 
cells via a PGE2-AC-cAMP linked system. 
7.5 DISCUSSION OF THE RELATIONSHIP BETWEEN PROSTAGLANDIN E2, 
ADENYLATE CYCLASE AND CYCLIC ADENOSINE MONOPHOSPHATE AND 
CELL GROWTH. 
The following discussion will examine the effect of INDO supplementation on the interreiationship 
between the levels of PGE2 , cAMP and AC activity described in this chapter, and their possible 
influence on cell growth and metabolism. 
Results from chapter 4 on the effects of vitamin E succinate supplementation on secondary messsngers 
in BL6 cells showed that vitamin E succinate supplementation significantly increased the levels of 
PGE2 , AC activity and cAMP in these cells. Relating these effects to BL6 cell growth, it was evident 
that an inverse relationship exists between the levels of COX activity, AC activity, PGE2 , cAMP and 
BL6 cell growth. In terms of PG synthesis inhibitors, although no general rule can be drawn 
regarding their role in tumour cell growth, it is clear that they greatly affect tumour cell proliferation 
both in vitro (237,492) and in vivo (207,235,490). 
Studies by Thomas et al (249) have shown that the mean basal levels of E series PGs are inversely 
related to HeLa and Hep2 growth, and furthermore that supplementation of these cells with INDO 
inhibits PGE synthesis and stimulates cell proliferation. Combined vitamin E succinate and INDO 
supplementation of BL6 cells in this study resulted in no significant increase or decrease in PGE2 
levels or cell growth (figure 31). 
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Figure 31: Effect of vitamin E succinate and indomethacin supplementation 
on prostaglandin E2 levels and BL6 cell growth. 
The relationship between AC activity and BL6 cell growth following combined vitamin E succinate 
and INDO supplementation is shown in figure 32. Again, BL6 cells showed no significant change in 
AC activity or cell growth when compared to control cultures OE. The only exception was that 
recorded at 1OlLg/ml vitamin E succinate, where cell growth was significantly decreased. 
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Figure 32: Effect of vitamin E succinate and indomethacin supplementation 
on adenyl ate cyclase activity and BL6 growth. 
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Similarly combined INDO and vitamin E succinate suppJementation of BL6 cells (figure 33) resulted 
-
in no significant increase or decrease in cAMP levels or cell growth when compared to control 
cultures OE, with the exception of the lOjLg/ml supplemented cultures where a significant decrease 
in growth occurred. 
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Figure 33: Effect of vitamin E succinate and indomethacin supplementation 
on cyclic adenosine monophosphate levels and BL6 cell growth. 
Consequent use of the COX inhibitor INDO, provides further evidence that the inhibitory effects of 
vitamin E succinate on BL6 cell growth, were a direct result of the vitamin's ability to increase 
endogenous levels of PGE2 and activate the AC-cAMP linked system (497). 
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GENERAL DISCUSSION 
Cancer, or more precisely malignant growth, is defined as a disorder in which some cell type in 
the organism begins to grow in an apparently unchecked fashion. During this proliferation, the 
cell type, irrespective of its origin, tends to lose or alter some of its normal biochemical 
characteristics (498). Examples of these fundamental differences between malignant and non-
malignant cells with respect to cellular functions and composition, are discussed in chapter one. In 
general, normal and tumour cells referred to in those reports originate from the same tissue type. 
In this study however, comparisons were made between malignant and non-malignant cells derived 
from murine melanoma and monkey kidney cells respectively. Although originating from different 
tissue types, these cells were used to shpw differences in the activities of certain enzymes and 
levels of various secondary metabolites determined in this study, and their response to vitamin E 
succinate supplementation. One characteristic property which differentiates tumour cells from 
normal cells is that of cell growth. Both maintenance and control cultures of BL6 cells have 
consistently shown higher rates of cell proliferation than non-malignant LLCMK contrqJ and 
maintenance cultures. 
Although our aerobic lifestyles are advantageous in many ways, the utilization of oxygen by cells 
for many of their biochemical reactions results in the formation of highly reactive free radical 
products (60,69). Numerous studies over the past decade have led researchers to suggest that-free 
radicals and products of free radical reactions may be involved in the aetiology of cancer 
(121,499). Substantial experimental evidence has implicated free radicals in both tumour initiation 
(8,136) and promotion (5,7-9,136,137). These findings have led to widespread interest in 
antioxidant vitamins as a means of preventing these processes. Attention has focused in particular 
on vitamin E, a major lipid-soluble antioxidant present in all membranes (60,69), which functions 
to scavenge free radicals and prevent lipid peroxidation both in vitro and in vivo (39,77). Since 
tumour incidence can be affected by nutritional manipulation (50,51), and an inverse relationship 
is believed to exist between serum vitamin E and cancer incidence (52,54,60,119,121), this study 
was directed towards determining the effect of vitamin E supplementation on the growth of a 
malignant BL6 melanoma and non-malignant monkey kidney (LLCMK) cell line. In addition to 
this, certain metabolic responses to vitamin E supplementation were studied. 
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With reference to the overall mean growth studies, supplementation of 5 to lOJLg/ml vitamin E 
succinate resulted in a significant decrease in _ BL6 cell growth, while LLCMK cells showed no 
significant increase or decrease in growth. This selective inhibition of vitamin E succinate in BL6 
cells may therefore be indicative of its value in the treatment of cancer. These growth inhibitory 
effects of vitamin E succinate have also been found in various other cell lines (123,126,127), although 
the mechanism by which the vitamin inhibits growth is at present unclear. In gerretaF non-malignant 
LLCMK cells exhibited no significant trends or relationships with respect to vitamin E succinate 
supplementation effects on cell growth, and between various metabolites and secondary messengers 
in the AA pathway (figure 4). Furthermore, with respect to those experiments showing an inverse 
relationship between LLCMK growth and the levels of secondary messengers and activity of various 
enzymes in this pathway, no definite conclusion could be made since the magnitude of this 
relationship varied considerably from one experiment to the other. The tumour cell line (BL6 
melanoma cells) used in this study on the other hand exhibited consistent and significant trends or 
relationships when supplemented with vitamin E succinate, and as a result this discussion will concern 
itself with the BL6 cells. 
This study considered the possibility that the toxic effect of vitamin E succinate on tumour cell growth 
in BL6 cells was mediated by the antioxidant properties associated with the vitamin E component of 
the vitamin E succinate molecule. BL6 cells supplemented with 7 and lOJLg/ml vitamin E succinate, 
showed a marked increase in free radical levels, with a significant increase occurring at lOJLg/ml 
supplementation. Lipid peroxidation levels on the other hand were significantly increased at 5;7 and 
lOJLg/ml vitamin E succinate. This increase in free radical and lipid peroxidation levels was inversely 
related to BL6 cell growth (484). These findings support reports that tumour cell growth is inversely 
related to lipid peroxidation levels (483,500), and that any agent capable of increasing lipid 
peroxidation levels within a cell could inhibit tumour cell growth (478,501). 
Studies by Cillard et al (502,503) have suggested that vitamin E's antioxidant properties can be 
reversed to a prooxidant effect especially when the concentration of the vitamin is increased. While 
vitamin E is a naturally-occurring antioxidant, vitamin E esters are non-physiological antioxidants 
which require esterase activity to liberate the vitamin E component with antioxidant properties 
(126,403,404). Since no species-specific hydrolysis of vitamin E succinate has been shown to occur 
in BL6 cells to date, an attempt was made to demonstrate vitamin E succinate cleavage in these cells. 
Supplementation of BL6 cells with 3 to lOJLg/ml vitamin E succinate resulted in a significant increase 
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in vitamin E succinate uptake compared to untreated control cultures OE, while vitamin E levels 
showed no significant increasing or decreasing !rend. This suggests that the growth inhibitory effect 
of vitamin E succinate on BL6 cells was due to the ~itamin E succinate molecule as a whole, rather 
than the antioxidant properties associated with the vitamin E component. 
Apart from its possible role as an antioxidant, vitamin E succinate may have numeI'Ous-Dther functions 
within a cell, such as altering membrane-bound enzyme activities (124,415,416). These effects are 
believed to be mediated through direct interactions with PUF As and polar phospholipid regions of the 
membranes (412,413). In an attempt to determine whether vitamin E succinate mediated its effects 
on BL6 cells through interactions with membranes, BL6 cells were supplemented with 3H-vitamin E 
succinate and the relative uptake and cellular distribution of the vitamin was determined. 
Supplementation with 3H-vitamin E succinate resulted in a significant increase in 3H-vitamin E 
succinate uptake in BL6 cells. With respect to the relative distribution of 3H-vitamin E succinate, 
generally higher levels of the vitamin occurred in the membrane fractions compared to stroma 
fractions. The only exceptions were those recorded at5 and 7J-tg/ml supplementation, where similar 
levels of vitamin E succinate were found in membrane and stroma fractions. From the results obtained 
from free radical, lipid peroxidation, cleavage and uptake studies, it would therefore appear that 
vitamin E succinate rather than vitamin E mediated its effects on BL6 cell growth, and furthermore 
that these effects did not involve an antioxidant role, but possibly a modulatory effect on membrane 
functions. This study then considered the possibility that the inhibitory effect of vitamin E succinate 
on BL6 cell growth was mediated to a certain extent through an effect on various metabolites, 
secondary messengers and enzymes in the AA cascade and eicosanoid pathway (figure 4). 
Supplementation with vitamin E succinate resulted in a general increase in Ca2+ levels in BL6 cells. 
The availability of Ca2+ within a cell is believed to be a key regulator of cell proliferation. In general 
malignant cells are believed to lose the ability to maintain Ca2+ levels below a critical point (283). 
However, in these studies an increase in Ca2+ levels resulted in a decrease in BL6 growth. A factor 
to consider is that the passage of cells through the G1 and G2 phases of the cell cycle is not only 
cAMP-dependant, but also Ca2+ -dependant (362). This cycle can become blocked in either phase 
under certain conditions and can be altered in tumour cells (289). 
The role of Ca2+ in modulating the activity of the PLA2 enzymes also needed to be examined (267-
274). These enzymes function to release AA (272,293,307-318,423), an important precursor of PG 
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and leukotriene biosynthesis (426-428). As regards its possible role in modulating 5-LOX and COX 
activitJ', and the inverse relationship that exists between the activity of these enzymes and BL6 growth 
described in chapter 4, ~he effect of vitamin E su~dnate supplementation on PLA2 activity was 
determined. Increased PLA2 activity was observed in BL6 cells at all vitamin E succinate 
concentrations tested. When comparing PLA2 activity and Ca2+ levels it was clear that PLA2 activity 
was positively correlated with changes in intracellular Ca2+ levels, and that PLA2 activity in BL6 cells 
was Ga2+ -dependant. The only exception was that recorded at lOfLg/ml supplementation, where Ca2+ 
levels decrease and PLA2 activity increases. This suggests that lower concentrations of vitamin E 
succinate may modulate PLA2 activity in BL6 cells through changes in intracellular Ca2+ levels, while 
at higher concentrations of vitamin E succinate (lOfLg/ml), these effects were independent of 
intracellular Ca2+ levels. Since vitamin E succinate is believed to stabilise membranes (412-414) and 
alter membrane-bound enzyme activities (124,415,416), the possibility exists that high concentrations 
of vitamin E succinate may modulate PLA2 activity through changes in membrane fluidity. As 
indicated, uptake studies showed markedly higher levels of vitamin E succinate in membrane fractions 
of BL6 cells supplemented with lOfLg/ml vitamin E succinate, compared to stroma fractions. 
Although 5-LOX and COX activities were similar in control cultures of BL6 cells, supplementation 
of vitamin E succinate resulted in markedly higher levels of COX activity in comparison with 5-LOX 
activity, at all concentrations of vitamin E succinate tested. An exception however did occur in the 
3fLg/ml supplemented cultures where 5-LOX activity was higher than COX activity. This suggests that 
vitamin E succinate's growth inhibitory effects on BL6 cells were more likely to be mediated tlirClligh 
changes in COX activity than 5-LOX and that products of COX activity may play an important role 
in modulating tumour cell growth. This hypothesis was further strengthened by findings that 
supplementation of BL6 cells with the COX inhibitor indomethacin, abolishes the growth inhibitory 
effects of vitamin E succinate supplementation on BL6 cells. Since net PG production is regulated by 
COX activity (166), and marked changes in COX activity have been shown to occur in BL6 cells 
supplemented with varying levels of vitamin E succinate, it was important to determine the effects 
of vitamin E succinate supplementation on PG levels in these cells. 
As previously mentioned, most PG-producing cells predominantly synthesis one type of PG due to 
the existence of a single PGH2-metabolising enzyme (165). When comparing the levels ofPGs in BL6 
control cultures, it was clear that BL6 cells convert AA to PGD2, F2a, E2 and 12 in descending order 
of magnitude (485). Other studies with BL6 cells have shown that PGD2 is the major AA metabolite 
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produced by these cells (255,256), while PGEz and PGF2a were produced in smaller amounts (cited 
in 232,255). PGI2 levels in BL6 cells on the oth~r hand were found to be markedly lower than PGD2, 
E2 and F2a levels. Upon supplementation with vitamin'E succinate in this study, a marked increase 
in PGE2 levels occurred in the 7 and lOj.tg/ml supplemented cultures, while PGI2 levels were also 
significantly increased at lOJLg/ml supplementation (PGIz levels were however markedly lower than 
PGE2 levels in BL6 cells). It has been suggested that AA metabolism can be diveffed"' towards PGE2 
synthesis when elevated levels of lipid hydroperoxides (known inhibitors of PGI2 synthase activity) 
occur (215). Since COX enzymes catalyse the conversion of AA to various lipid hydroperoxides, and 
vitamin E succinate supplementation has been shown to significantly increase COX activity in BL6 
cells, it is reasonable to assume that the growth inhibitory effects of vitamin E succinate 
supplementation on BL6 cells were mediated largely through an increase in PGE2 synthesis rather than 
an increase in PGI2 synthesis. 
One major intracellular signalling system identified thus far is that ofthe AC enzyme, which functions 
to generate cAMP from ATP and is regulated by G-proteins (422). PGE2 is believed to stimulate 
cAMP formation through a PGE2-receptor-cAMP-linked system (366), with the cAMP acting as a 
secondary messenger for PGE2 mediated modulation of biological activity within the cell (368). In 
this study, supplementation with vitamin E succinate significantly increased both AC activity and 
cAMP levels in BL6 cells, while cell growth was significantly decreased. Since PGE2 levels were 
inversely related to BL6 cell growth, and an increase in PGE2 was positively correlated with increases 
in AC activity and cAMP levels, it is reasonable to conclude that the increase in AC activity' and 
cAMP levels observed in BL6 cells supplemented with vitamin E succinate was due to an increase 
in PGE2 synthesis (486). Supplementation of E-series PGs to various malignant and non-malignant 
cell lines have been shown to inhibit the growth of these cells, and furthermore this inhibition of 
growth correlated with changes in cAMP levels (205,248,347). 
With respect to another possible effector of cAMP levels in cells, and the consequent effects of cAMP 
on BL6 cell growth already described, the effect of vitamin E succinate supplementation on PDE 
activity in BL6 cells was determined. Total PDE activity in BL6 cells was neither significantly 
increased nor decreased upon vitamin E succinate supplementation, suggesting that PDE activity plays 
no role in altering intracellular cAMP levels. However, caution should be exercised when drawing 
such conclusions, since two distinct forms of PDE are known to occur, namely a sPDE and pPDE 
enzyme (326,371). Of interest to this study was the pPDE enzyme, which controls basal levels of 
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cAMP and whose activity is dependant on the levels of intracellular activators such as cAMP 
(326,370,372). 
As indicated, in BL6 cells, supplementation of vitamin E succinate resulted in a significant increase 
in cAMP levels (486). In contrast, a non-significant decrease in pPDE activity was observed in BL6 
cells following vitamin E succinate supplementation. The only exception was that recorded at 10p,g/ml 
supplementation, where a non-significant increase in pPDE activity occurs. This effect was contrary 
to the expected result. If cAMP was responsible for modulating pPDE activity as suggested 
(326,370,372), one would have expected pPDE activity to increase as the levels of cAMP were 
increased. One important consequence of this decreased PDE activity, however, is that lower pPDE 
would result in an increase in cAMP levels within the cell, which was found in these cells. Since 
pPDE activity is a membrane-bound enzyme (369,370), and vitamin E succinate is known to modulate 
the activity of membrane-bound enzymes (124,415,416), we propose that the observed decrease in 
pPDE activity may therefore be a direct result of the vitamin E succinate supplementation. 
One question that may arise, is how cAMP levels in BL6 cells increase at lOp,g/ml vitamin E 
succinate supplementation, when some increase in pPDE and sPDE activity occurred. This may be 
explained by the fact that intracellular cAMP levels are determined in large part by AC and cPDE 
activity (325,378,379). Supplementation of BL6 cells with lOp,g/ml vitamin E succinate resulted in 
a significant increase in AC activity and this increase in AC activity was greater than the small rise 
noted in pPDE and sPDE activity, resulting in a net production of cAMP rather than net removal. 
Thus, the increase in cAMP levels in BL6 cells following vitamin E succinate supplementation was 
largely due to changes in AC activity rather than PDE activity. 
In an attempt to provide further evidence that vitamin E succinate mediated its growth inhibitory 
effects on BL6 cells through a PGE2-AC-cAMP linked system and that a direct link exists between 
free radical formation, lipid peroxidation levels and COX activity, BL6 cells were supplemented with 
COX inhibitor INDO. With reference to overall mean growth studies, supplementation of BL6 cells 
with 0.15p,M INDO and 1-1Op,g/ml vitamin E succinate resulted in no significant increase or decrease 
in growth when compared to control cultures. Since vitamin E succinate is believed to inhibit BL6 
growth through increases in the levels of PGE2, cAMP and AC activity (486), the possibility that 
INDO stimulatory effects on BL6 growth were due to decreased levels of PGE2, cAMP and AC 
activity was considered. Supplementation of BL6 cells with INDO and vitamin E succinate revealed 
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that no significant increase or decrease in PGE2 and cAMP levels or AC activity occurred when 
comP'!fed to control cultures (498). These results provide further evidence that vitamin E succinate's 
growth inhibitory effects on BL6 cells were mediated through a PGE2 -AC-cAMP linked system. 
As regards free radical and lipid peroxidation levels in BL6 cells. The metabolism of AA by COX 
and LOX enzymes are believed to contribute to free radical formation (235) and-lipid peroxidation 
level&. within a cell (159,235), and since vitamin E succinate supplementation significantly increased 
free radical formation and lipid peroxidation levels in BL6 cells (484), this study considered the effect 
of vitamin E succinate supplementation on the activity of these enzymes. Supplementation with 7 and 
lOJLg/ml vitamin E succinate resulted in a significant increase in COX activity, while 5-LOX activity 
was significantly increased at lOJLg/ml. Furthermore, it was established in chapter 4 that an inverse 
relationship existed between the activities of these two enzymes and BL6 cell growth. Although 
vitamin E succinate is believed to stabilise membranes (412-414) and modulate the activities of 
membrane-bound enzymes (124,415,416), the effects of vitamin E succinate supplementation on BL6 
cells may be more complex than simply stabilising membranes, since 5-LOX enzymes are located in 
the cytosol and not in the membranes (438,443,446). Another important factor to also consider-is the 
'"" 
intracellular Ca2+ found in vitamin supplemented cells, since Ca2+ is believed to influence the pattern 
of AA metabolites formed, by regulating the activities of both the COX and 5-LOX enzymes (276). 
INDO supplementation resulted in a significant decrease in lipid peroxidation levels, while free 
radicals returned to levels similar to those found in control cultures. It is therefore reasonable to 
conclude that the observed increase in free radical and lipid peroxidation levels in BL6 cells folluwing 
supplementation with vitamin E succinate was an indirect result of the vitamin's ability to increase 
COX activity in these cells. 
Results from these studies suggest that vitamin E in the form of vitamin E succinate inhibits BL6 
growth, and furthermore that this inhibitory effect on cell growth did not involve antioxidant 
properties, but rather changes in AA and eicosanoid metabolism. This alteration in AA metabolism 
was brought about by a cascade effect, initiated by vitamin E succinate increasing PLA2 activity 
possibly via an alteration in intracellular Ca2+ levels and/or membrane-stabilising properties of the 
vitamin. This in turn results in an increase in PGE2 levels in BL6 cells via the action of the COX 
enzyme. These increases in PGE2 stimulate AC activity and increase cAMP levels in BL6 cells. Since 
cAMP functions as a negative regulator of the cell cycle (362), elevated levels of cAMP may inhibit 
BL6 cell proliferation through cell cycle inhibition. 
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In conclusion, it is clear that vitamin E succinate has a profound effect on malignant cell growth in 
in vitro cultured cells and that this effect can be .explained by the interaction of the vitamin ester with 
a number of biochemical pathways. The extension of these findings to chemoprevention of cancer will 
however require further investigation. 
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